Long-acting beta₂-agonists for chronic obstructive pulmonary disease (Review)

Kew KM, Mavergames C, Walters JAE



This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2013, Issue 10

http://www.thecochranelibrary.com

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	4
BACKGROUND	6
OBJECTIVES	7
METHODS	7
RESULTS	9
Figure 1	10
Figure 2	14
Figure 3	16
Figure 4	17
DISCUSSION	19
AUTHORS' CONCLUSIONS	21
ACKNOWLEDGEMENTS	21
REFERENCES	22
CHARACTERISTICS OF STUDIES	35
DATA AND ANALYSES	81
Analysis 1.1. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 1 Quality of life (SGRQ total	
score)	86
Analysis 1.2. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 2 Quality of life (number of people	
achieving the MCID on the SGRQ)	88
Analysis 1.3. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 3 Quality of life (CRQ)	89
Analysis 1.4. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 4 Severe exacerbations	
(hospitalisations)	90
Analysis 1.5. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 5 Severe/moderate exacerbations	
(hospitalisation or course of meds or ER visit	91
Analysis 1.6. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 6 Moderate exacerbations (course of	
antibiotics and/or steroids)	92
Analysis 1.7. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 7 Mortality (all-cause)	93
Analysis 1.8. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 8 People with one or more non-fatal	
serious adverse event	95
Analysis 1.9. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 9 Predose FEV1 (mL)	97
Analysis 1.10. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 10 Withdrawal	98
Analysis 2.1. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 1 Quality of life	
(SGRQ)	100
Analysis 2.2. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 2 Severe	
exacerbations (hospitalisations).	101
Analysis 2.3. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 3 Moderate	
exacerbations (course of antibiotics and/or steroids).	102
Analysis 2.4. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 4 Mortality (all-	
cause).	103
Analysis 2.5. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 5 Patients with one	
or more serious adverse event	104
Analysis 2.6. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 6 Predose FEV1	
(mL)	106
Analysis 2.7. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 7 Withdrawal.	107
Analysis 3.1. Comparison 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration], Outcome 1 Quality of life	
(SGRQ)	108
Analysis 3.2. Comparison 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration], Outcome 2 Severe	
exacerbations (hospitalisations).	109
Long-acting beta ₂ -agonists for chronic obstructive pulmonary disease (Review)	i

Analysis 3.3. Comparison 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration], Outcome 3 Moderate	
	110
Analysis 3.4. Comparison 3 Formoterol 24 µg versus placebo [subgrouped by trial duration], Outcome 4 Mortality (all- cause).	110
Analysis 3.5. Comparison 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration], Outcome 5 People with one	
	111
	112
Analysis 4.1. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 1 Quality of life	
	113
Analysis 4.2. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 2 Severe	
	114
Analysis 4.3. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 3 Moderate	
	115
Analysis 4.4. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 4 Mortality (all-	/
	116
Analysis 4.5. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 5 People with one	
	117
Analysis 4.6. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 6 Predose FEV1	,
	119
	120
	121
Analysis 5.2. Comparison 5 [Sensitivity analysis-ICS use] All LABA versus placebo, Outcome 2 Severe exacerbations	
	123
	124
	125
	126
	128
	128
SOURCES OF SUPPORT	128
	128
INDEX TERMS	128

[Intervention Review]

Long-acting beta2-agonists for chronic obstructive pulmonary disease

Kayleigh M Kew¹, Chris Mavergames², Julia AE Walters³

¹Population Health Sciences and Education, St George's, University of London, London, UK. ²The Cochrane Collaboration, Freiburg, Germany. ³School of Medicine, University of Tasmania, Hobart, Australia

Contact address: Kayleigh M Kew, Population Health Sciences and Education, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK. kkew@sgul.ac.uk.

Editorial group: Cochrane Airways Group. Publication status and date: New, published in Issue 10, 2013. Review content assessed as up-to-date: 12 June 2013.

Citation: Kew KM, Mavergames C, Walters JAE. Long-acting beta₂-agonists for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2013, Issue 10. Art. No.: CD010177. DOI: 10.1002/14651858.CD010177.pub2.

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough and mucus build-up. It is the fourth or fifth most common cause of death worldwide and is associated with significant healthcare costs.

Inhaled long-acting beta₂-agonists (LABAs) are widely prescribed to manage the symptoms of COPD when short-acting agents alone are no longer sufficient. Twice-daily treatment with an inhaled LABA is aimed at relieving symptoms, improving exercise tolerance and quality of life, slowing decline and even improving lung function and preventing and treating exacerbations.

Objectives

To assess the effects of twice-daily long-acting beta₂-agonists compared with placebo for patients with COPD on the basis of clinically important endpoints, primarily quality of life and COPD exacerbations.

Search methods

We searched the Cochrane Airways Group trials register, ClinicalTrials.gov and manufacturers' websites in June 2013.

Selection criteria

Parallel, randomised controlled trials (RCTs) recruiting populations of patients with chronic obstructive pulmonary disease. Studies were required to be at least 12 weeks in duration and designed to assess the safety and efficacy of a long-acting beta₂-agonist against placebo.

Data collection and analysis

Data and characteristics were extracted independently by two review authors, and each study was assessed for potential sources of bias. Data for all outcomes were pooled and subgrouped by LABA agent (formoterol 12 μ g, formoterol 24 μ g and salmeterol 50 μ g) and then were separately analysed by LABA agent and subgrouped by trial duration. Sensitivity analyses were conducted for the proportion of participants taking inhaled corticosteroids and for studies with high or uneven rates of attrition.

Main results

Twenty-six RCTs met the inclusion criteria, randomly assigning 14,939 people with COPD to receive twice-daily LABA or placebo. Study duration ranged from three months to three years; the median duration was six months. Participants were more often male with moderate to severe symptoms at randomisation; mean forced expiratory volume in 1 second (FEV₁) was between 33% and 55% predicted normal in the studies, and mean St George's Respiratory Questionnaire score (SGRQ) ranged from 44 to 55 when reported.

Moderate-quality evidence showed that LABA treatment improved quality of life on the SGRQ (mean difference (MD) -2.32, 95% confidence interval (CI) -3.09 to -1.54; $I^2 = 50\%$; 17 trials including 11,397 people) and reduced the number of exacerbations requiring hospitalisation (odds ratio (OR) 0.73, 95% CI 0.56 to 0.95; $I^2 = 10\%$; seven trials including 3804 people). In absolute terms, 18 fewer people per 1000 were hospitalised as the result of an exacerbation while receiving LABA therapy over a weighted mean of 7 months (95% CI 3 to 31 fewer). Scores were also improved on the Chronic Respiratory Disease Questionnaire (CRQ), and more people receiving LABA treatment showed clinically important improvement of at least four points on the SGRQ.

The number of people who had exacerbations requiring a course of oral steroids or antibiotics was also lower among those taking LABA (52 fewer per 1000 treated over 8 months; 95% CI 24 to 78 fewer, moderate quality evidence).

Mortality was low, and combined findings of all studies showed that LABA therapy did not significantly affect mortality (OR 0.90, 95% CI 0.75 to 1.08; $I^2 = 21\%$; 23 trials including 14,079 people, moderate quality evidence). LABA therapy did not affect the rate of serious adverse events (OR 0.97, 95% CI 0.83 to 1.14; $I^2 = 34\%$, moderate quality evidence), although there was significant unexplained heterogeneity, especially between the two formoterol doses.

LABA therapy improved predose FEV₁ by 73 mL more than placebo (95% CI 48 to 98; $I^2 = 71\%$, low quality evidence), and people were more likely to withdraw from placebo than from LABA therapy (OR 0.74, 95% CI 0.69 to 0.80; $I^2 = 0\%$). Higher rates of withdrawal in the placebo arm may reduce our confidence in some results, but the disparity is more likely to reduce the magnitude of difference between LABA and placebo than inflate the true effect; removing studies at highest risk of bias on the basis of high and unbalanced attrition did not change conclusions for the primary outcomes.

Authors' conclusions

Moderate-quality evidence from 26 studies showed that inhaled long-acting beta₂-agonists are effective over the medium and long term for patients with moderate to severe COPD. Their use is associated with improved quality of life and reduced exacerbations, including those requiring hospitalisation. Overall, findings showed that inhaled LABAs did not significantly reduce mortality or serious adverse events.

PLAIN LANGUAGE SUMMARY

Long-acting beta2-agonists for people with COPD

We wanted to know whether twice-daily treatment with an inhaled long-acting beta₂-agonist was better than treatment with a dummy inhaler for people with chronic obstructive pulmonary disease (COPD).

Background to the review

COPD is a disease of the lungs that causes airways to narrow. As a result, people with COPD experience symptoms of breathlessness, cough and mucus buildup, which worsen over time. Cigarette smoking is the most common cause of COPD, and it is the fourth or fifth most common cause of death worldwide.

Inhaled salmeterol and formoterol, known as long-acting beta₂-agonists (LABAs), are widely used to manage the symptoms of COPD, so it is important to understand their benefits and side effects. They are often introduced when inhaled treatments for quick relief from symptoms (e.g. salbutamol) are no longer helpful. LABAs are designed to be taken twice a day to control symptoms and reduce the likelihood of flare-ups.

What did we find?

Twenty-six studies (including 14,939 people with moderate to severe symptoms of COPD) compared twice-daily salmeterol or formoterol with a dummy inhaler. The evidence gathered for this review is current up to June 2013. Results within studies were described most often after six months of treatment, but some were reported at three months and others after as long as three years. More men than women took part, and they had moderate to severe symptoms when they began treatment. People who took LABA inhalers showed greater improvement on quality of life scales than those taking dummy inhalers, and they had fewer serious flare-ups that resulted in a hospital stay (18 fewer per 1000). They also had better lung function than people who had taken placebo. LABA inhalers did not reduce the number of people who died, and no significant difference was noted in the number who had serious adverse events while taking the medication.

These studies were most often sponsored by drug companies and were generally well designed. People in the studies did not know which treatment they were getting, and neither did the people doing the research. Several studies did not describe flare-ups, hospital stays or lung volume, so there is a chance that evidence obtained in future studies would change the strength of what has been concluded. Additionally, quite a lot of variation was noted between studies in the effects of LABA inhalers on quality of life, serious side effects and lung function. This may be explained in part by variation in study methods regarding what medications people could continue to take.

SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation]

Long-acting beta₂-agonists compared with placebo for chronic obstructive pulmonary disease

Patient or population: people with chronic obstructive pulmonary disease Intervention: long-acting beta₂-agonists Comparison: placebo

Setting: community

Setting. community						
Outcomes Follow-	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
up: weighted means pre- sented for each outcome	Assumed risk	Corresponding risk				
	Placebo	Long-acting beta ₂ -ago- nists				
Quality of life ¹ St George's Respiratory Questionnaire (SGRQ); lower scores are better 16 months	45.3 (mean of reported placebo endpoints)	Mean score in the inter- vention groups was 2.32 units lower (3.09 to 1.54 lower)	MD -2.32 (-3.09 to -1.54)	11,397 (17 studies)	$\oplus \oplus \oplus \bigcirc$ moderate2 ¹	A difference of 4 points is generally accepted to be of clinical significance
Severeexacerbations(hospitalisations)7 months	71 per 1000	53 per 1000 (40 to 68)	OR 0.73 (0.56 to 0.95)	2859 (7 studies)	$\oplus \oplus \oplus \bigcirc$ moderate ³	$l^2 = 10\%, P = 0.35$
Moderate exacerbations (course of antibiotics or oral steroids) 8 months	238 per 1000	186 per 1000 (160 to 214)	OR 0.73 (0.61 to 0.87)	3375 (7 studies)	⊕⊕⊕⊖ moderate ³	$I^2 = 8\%, P = 0.37$
Severe/moderate exac- erbations (hospitalisa- tion or course of medi- cation or ER visit) 8 months	336 per 1000	308 per 1000 (278 to 340)	OR 0.88 (0.76 to 1.02)	3968 (7 studies)	⊕⊕⊕⊖ moderate ³	$I^2 = 0\%, P = 0.80$

4

Mortality (all-cause) 14 months	5 per 1000	5 per 1000 (4 to 5)	OR 0.90 (0.75 to 1.08)	14,079 (23 studies)	$\oplus \oplus \oplus \bigcirc$ moderate ⁴	$I^2 = 21\%, P = 0.21$
Participants with one or more serious adverse event (non-fatal) ¹ 15 months	86 per 1000	84 per 1000 (74 to 97)	OR 0.97 (0.83 to 1.14)	12,446 (20 studies)	⊕⊕⊕⊖ moderate⁵	
Predose FEV ₁ (mL) ¹ 7 months; higher is better	1221 mL (mean of reported placebo endpoint scores)	Mean predose FEV ₁ in the intervention groups was 73 mL higher (48 to 98 mL higher)	MD 73 mL (48 to 98 mL)	6125 (14 studies)	⊕⊕⊖⊖ Iow ^{6,7}	Subgroup differences ($^2 = 84\%$) discussed in high heterogeneity within subgroups, with potentia baseline differences
CI: Confidence interval; O GRADE Working Group gr	ades of evidence.		(and its 95% Cl).			
GRADE Working Group gr High quality: Further rese Moderate quality: Further	ades of evidence. arch is very unlikely to o r research is likely to hav arch is very likely to hav	change our confidence in the es ve an important impact on our o e an important impact on our c	stimate of effect. confidence in the estin			

BACKGROUND

Description of the condition

Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterised by chronic and progressive breathlessness, cough, sputum production and airflow obstruction, which leads to restricted activity and poor quality of life (GOLD 2013). The World Health Organization (WHO) has estimated that COPD, which includes emphysema, chronic bronchitis and small airways disease, is the fourth or fifth most common single cause of death worldwide, and that the treatment and management costs associated with COPD present a significant burden to public health. In the United Kingdom (UK), the annual cost of COPD for the National Health Service (NHS) is estimated to be £1.3 million per 100,000 people (NICE 2011). Furthermore, because of its slow onset and under-recognition of the disease, it is heavily underdiagnosed (GOLD 2013).

COPD comprises a combination of bronchitis and emphysema and involves chronic inflammation and structural changes in the lung. Cigarette smoking is the most important risk factor, but air pollution and occupational dust and chemicals are also recognised risk factors. COPD is a progressive disease that leads to decreased lung function over time, even with the best available care. No cure for COPD is known, although it is a preventable and treatable disease. As yet, apart from smoking cessation and non-pharmacological treatments such as long-term oxygen therapy in hypoxic patients, and pulmonary rehabilitation, no intervention has been shown to reduce mortality (GOLD 2013; Puhan 2011). Management of the disease is multifaceted and includes interventions for smoking cessation (van der Meer 2001), pharmacological treatments (GOLD 2013), education (Effing 2007), and pulmonary rehabilitation (Lacasse 2006; Puhan 2011). Pharmacological therapy is aimed at relieving symptoms, improving exercise tolerance and quality of life, slowing decline and even improving lung function, and preventing and treating exacerbations. COPD exacerbations impair patients' quality of life (GOLD 2013), and a large part of the economic burden of COPD is attributed to the cost of managing exacerbations, particularly those resulting in the use of acute care services, or hospitalisations (Hutchinson 2010). In the UK, one in eight emergency admissions to hospital is for COPD, which makes it the second largest cause of emergency admissions, and one of the most costly conditions treated by the NHS (NICE 2011). Appropriate pharmacological management of the disease is therefore important, particularly for reducing and preventing exacerbations.

Description of the intervention

Pharmacological management of COPD tends to begin with one treatment, and additional therapies are introduced as necessary to

relieve symptoms and reduce the frequency and severity of exacerbations (ATS/ERS 2011; GOLD 2013). The first step often involves a short-acting bronchodilator for control of breathlessness when needed: either a short-acting beta2-agonist (SABA), such as salbutamol, or the short-acting muscarinic antagonist (SAMA) ipratropium. For persistent or worsening breathlessness associated with lung function decline, long-acting bronchodilators may be introduced (ATS/ERS 2011; GOLD 2013). These comprise twice daily long-acting beta2-agonists (LABAs; duration of action 12 hours); once-daily long-acting beta2-agonists (sometimes referred to as ultra long-acting; duration of action 24 hours); and the oncedaily long-acting anticholinergic agent tiotropium. Regular treatment with long-acting bronchodilators is preferred over treatment with regular short-acting bronchodilators on the basis of efficacy and side effects (Beeh 2010; GOLD 2013). Theophylline, an oral phosphodiesterase (PDE) inhibitor, is an alternative when bronchodilators are not available or affordable. However, theophylline is less effective and is less well tolerated than inhaled long-acting bronchodilators. For patients with severe or very severe COPD (i.e. with forced expiratory volume in 1 second (FEV₁) < 50% predicted) and with repeated exacerbations, GOLD 2013 recommends the addition of inhaled corticosteroids (ICS) to bronchodilator treatment. ICS are anti-inflammatory drugs that are licenced as combination inhalers with LABAs. This group of patients with severe COPD may also benefit from treatment with the PDE4 inhibitor roflumilast, which may reduce the risk of exacerbations (GOLD 2013).

How the intervention might work

LABAs are widely used in the management of COPD, alone or in combination with other bronchodilators, ICS or both. Commonly used LABAs include twice-daily salmeterol and formoterol and the new once-daily preparation, indacaterol. All inhaled beta₂agonists activate beta₂-receptors on different cells in the lung. Activation of the receptor on airway smooth muscle leads to a cascade of reactions that result in dilation of the airways. However, the exact mechanism of action differs between the various LABAs, and different efficacy and safety profiles can be expected between them. LABAs are commonly used to relieve symptoms and reduce exacerbations in stable COPD (Rodrigo 2008). Possible side effects of LABAs include cardiac effects such as arrhythmia and palpitations, muscle tremors, headache and metabolic imbalances such as hypokalaemia and increased glucose levels (Berger 2008).

Why it is important to do this review

LABAs are used widely and play a central role in the management of COPD (ATS/ERS 2011; GOLD 2013; NICE 2010). An earlier Cochrane systematic review has presented evidence on the effects of LABAs for patients with poorly reversible COPD (Appleton

2006). However, in this systematic review, we summarised the evidence regarding the efficacy and safety of twice-daily LABAs (i.e. those with a 12-hour duration of action) compared with placebo in all patients with COPD. The efficacy and safety of the once-daily LABA indacaterol in comparison with other LABAs and placebo will be assessed in another Cochrane systematic review (Geake 2012).

This review forms part of a suite of reviews on long-acting therapies for COPD, including long-acting anticholinergics, long-acting beta₂-agonists, ultra-long-acting beta₂-agonists, PDE₄ inhibitors, and ICS (Cheyne 2012; Chong 2011; Chong 2012; Geake 2012; Karner 2011; Karner 2011a; Karner 2012; Karner 2012a; Karner 2012b; Nannini 2010; Nannini 2010a; Nannini 2012; Spencer 2011; Welsh 2011; Yang 2012). These reviews, which look at longterm treatment for COPD, will ultimately be summarised in an overview.

OBJECTIVES

To assess the effects of twice-daily long-acting beta₂-agonists compared with placebo for patients with COPD on the basis of clinically important endpoints, primarily quality of life and COPD exacerbations.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs) with a parallelgroup design, of at least 12 weeks' duration. We did not exclude studies on the basis of blinding. We excluded cross-over trials, as we were looking at long-term effects including adverse events.

Types of participants

We included RCTs that recruited participants with a clinical diagnosis of COPD based on the following (GOLD 2013).

1. Forced expiratory volume after one second $(FEV_1)/forced$ vital capacity (FVC) ratio < 0.7, which confirms the presence of persistent airflow limitation.

- 2. Several of the following key indicators:
 - i) Progressive and/or persistent dyspnoea
- (breathlessness);
 - ii) Chronic cough;
 - iii) Chronic sputum production; and

iv) History of exposure to risk factors (tobacco smoke, smoke from home cooking and heating fuels, occupational dusts and chemicals).

We excluded RCTs in which participants had to have asthma as well as COPD to be included.

Types of interventions

We included studies in which participants were randomly assigned to receive the following.

- 1. Salmeterol 50 μ g or placebo twice daily.
- 2. Formoterol 12 μ g or placebo twice daily.
- 3. Formoterol 24 μ g or placebo twice daily.

We included studies that allowed concomitant short-acting bronchodilators, provided they were not part of the trial treatment under study. We did not include studies in which most participants were receiving other COPD treatments.

Types of outcome measures

Primary outcomes

1. Quality of life; mean difference and responders analysis (number of participants with clinically significant improvement or worsening); measured with a scale validated for COPD, such as St George's Respiratory Questionnaire (SGRQ) or the Chronic Respiratory Disease Questionnaire (CRQ).

2. Severe COPD exacerbations (COPD exacerbations leading to hospitalisation).

Secondary outcomes

- 1. Moderate COPD exacerbations.^a
- 2. Mortality; all-cause.
- 3. Non-fatal serious adverse events; all-cause.
- 4. Trough (predose) FEV₁.
- 5. Withdrawals from study treatment.

^{*a*}A sample definition of COPD exacerbation is "an acute event characterised by a worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication" (GOLD 2013).

Search methods for identification of studies

Electronic searches

We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and conference abstracts found through handsearching (see Appendix 1 for further

details). We searched all records in the CAGR coded 'COPD' using the following terms:

(*formoterol or salmeterol or Serevent or Foradil or Oxis or LABA or long-acting* or "long acting*")

We also searched ClinicalTrials.gov using search terms described in Appendix 2. We searched all databases up to June 2013, with no restriction on date or language of publication.

Searching other resources

We checked reference lists of all primary studies and review articles for additional references. We searched the manufacturers' websites (GlaxoSmithKline and AstraZeneca) for additional information on studies identified through the electronic searches.

Data collection and analysis

Selection of studies

Two review authors independently screened the titles and abstracts of citations retrieved through literature searches and obtained in full text those deemed to be potentially relevant. We assigned each reference to a study identifier and assessed each against the inclusion criteria of this protocol (see Criteria for considering studies for this review). Any disagreements were resolved by consensus.

Data extraction and management

Two review authors independently extracted information from each study to record the following characteristics.

• Design (design, total study duration, number of study centres and location).

• Participants (number randomly assigned to each treatment, mean age, gender, baseline lung function, smoking history, reversibility, inclusion criteria and exclusion criteria).

• Interventions (run-in, intervention and control treatments including concentration and formulation).

• Outcomes (definition of exacerbation and outcome data using end of study as time of analysis for all studies).

In the event that treatment arms of interest with different doses were included, these findings were combined when possible according to recommendations outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2009). If the data could not be combined, we used the trial arm with the dose offering greatest homogeneity with other trials regarding dose. We also subgrouped primary outcome data according to dose. Any discrepancies in the data were resolved by discussion, or by consultation with a third party when necessary.

Assessment of risk of bias in included studies

For the following items, two review authors independently assessed the risk of bias and graded each potential source of bias as high risk, low risk or unclear risk and resolved disagreements by consensus, according to recommendations outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2009).

- Random sequence generation.
- Allocation concealment.
- Blinding of participants and personnel.
- Blinding of outcome assessment.
- Incomplete outcome data.
- Selective outcome reporting.

Measures of treatment effect

Dichotomous data: We analysed dichotomous data variables (such as mortality and withdrawals) using Mantel-Haenzsel odds ratios (ORs) with 95% confidence intervals (CIs). If events were rare, we employed the Peto odds ratio. If count data were not available as the number of participants experiencing an event but rather were reported as rate ratios, we transformed them into log rate ratios and analysed the data using generic inverse variance (GIV).

Continuous data: We analysed continuous outcome data as fixedeffect mean differences (MDs) with 95% CIs unless excessive heterogeneity was found.

Unit of analysis issues

We analysed dichotomous data using participants as the unit of analysis. For continuous data, the MD based on change from baseline was preferred over the MD based on absolute values.

Dealing with missing data

If outcome data or key study characteristics were not reported in the primary publication, we searched clinical trial reports and contacted study authors and sponsors for additional information. We used intention-to-treat (ITT) analysis on outcomes from all randomly assigned participants when possible. We also considered, as part of the sensitivity analysis, the impact of the unknown status of participants who withdraw from the trials.

Assessment of heterogeneity

We assessed clinical and methodological heterogeneity by recording differences in study design and participant characteristics between individual studies. We assessed the extent of statistical variation among study results by using the I² measurement.

Assessment of reporting biases

We tried to minimise reporting bias from non-publication of studies or selective outcome reporting by using a broad search strategy,

checking references of included studies and relevant systematic reviews and contacting study authors to request additional outcome data. We visually inspected funnel plots when 10 or more studies were included.

Data synthesis

For all outcomes, we analysed each LABA and dose separately; however for our primary outcomes, we also pooled the three comparisons. We analysed data using a fixed-effect model, but when heterogeneity was noted ($I^2 > 30\%$), we used a random-effects model and explored the heterogeneity (see Subgroup analysis and investigation of heterogeneity). We presented the findings of our primary outcomes in a 'Summary of findings' table generated with the use of GradePro software and according to recommendations provided in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2009).

Subgroup analysis and investigation of heterogeneity

When substantial heterogeneity was identified among the studies $(I^2 > 30\%)$, we explored it by analysing the data by the following subgroups.

- Duration of LABA therapy (≤ 1 year; > 1 year).
- Disease severity at baseline (FEV₁ < 50% predicted; FEV₁ \geq 50% predicted).

Sensitivity analysis

We assessed the robustness of our analyses by performing sensitivity analyses and systematically excluding the following studies from the overall analysis.

• Those at high risk of bias.

- Those with high and/or uneven withdrawal rates
- Concurrent use of inhaled steroids*


*Studies where more than fifty percent of patients continued taking ICS or other COPD medications were excluded. However, included studies in which a significant proportion (but not the majority) of patients continued taking ICS or other COPD medications were removed in a sensitivity analysis.


RESULTS

Description of studies

Results of the search

Nine hundred and seventy-two references were identified through searches of online databases, and 63 additional references were found by searching other resources (drug company websites, reference lists of systematic reviews, clinicaltrials.gov). After 16 duplicates were removed, 802 of the remaining 1019 references were excluded by sifting titles and abstracts. The most common reasons for exclusion were that no LABA versus placebo comparison was performed (n = 359) and that the study used a cross-over design (n = 184). Full reasons for exclusion are listed in Figure 1. Full texts were consulted for the remaining 217 references, and 191 were found to meet all of the inclusion criteria, representing 26 studies. The main reason for exclusion at this stage was that more than 50% of participants in the trials were taking concomitant COPD medications (n = 22). Full details of the search history can be found in Appendix 1 and Appendix 2.





Included studies

Twenty-six studies met the inclusion criteria, randomly assigning 14,939 people with a diagnosis of COPD to LABA or placebo. All but one of the trials (Watkins 2002) contributed data to at least one analysis. Calverley 2007 [TORCH] contributed the greatest number of people to the analyses, with 3087 people randomly assigned to the two groups of interest. A small industry-funded trial, SLMF4010 2005 included the smallest number of people, with 17 people randomly assigned to each group.

Design and duration

All twenty-six studies were randomised, double-blind, parallelgroup controlled trials. Nine trials lasted for three months, 10 for six months and six for a year. The remaining trial (Calverley 2007 [TORCH]) was a three-year study. In accordance with the protocol, separate analyses of the three included LABA doses were subgrouped according to length of trial (three, six, 12 and 36 months). Distribution of studies among the four duration categories and descriptive statistics of age and sex are given in Table 1.

Participant inclusion and exclusion criteria

Full details of the inclusion and exclusion criteria for each trial can be found in Characteristics of included studies. Inclusion and exclusion criteria were largely similar across trials. Participants were required to be over the age of 40 (35 in three studies) and to have a smoking history of at least 10 pack-years.

Baseline characteristics of participants

Full details of the baseline characteristics of participants in each study can be found in Characteristics of included studies. Participants' mean age was similar across trials, ranging from 58.8 to 67.2 years in individual trial arms. Trial participants were most often male (range 50% to 94%, median 75%) and Caucasian (range 46% to 100%, median 92%). Seventeen trials reported mean or median smoking pack-years; medians ranged from 40 to 60, and means ranged from 35.4 to 52.5, pack-years. Twenty studies reporting percentage predicted FEV₁ indicated that the populations were of moderate to high disease severity, with baseline means ranging from 32.6% to 54.7%. Distribution of mean percentage predicted FEV₁ at baseline within studies and mean baseline SGRQ (when reported) are presented in Table 2.

Descriptive statistics were analysed separately for the formoterol and salmeterol studies to check for systematic differences between trials of drugs made by different manufacturers. Percentage reversibility was reported in only 12 studies (46%), of which only two were studying salmeterol. Within the ten formoterol studies (both doses), reversibility reported for each arm ranged from 4.7% to 19.5%, with a mean value of 8.8. For the salmeterol studies, the mean was 7.9 and ranged from 4 to 13 in individual trial arms. Mean percentage predicted FEV₁ was better reported (77% of studies), and no differences in baseline severity were apparent between formoterol and salmeterol; the formoterol studies had a mean of 44.7, ranging from 32.6 to 54.7, and the salmeterol studies a mean of 43.0, ranging from 37.7 to 53. Given the relative homogeneity of these metrics between subgroups and between the individual trials, it was not deemed appropriate to subgroup results on the basis of severity.

Characteristics of the interventions

Fourteen studies included the comparison of formoterol 12 μ g twice daily (or metered dose equivalent) and placebo. Three of these studies (Aalbers 2002; Dahl 2001; Rossi 2002) also included a formoterol 24 μ g twice-daily arm. One additional study, Wadbo 2002, used only the comparison of formoterol 24 μ g. Most formoterol studies used matching dry powder Turbuhaler devices to deliver blinded study medication. The remaining 11 studies compared salmeterol 50 μ g twice daily (or equivalent) with placebo, primarily using blinded Diskus dry powder inhalers. Studies allowed the use of a short-acting beta₂-agonist as reliever medication during the study period (salbutamol or terbutaline).

Outcomes and analysis structure

Health-related quality of life measured on the St George's Respiratory Questionnaire (SGRQ) was reported in most of the studies. The SGRQ is a well-validated and widely used measure of health status in patients with chronic airflow limitation; the total score ranges from 0 (perfect health) to 100 (most severe status) and includes three components of symptoms, activity and impacts. Only three of these studies (Bogdan 2011; Brusasco 2003; Kornmann 2011) reported the number of people improving by four or more points on the SGRQ, which is generally accepted to be the minimal clinically important difference. In two studies (Doherty 2012 and Szafranski 2003), variance was not given for the comparison of interest. In these cases, standard deviations of 14.5 were imputed on the basis of population variance and on that of other arms within the studies to increase the number of studies in the analysis. Four additional studies reported quality of life data using the Chronic Respiratory Diseases Questionnaire (CRQ) (Hanania 2003; Mahler 1999; Mahler 2002; Rennard 2001), of which two reported mean change with no measure of variance. All four were analysed separately from the main SGRQ analysis to reduce possible sources of heterogeneity, with missing variances imputed from those reported in Mahler 1999 and Rennard 2001. Because these four studies all compared salmeterol with placebo and were of three months' and six months' duration, results for the CRQ were not part of the subgroup analyses. Therefore, the quality of life data could be presented in a more clinically meaningful format by using mean differences on the SGRQ scale. For this outcome and predose FEV₁, mean change and endpoint data were analysed together, and footnotes were entered to clarify which data were available.

The second primary outcome, severe COPD exacerbations requiring hospitalisation, was quite poorly reported. Seven studies (nine comparisons) reported this as an outcome, of which five also reported the number of people with one or more moderate COPD exacerbations (those requiring a course of antibiotics or oral steroids). Rennard 2001 and Calverley 2003b [TRISTAN] reported data that could be included in the moderate exacerbations analyses but not hospitalisations. Two additional studies, Mahler 1999 and Nelson 2007, did not explicitly define exacerbations but were included in the moderate exacerbations analysis because rates were more consistent with these rates in other studies. Data for hospitalisations are collated in Analysis 1.4 and for moderate exacerbations in Analysis 1.6.

Seven additional studies reported the overall number of people who had *either* one or more moderate *or* severe exacerbations during the study, and these data are presented separately in Analysis 1.5. Overall, 18 studies reported exacerbation count data that could be included in at least one of these three analyses. Four studies presented no data related to exacerbations (Aalbers 2002; Kornmann 2011; Wadbo 2002; Watkins 2002), and four further studies reported data as rate ratios or yearly patient rates that could not be incorporated with data from the other studies (Calverley 2007 [TORCH]; SLMF4010 2005; Szafranski 2003; Tashkin 2008 [SHINE]).

Mortality was well reported and was missing only in Aalbers 2002, Wadbo 2002 and Watkins 2002. Watkins 2002 did not contribute data to any analysis. Calverley 2007 [TORCH], the largest and longest study, was unique in tracking the status of all participants at endpoint, regardless of how long they stayed in the study. For this reason, the nature and quality of mortality data from this study are likely to differ from those of other studies in the analysis. The number of participants experiencing one or more serious adverse events was reported in slightly fewer studies. Within the six studies that could not be included, one reported only the number of serious cardiac adverse events, and the others reported overall serious and non-serious events combined.

Lung function as measured by predose FEV₁ was not consistently reported. Half of the studies reported data that could be used in meta-analysis as mean change or endpoint scores with corresponding variance. Two studies reported absolute means at endpoint, and all other studies reported mean change from baseline. Two studies reporting change did not report a measure of variance (Calverley 2003a; Tashkin 2012), so standard deviations were imputed by calculating the mean of the change variances from the re-

maining nine studies. The remaining studies either reported other lung function measures that could not be analysed with predose FEV_1 (e.g. peak expiratory flow, postbronchodilator FEV_1) or did not present the data in a format that could be incorporated in the meta-analysis. Rennard 2001 aimed to detect differences of effect between participants with high or low reversibility, and so the merged results may represent a heterogeneous population that is different from that seen in other studies.

Three trials-Aalbers 2002, Dahl 2001 and Rossi 2002-included two LABA arms that met inclusion criteria for the review, and in these cases, all three arms were included and the placebo arm of each was split in comparison 1. In these cases, the power of the overall analysis is accurate, but the power to detect subgroup differences may be reduced. In comparisons 2, 3 and 4, where LABA doses are split into different analyses, no adjustments were made to the participant totals. When studies reported data at more than one time point of interest, we reported only the duration subgroup totals-not the pooled effect (i.e. data for the same participants were not double counted, but power to detect subgroup differences may be increased). For this reason, slight discrepancies may be evident between a subgroup result in comparison 1 and the corresponding effect in the following comparisons subgrouped by trial duration.

Sensitivity analyses

Use of inhaled corticosteroids (ICS) during the study period

As stated in the protocol, we intended to exclude trials in which more than 50% of participants were taking other COPD medications. Most available data in the study reports related to ICS use during the randomised period, and this was used as a proxy in cases where the preferred data were not available. Ten studies required that other medications, including ICS, were stopped during the run-in. Eight further studies did not explicitly report the proportion of participants taking other medications, and inferences based on pharmacological exclusion criteria could not be made. Hanrahan 2008 reported that 28.6% and 23.9% of participants in the salmeterol and placebo groups, respectively, were taking regular ICS during the study period, and so the study was included. Similarly, Nelson 2007 reported that 33% and 38% of participants in the formoterol and placebo groups were taking COPD medications during the study period that were not part of the randomised interventions. Because ICS use fell just above or just below the predefined 50% threshold in the remaining six studies (Campbell 2005; Dahl 2001; Dahl 2010; Kornmann 2011; Rossi 2002; Vogelmeier 2008), these studies were removed from the primary outcomes in a sensitivity analysis.

Studies at high risk of bias/those with high or uneven withdrawal rates

Because no studies were rated at high risk of bias for either of the selection bias parameters, or for detection or performance bias, a


sensitivity analysis was performed to remove the eight studies that were rated at high risk of bias due to attrition (Dahl 2010; Hanania 2003; Mahler 1999; Mahler 2002; Nelson 2007; Rennard 2009; SLMF4010 2005; Szafranski 2003). Given that high risk judgements in the reporting bias parameter usually were made because studies were already missing from analyses, it was not appropriate to perform a sensitivity analysis on selective outcome reporting. Reporting bias is reflected in the grade ratings of the affected outcomes.


Excluded studies

Details of why studies were excluded from the review, including exact percentages of participants taking additional COPD medications, can be found in Characteristics of excluded studies. Six studies (22 citations) were excluded because a clear majority of the participants were taking other COPD medications (Boyd 1995; Celli 2003; Chapman 2002; Dal Negro 2003; Rutten-van Molken 1999; Stockley 2006). One additional trial (two publications) was excluded because the inclusion criteria allowed for participants with asthma or COPD, and data for diagnostic subgroups were not presented (Steffensen 1996).

Risk of bias in included studies

The methodological quality of the included trials was good. None of the studies were at high risk of selection, performance or detection bias, but there was high risk of bias for attrition in eight studies and selective reporting of outcomes in 11 studies. More detailed descriptions by domain (allocation generation, allocation concealment, blinding and incomplete data) are given below. Details of the risk of bias rating for each study and the reasons for each rating can be found in Characteristics of included studies and a summary of judgements by study and domain can be found in Figure 2. When studies funded by the same company were rated as unclear for one or more domain, we attempted to clarify study methods with the funder.





Allocation

None of the included studies were rated as having high risk of bias for either of the two allocation parameters (random sequence generation and allocation concealment).

With the exception of Watkins 2002 (which was not a full trial report and hence was rated as unclear), all of the trials were rated as having low risk of bias for random sequence generation. Although several of the trials did not adequately describe the methods of sequence generation used, the authors agreed that this was likely due to variations in reporting standards. All of the studies were industry sponsored; therefore the authors deemed it reasonable to assume that standardised drug company methods were used (i.e. computerised random list generators).

Nine studies (Aalbers 2002; Brusasco 2003; Calverley 2003b [TRISTAN]; Calverley 2007 [TORCH] Campbell 2005; Dahl 2010; Kornmann 2011; Rennard 2009; Tashkin 2012) fully described methods used for allocation concealment and were thus rated as having low risk of bias. Although some drug companies might have standard protocols for concealing allocation, the authors agreed that studies would be rated as unclear unless the methods used were properly described for this parameter. The remaining 17 studies were rated as unclear for this reason.

Blinding

None of the studies were rated as having high risk of bias for either of the two blinding parameters (participants and personnel, and outcome assessment).

When a study was described as double-blind and no specific details were reported in the original report, trial registrations most often confirmed that the blind applied to participants and investigators. As a result, all trials were rated as having low risk of bias for this parameter. Twelve studies specifically described double-dummy procedures and matched inhalers.

Studies were not rated as having low risk of bias for blinding of outcome assessors unless blinding was explicitly stated in the trial report or the protocol registration. This was the case for only nine of the studies; therefore most were rated as unclear.

Incomplete outcome data


More than half of the included studies were rated as having low risk of bias for this parameter (N = 16), either because dropout was deemed to be low and even between groups, or because dropout was considered acceptable given the methods of imputation described in the report. Two studies were rated as unclear: Calverley 2003b [TRISTAN] had high and even dropout in both arms but did not sufficiently describe the method of imputation to warrant a 'low' rating, and Watkins 2002 provided no information related to attrition. The remaining eight studies were considered to be at high risk of bias, either because dropout was very high in both groups, or because dropout was deemed excessive or uneven given the method of imputation or the analysis method used (i.e. per protocol or completers only).


Selective reporting


Twenty studies could be linked with their protocol registration on clinicaltrials.gov or with their industry report, allowing comparison of prespecified outcomes with published or unpublished results. Of these, ten reported all stated outcomes in a way that allowed them to be combined in meta-analysis (Bogdan 2011; Calverley 2003a; Calverley 2003b [TRISTAN]; Calverley 2007 [TORCH]; Dahl 2010; Hanania 2003; Mahler 2002; Rennard 2001; SLMF4010 2005; Tashkin 2008 [SHINE]). Five studies that could not be linked to their trial registration documents but did not show clear evidence of selective outcome reporting were rated as unclear (Campbell 2005; Dahl 2001; Rossi 2002; Szafranski 2003; Tashkin 2012). Eleven studies were rated as having high risk of bias either because outcomes that were stated in the protocol were not reported in sufficient detail in the results, or because key outcomes expected in COPD trials were not included, regardless of whether they were named in a protocol (e.g. mortality, adverse events, exacerbations).

Funnel plots were constructed for the primary outcomes. Figure 3 is not suggestive of any serious publication bias of the SGRQ. However, some evidence suggests a small study effect on severe exacerbations (those resulting in hospitalisation), which might be due to publication bias, as shown in Figure 4.

Figure 3. Funnel plot of comparison: I All LABA versus placebo [subgrouped by drug], outcome: I.I Quality of life (SGRQ total score).







Other potential sources of bias

No other sources of bias were identified in the included studies.

Effects of interventions

See: Summary of findings for the main comparison Long-acting beta₂-agonists compared with placebo for chronic obstructive pulmonary disease

Full details of the analyses and their GRADE ratings can be found in Data and analyses and Summary of findings for the main comparison. The first comparison presents results for all outcomes, with studies subgrouped according to the type and dose of LABA. Comparisons 2, 3 and 4 show results for formoterol 12 μ g, formoterol 24 μ g and salmeterol 50 μ g, respectively (all twice daily), subgrouped according to study duration. The final comparison presents data for the two primary outcomes, excluding six studies in which relatively large proportions of the population were taking regular COPD therapies other than the study medication (see 'Use of inhaled corticosteroids (ICS) during the study period' in Included studies).

Primary outcomes

Health-related quality of life

Improvement on the St George's Respiratory Questionnaire (SGRQ) was greater with LABA therapy than with placebo (MD -2.32, 95% CI -3.09 to -1.54; $I^2 = 50\%$, P = 0.007; Analysis 1.1), based on data from 11,397 people in 17 studies. Results were analysed using a random-effects model because heterogeneity was high, and the outcome was downgraded from high to moderate quality for this reason. Heterogeneity could not be explained by differences between the effects of LABA drug and dose (test for subgroup difference, $I^2 = 0\%$, P = 0.45). The difference between LABA and placebo was significant for all three LABA agents separately, but important heterogeneity was noted within the formoterol 12 μ g and salmeterol 50 μ g subgroups ($I^2 = 57\%$ and 48%, respectively).

More people taking a LABA showed clinically important improvement of at least four points on the SGRQ (OR 1.58, 95% CI 1.32 to 1.90; $I^2 = 86\%$, P = 0.0007; Analysis 1.2) based on 1871 people in three studies. Data were insufficient to allow conclusions regarding the difference between formoterol and salmeterol.

Four salmeterol studies reporting the Chronic Respiratory Dis-

ease Questionnaire (CRQ) were analysed separately and showed a significant benefit of LABA therapy (MD 3.10, 95% CI 1.22 to 4.98; $I^2 = 0\%$, P = 0.58; Analysis 1.3) with no heterogeneity. Because so few trials reported the CRQ and the number of people achieving a minimally clinically important difference (MCID) on the SGRQ of 4 units, we did subgroup and sensitivity analyses on the SGRQ continuous data only.

A test for subgroup differences suggested that some of the heterogeneity within the 12 trials which randomised people to either formoterol or placebo may be explained by differences in study duration ($I^2 = 75\%$, P = 0.02; Analysis 2.1). The effect of twicedaily formoterol 24 μ g was significant when analysed separately but lacked precision because only three studies compared the dose with placebo (MD -2.32, 95% CI -4.52 to -0.13; $I^2 = 0\%$, P = 0.76; Analysis 3.1). No difference was detected between the two three-month trials (Dahl 2001; Wadbo 2002) and the year-long Rossi 2002 study. With so few studies, no heterogeneity was evident between or within subgroups. Unlike the formoterol 12 μ g analysis, trial duration did not appear to be an important source of heterogeneity in the salmeterol included trials ($I^2 = 0\%$, P = 0.41; Analysis 4.1).

The overall pooled effect and drug subgroup effects were largely consistent with the original analysis after removal of five studies identified as having a high proportion of ICS use during the trial (see Included studies-*Use of inhaled corticosteroids (ICS) during the study period).* The magnitude of improvement due to LABA therapy was reduced after the studies were removed, but somewhat tighter confidence intervals and less between-study heterogeneity were noted (MD -1.53, 95% CI -2.08 to -0.98; $I^2 = 34\%$, P = 0.12; Analysis 5.1).

Four of the eight studies rated as having high risk of bias reported the SGRQ: three from the formoterol 12 subgroup and one from the salmeterol subgroup. After these studies were removed, the pooled difference between LABA and placebo remained significant but was again reduced (MD -1.60, 95% CI -2.15 to -1.05; $I^2 =$ 42%, P = 0.04; Analysis 6.1).

Severe COPD exacerbations (requiring hospitalisation)

When data from seven studies were combined (nine comparisons), the number of people hospitalised for COPD exacerbations was lower among LABA-treated participants than in those receiving placebo (OR 0.73, 95% CI 0.56 to 0.95; Analysis 1.4). Although little evidence was found for explicit selective outcome reporting within trials, the outcome was downgraded for publication bias and was rated as having moderate quality; more than half of the studies did not report the outcome of high interest to patients and clinicians, and the estimate might have been different if all studies could have been included in the analysis (see Included studies-*Outcomes and analysis structure*). No heterogeneity was noted between trials, and the results of a test for subgroup differences between drugs/doses were not significant ($I^2 = 57.5\%$, P = 0.10). No evidence of a statistically significant effect of trial duration was observed in the formoterol 12 μ g trials (six studies across three duration subgroups). Similarly, no significant difference was observed between the three-month Dahl 2001 study and the 12-month Rossi 2002 study comparing formoterol 24 μ g with placebo. Only one six-month study comparing salmeterol and placebo reported hospitalisation rates, so no assumptions could be made regarding relative effects of trial duration.

The pooled effect of LABA *versus* placebo decreased in magnitude and was no longer significant after four studies with a high percentage of participants taking inhaled corticosteroids (six comparisons) were removed. This effect was based on only three remaining trials (OR 0.85, 95% CI 0.62 to 1.16; Analysis 5.2), and the change in effect could be explained by another variable. None of the eight studies rated as having high risk of bias reported the number of participants with exacerbations requiring hospitalisation, so the outcome does not appear in the sensitivity analysis.

Secondary outcomes

Moderate COPD exacerbations (requiring a course of antibiotics *and/or oral steroids*)

LABA treatment reduced the number of people who had one or more exacerbations requiring a course of antibiotics, oral steroids or both compared with placebo (OR 0.73, 95% CI 0.61 to 0.87; $I^2 = 8\%$, P = 0.37; Analysis 1.6), with minimal heterogeneity. The quantity of data for the outcome was similar to that provided for severe COPD exacerbations, so the outcome was downgraded for publication bias for the same reasons and was rated as having moderate quality. No evidence suggested important subgroup differences on the basis of which LABA/dose was used ($I^2 = 0\%$, P = 0.68). The three studies that compared formoterol 12 μ g with placebo showed no significant benefit (OR 0.78, 95% CI 0.56 to 1.07; $I^2 = 7\%$, P = 0.34; Analysis 2.3) with little heterogeneity, and no evidence was found of differential effectiveness related to study duration. The higher-dose formoterol 24 μ g did show a significant reduction relative to placebo (OR 0.57, 95% CI 0.38 to 0.88; Analysis 3.3), although this was based on a total of 124 events in one study (Rossi 2002). Four studies that compared salmeterol with placebo showed an overall reduction in moderate exacerbations with the study drug (OR 0.75, 95% CI 0.60 to 0.94; $I^2 = 40\%$, P = 0.17; Analysis 4.3), with some non-significant heterogeneity and no observed differences related to study duration. Moderate/severe COPD exacerbations (requiring hospitalisation or a course of antibiotics/oral steroids or ER visit)

Around half of the studies did not report rates of moderate and severe COPD exacerbations as separate outcomes, as we had defined in the protocol, but rather reported a composite rate, which could not be combined with the other data; therefore we decided to present these data separately in the review. As with the other two exacerbation outcomes, the outcome was rated of moderate quality after it was downgraded for publication bias.

LABA treatment did not significantly reduce the number of people with moderate or severe exacerbations compared with placebo (OR

0.88, 95% CI 0.76 to 1.02; $I^2 = 0\%$, P = 0.80; Analysis 1.5), as determined on the basis of seven studies with 1142 participants. No between-study or between-drug heterogeneity was observed. Since the outcome was added, post hoc and subgroup analyses have been reported for the other two exacerbation outcomes, and we did not perform separate subgroup analyses of trial duration for this outcome.

Mortality; all-cause

Study deaths were relatively uncommon; therefore the analyses were conducted using Peto odds ratio, as this method does not require adjustment for zero cells. LABA treatment did not significantly reduce mortality compared with placebo (OR 0.90, 95% 0.75 to 1.08; I² = 21%, P = 0.21; Analysis 1.7), and a degree of between-study heterogeneity was noted. The outcome was downgraded for imprecision and was rated as having moderate quality because the confidence intervals for the pooled effect included important benefit and potential harm. A test for subgroup differences between drugs was not statistically significant ($I^2 = 55\%$, P = 0.11). Results of a test for subgroup differences related to the duration of the formoterol trials were not significant (Analysis 2.4). In the two formoterol 24 μ g trials that reported all-cause mortality, only one death occurred in the LABA group of Rossi 2002; the confidence intervals were too wide to allow interpretation of direction or magnitude of effects (Analysis 3.4) or assumptions based on trial length. Four studies with no events did not contribute to the salmeterol analysis (Analysis 4.4), and the effect was largely influenced by the large Calverley 2007 [TORCH] study (93% of total weight). This large study was unique because it was much longer than the other trials (at three years), and investigators logged mortality for all participants, regardless of how long they stayed in the study. Between-trial heterogeneity was not significant in the salmeterol analysis ($I^2 = 29\%$, P = 0.22); a test for subgroup differences regarding trial duration also was not significant (I^2 = 0%).

Non-fatal serious adverse events; all-cause

All studies included in the analysis reported this outcome with participants as the level of analysis (i.e. number of people who had serious adverse events as opposed to the number of adverse events in total). When findings of all studies were pooled, no difference was observed between LABA and placebo (OR 0.97, 95% CI 0.83 to 1.14; $I^2 = 34\%$, P = 0.06; Analysis 1.8). Heterogeneity was significant at P = 0.1, and unexplained differences between the two formoterol doses showed opposite directions of effect. A test for subgroup differences indicated that some of the heterogeneity may be explained by these differences in individual drugs/doses, which were significant ($I^2 = 83\%$, P = 0.002). It is unclear whether formoterol 12 μ g significantly increases rates of serious adverse events, as the confidence interval touched the line of no effect (OR 1.20, 95% CI 1.00 to 1.43; I² = 14%, P = 0.32; Analysis 2.5), and differences in trial duration were not statistically significant. Three formoterol 24 μ g studies showed that serious adverse events were lowered by LABA use (OR 0.53, 95% CI 0.36 to 0.79; I² = 0%, P = 0.67; Analysis 3.5) with no significant heterogeneity, although confidence intervals were quite wide. Studies that compared salmeterol 50 μ g with placebo showed no significant differences between groups (OR 0.94; 95% CI 0.83 to 1.06; I² = 13%, P = 0.33; Analysis 4.5) based on nine studies with 1608 events. Some statistically insignificant heterogeneity between trial results was noted and could not be explained by reliable differences in trial duration.

Predose forced expiratory volume in one second (trough FEV₁) The predose FEV1 of participants taking LABA was 73 mL higher at the end of the trials than that of participants taking placebo inhalers (95% CI 48 to 98; I² = 71%, P < 0.0001; Analysis 1.9); this finding was based on data from 6125 participants in thirteen studies that reported the outcome. A large degree of heterogeneity was noted, so the analysis was downgraded for inconsistency. Half of the studies did not report the outcome or reported the outcome in a way that could not be entered in meta-analysis; therefore it was downgraded for publication bias and was rated as having low quality. A test for subgroup differences suggested that the heterogeneity may be accounted for by differences between formoterol 12 μ g and salmeterol 50 μ g (no formoterol 24 studies reported trough FEV₁) ($I^2 = 84\%$, P = 0.01). Individually, formoterol 12 μ g (MD 45 mL, 95% CI 29 to 60) and salmeterol 50 μ g (MD 101 mL, 95% CI 60 to 142) were associated with improved predose FEV1 relative to placebo.

No heterogeneity was observed between the formoterol 12 μ g studies (I² = 0%, P = 0.57), and no observable differences related to trial duration were reported. In the salmeterol 50 μ g studies, heterogeneity was substantial (I² = 69%, P = 0.003), and a test for subgroup differences of study duration suggested that the benefits of LABA treatment over placebo become less distinct over time (I² = 87%, P = 0.0005; Analysis 4.6). Some of the heterogeneity may have been introduced by within-subgroup variation in the recruited populations. For example, Rennard 2001 split the population by high and low reversibility to compare the effects of salmeterol on different participant groups, and the data entered into the analysis represent the population as a whole.

Withdrawal from study treatment

Withdrawal rates were higher for placebo than for LABA treatment (OR 0.74, 95% CI 0.69 to 0.80; $I^2 = 0\%$, P = 0.75; Analysis 1.10), as determined on the basis of data from all studies except Watkins 2002. The formoterol 24 μ g studies contributed the least data to the analysis and showed no difference between LABA and placebo, although subgroup differences between drugs and doses were not significant ($I^2 = 0\%$, P = 0.66). No heterogeneity between trials was noted, and no evidence showed significant subgroup differences between dose categories. No clear effects of trial duration were evident.

DISCUSSION

Summary of main results

Twenty-six studies including nearly 15,000 people with moderate to severe COPD were included in the review. Participants in the studies were more often male with mean baseline FEV_1 between 33% and 55% predicted normal and mean SGRQ ranging from 44 to 55.

LABA treatment significantly improved quality of life and reduced hospitalisations relative to placebo, although unexplained variation was noted within the quality of life data. Exacerbations were not consistently defined in trials, but across three definitions (those leading to hospitalisation, requiring a course of antibiotics or steroids or either), good evidence suggested that LABA therapy was effective. In terms of adverse events, no significant difference was observed in rates of mortality or serious adverse events between LABA and placebo.

Most subgroup differences between drugs and between dose groups were not significant. Significant differences in serious adverse events data were complicated by the unexplained disparity of effect direction for the two formoterol doses, and the difference in FEV₁ between formoterol and salmeterol is complicated by substantial heterogeneity within the salmeterol studies for that outcome. Systematic differences between drug company methodology and recruitment procedures may preclude comparisons between salmeterol and formoterol.

Participants were more likely to withdraw from placebo than from LABA therapy (OR 0.74, 95% CI 0.69 to 0.80; $I^2 = 0\%$), although sensitivity analyses removing studies at highest risk of bias for this reason did not change conclusions for the primary outcomes.

Overall completeness and applicability of evidence

The current review expanded and updated a previous Cochrane review that looked only at patients with poorly reversible COPD (Appleton 2006). Because the inclusion criteria were widened to include all patients with a diagnosis of COPD, findings are likely to apply to a larger group of patients for whom LABA therapy is indicated. Trials were largely consistent in their inclusion of moderately to severely affected participants, as confirmed through smoking and medication history and spirometric indices.

Because of variation in study protocols regarding the use of other COPD medications, it is difficult to accurately judge to which groups of patients the evidence accurately applies. However, the sensitivity analysis removing studies in which a large proportion of participants were taking other COPD medications goes some way to dispel this uncertainty, given that results were very similar to those of the original pooled analysis. Similarly, systematic differences may be noted between trials of salmeterol and those of formoterol because different manufacturers conducted most of the trials for these two drugs. However, analysis of descriptive statistics for the baseline measurements showed that the populations recruited to trials of salmeterol were similar to those enrolled in the formoterol trials (percentage reversibility and percentage predicted FEV_1). Outlier studies (those recruiting unusually severe or mild participants) may still have introduced heterogeneity within analyses, and differences may have been masked by inconsistent reporting of severity metrics across the data set and the lack of individual participant data. Additionally, significantly higher withdrawal in the placebo groups is likely to be due primarily to lack of efficacy leading to protocol violations (Calverley 2003). This may have reduced the effectiveness of randomisation and decreased the magnitude of difference between groups by removing from the analysis participants with the most severe conditions who had been assigned to placebo.

Only three trials tested the higher dose of formoterol (24 μ g twice daily) against placebo, of which two also included an arm that received the more commonly prescribed 12 μ g dose. The higher dose is the maximum indicated by the British National Formulary (BNF) for additional symptom relief (BNF 2009), and, in this sense, the tendency for trials to use the lower dose is consistent with licensing and practice. Similarly, the use of 12 μ g twice daily is consistent and hence comparable with the dose received through combination preparations of budesonide and formoterol. In addition, little variation in inhaler devices was seen within the formoterol or salmeterol studies, with most formoterol studies using masked Turbuhaler devices, and most salmeterol trials using the Diskus. However, fact that inhaler devices differed fairly systematically between the two drugs may have contributed to subgroup differences.

It is unclear whether unpublished trials are missing from the review or, in some cases, whether all data are reported in the available papers and unpublished industry summaries. Attempts to ascertain with GlaxoSmithKline, AstraZeneca and Novartis whether all conducted studies and measures within them were included were not fruitful in time for publication.

Quality of the evidence

The methodological quality of the included trials was good, and the single conference abstract of unknown quality did not contribute any data to the analysis. All studies were double-blind, and so results are unlikely to be compromised by detection or performance biases. Similarly, most studies controlled adequately for selection bias or were presumed to do so, in accordance with industry protocol. Although evidence suggested bias from high and unbalanced attrition in some trials and significantly higher withdrawal in the placebo arm when analysed, sensitivity analyses showed that conclusions did not change when studies at highest risk of bias were removed from the primary outcomes. It is possible that higher attrition in the placebo group across many of the trials could have diluted the true difference between LABA and placebo for some outcomes; if we accept that people who drop out of studies have a less positive outcome than those who do not, the

placebo estimate could appear more favourable than if everyone had contributed endpoint data, depending on the method used to impute values for missing data points (i.e. last observation carried forward or other imputation models).

As described above, some evidence of selective reporting bias was found, both within trials that failed to report key outcomes or those stated in the prospectively registered protocols, and in terms of the possibility that trials (industry funded or independent) may remain unpublished (Song 2010). Several studies did not report exacerbations or trough FEV₁ in a way that could be included in the review, so additional evidence obtained in future studies might change our confidence in these results.

Most studies were sponsored by drug companies, and they generally were of good quality. A lot of variation between studies was noted in the effect of LABA inhalers on quality of life, serious side effects and lung function. Although studies with around half of people taking additional medications were removed in a sensitivity analysis, the variation in allowed co-medications and the numbers taking them may explain some of the variation in reported findings. 100 μ g was not included in the current review, as this dose is not recommended in current clinical practice.

Kliber 2010 concluded that mortality was not significantly reduced by LABA therapy, and this conclusion was consistent with this review, despite some differences in trial inclusion criteria. Similarly, Rodrigo 2008 found comparable benefits of LABA on exacerbation frequency, spirometry and quality of life, and again, no significant effect on mortality.

Upon looking solely at salmeterol, Stockley 2006a found that study participants were less likely to withdraw when taking the study drug than when taking placebo, and that key efficacy measures were improved at three, six and 12 months.

Wang 2012 concluded that formoterol did not improve exacerbations unless used in conjunction with inhaled corticosteroids. However, Wang 2012 did not include trials of less than six months, excluded small trials and included trials of indacaterol, which may explain why the results differ.

AUTHORS' CONCLUSIONS

Potential biases in the review process

Review authors made every effort to identify all relevant published and unpublished studies by using additional methods to catch anything that might not have been found in the main electronic search (e.g. searching drug company databases and clinical trial registration sites, checking reference lists). However, attempts to obtain data directly from drug companies were not successful, and we did not routinely contact individual trial authors for additional data unless outcomes were clearly selectively reported. Unpublished studies (industry funded or otherwise) may exist that might change our confidence in the conclusions. All authors adhered to the most recent best practice guidelines in terms of study selection, resolution of disagreements, data extraction and analysis to reduce bias and errors.

Agreements and disagreements with other studies or reviews

Five previous reviews were identified that specifically analysed LABA versus placebo. Results of this review were consistent with results for salmeterol 50 μ g as reported in the previous Cochrane review specifically looking at patients with poorly reversible COPD (Appleton 2006). Specifically, benefit was associated with twice-daily salmeterol 50 μ g in terms of FEV₁, quality of life and exacerbations. This review found that formoterol 12 μ g also improves these outcomes-a fact that was previously unclear. The benefits of formoterol 24 μ g remain unclear, and salmeterol

This review and meta-analysis provide moderate-quality evidence that inhaled long-acting beta₂-agonists are effective over medium and long term for use in patients with moderate or severe COPD. Excluding trials in which about half of people were receiving ongoing treatment with inhaled corticosteroids or other medications for COPD gave similar effect estimates and reduced variation in the results. LABA therapy is associated with improved patient quality of life and reduced exacerbations, including those requiring hospitalisation. Overall, it was found that inhaled LABAs did not significantly reduce mortality or serious adverse events.

Implications for research

Implications for practice

More consistent reporting of exacerbations in clinically and financially meaningful categories is needed (i.e. those requiring hospitalisation as distinct from those requiring changes to medication). We have found plenty of evidence for the comparison between the LABAs salmeterol and formoterol and placebo in relation to quality of life, and we would not suggest that any further research is needed. However, for new and emerging LABAs (such as indacaterol), trials will be needed to determine whether they are safe, effective and cost-effective. Future clinical trials on LABAs in COPD should focus on head-to-head comparisons with other long-acting agents.

ACKNOWLEDGEMENTS

We acknowledge the authors of the Appleton 2006 review, which has informed this review. We thank Charlotta Karner for sifting the search and writing the protocol. We also thank Alison Cooper, who helped extract data. We thank Elizabeth Stovold for designing the search strategy and providing feedback and suggestions on the methods.

CRG Funding Acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the

Cochrane Airways Group.

Disclaimer: The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the NIHR, the NHS or the Department of Health.

Christopher Cates was the Editor for this review and commented critically on the review.

REFERENCES

References to studies included in this review

Aalbers 2002 {published data only}

* Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, et al.Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. *European Respiratory Journal* 2002;**19**(5): 936–43. [: 0903–1936]

Sybrecht GW. Inhaled formoterol was an effective and safe treatment in COPD patients. European Respiratory Society; 1999 October 9-13; Madrid, p 2510.

Bogdan 2011 {published data only}

* Bogdan M, Aizawa H, Fukuchi Y, Mishima M, Nishimura M, Ichinose M. Efficacy and safety of inhaled formoterol 4.5 and 9 microg twice daily in Japanese and European COPD patients: Phase III study results. BMC Pulmonary Medicine 2011;11(1):51. [: 1471-2466] Bogdan MA, Kudo T, Umemiya M. Efficacy and safety of inhaled formoterol 4.5 and 9 1/4g twice daily in Japanese and European patients with COPD: results of a Phase III study [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181:A4494. Ichinose M, Aizawa H, Fukuchi Y, Mishima M, Nishimura M, Bogdan M. Patient-reported outcomes (PROs) and reliever use in Japanese and European patients with chronic obstructive pulmonary disease receiving formoterol 4.5 and 9 microg twice daily: Results of the OCEAN phase III study [Abstract]. European Respiratory Society Annual

Brusasco 2003 {published data only}

Bateman ED, Hodder R, Miravitlles M, Lee A, Towse L, Serby C. A comparative trial of tiotropium, salmeterol and placebo: health-related quality of life. *European Respiratory Journal* 2001;**18**(Suppl 33):26s.

Congress; 2010 Sep 18-22; Barcelona, p 4591.

Bateman ED, Jenkins C, Korducki L, Keston S. Tiotropium (TIO) improves health care resource utilization (HRU) and patient disability in patients with COPD. *American Journal of Respiratory and Critical Care Medicine* 2002;**165**(Suppl 8):A111.

* Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. *Thorax* 2003;**58** (5):399–404.

Brusasco V, Menjoge SS, Kesten S. Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle, Poster 420.

Brusasco V, Menjoge SS, Kesten S. Flow and volume responders over 12 hours following treatment with tiotropium or salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19-24; San Diego, A110 [Poster J10].

Brusasco V, Thompson P, Vincken W, Lee A, Towse L, Witek TJ. Improvement of dyspnea following of six months treatment with tiotropium but not with salmeterol in patients with COPD. *European Respiratory Journal* 2001;**18** (Suppl 33):26s.

Donohue JF. Alterations in bronchodilator effectiveness over six months with Tiotropium and Salmeterol. *American Journal of Respiratory and Critical Care Medicine* 2002;**165** (Suppl 8):A227.

Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. *Respiratory Medicine* 2003;**97**(9):1014–20.

Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, et al.A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. *Chest* 2002;**122**(1):47–55. [: 0012–3692]

Donohue JF, van Noord JA, Langley SJ, Lee A, Kesten S, Towse LJ. Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. *European Respiratory Journal* 2001;**18**(Suppl 33):26s.

Gunther K, Lee A, Kesten S, Towse L. Superior bronchodilation of once daily tiotropium compared with twice daily salmeterol in patients with COPD [Abstract]. International Primary Care Respiratory Group Congress; 2002 Jun 7-9; Amsterdam, p 112.

Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. *The*

European Journal of Health Economics: Health Economics in Prevention and Care 2007;**8**(2):123–35.

Calverley 2003a {published data only}

AstraZeneca. A placebo-controlled 12-month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with Chronic Obstructive Pulmonary Disease (COPD). SD-039-0670. http://www.astrazenecaclinicaltrials.com/ (accessed 12 December 2012).

Borgstrom L, Asking L, Olsson H, Peterson S. Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando, C22 Poster 505.

* Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. *European Respiratory Journal* 2003;**22**(6):912–9. [: 0903–1936]

Calverley PM, Szafranski W, Anderson JA. Budesonide/ formoterol is a well-tolerated long term maintenance therapy for COPD [Abstract]. *European Respiratory Journal* 2005;**26**(Suppl 49):Abstract No. 1917.

Calverley PMA, Cseke Z, Peterson S. Budesonide/ formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. *European Respiratory Journal* 2003;**22(Suppl 45)**:Abstract No. P436.

Calverley PMA, Kuna P, Olsson H. COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. *European Respiratory Journal* 2003;**22(Suppl 45)**:Abstract No. P1587.

Calverley PMA, Olsson H, Symbicort International CSG. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle, B024 Poster 418. Calverley PMA, Peterson S. Combining budesonide/ formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle, D092 Poster 211.

Calverley PMA, Sthal E, Jones PW. Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego, B93 Poster 303. Calverley PMA, Thompson NC, Olsson H. Budesonide/ formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. *European Respiratory Journal* 2003;**22(Suppl 45)**:Abstract No. P435. Halpin D, Stahl E, Lundback B, Anderson F, Peterson S. Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando, D22 Poster 525. Halpin DMG, Larsson T, Calverley PMA. How many patients with COPD must be treated with budesonide/ formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego, B93 Poster 314.

Jones PW, Stahl E. Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. *European Respiratory Journal* 2005;**26(Suppl 49)**:Abstract No. 1352.

Jones PW, Stahl E. Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle, B024 Poster 419. Lofdahl CG. Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. *European Respiratory Review* 2004;**13**(88):14–21.

Lofdahl CG, Andreasson E, Svensson K, Ericsson A. Budesonide/formoterol in a single inhaler improves overall health status in patients with COPD without increasing healthcare costs [abstract].. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle, A035 Poster D46.

Lofdahl CG, Andreassson E, Svensson K, Ericsson A. Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. *European Respiratory Journal* 2003;**22** (**Suppl 45**):Abstract No. P433.

Lofdahl CG, Ericsson A, Svensson K, Andreasson E. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. *Pharmacoeconomics* 2005;**23**(4):365–75. [: 1170–7690]

Calverley 2003b [TRISTAN] {published data only}

Calverley P, Pauwels R, Vestbo J. Erratum: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 2003;**361**(9369):449–56. [: 0140–6736] * Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al.Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 2003;**361**(9356): 449–56. [: 0140–6736]

Calverley P, Pauwels RA, Jones PW, Anderson JA, Vestbos J. The severity of airways obstruction as a determinant of treatment response in COPD. *International Journal of COPD* 2006;1(3):209–18.

Calverley PMA, Pauwels R, Vestbo J, Jones P, Pride NB, Gulsvik A, et al.Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year [abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1572.

Calverley PMA, Pauwels RA, Vestbo J, Jones PW, Pride NB, Gulsvik A, et al.Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD. *American Journal of Respiratory and Critical Care Medicine* 2002;**165(Suppl 8)**:A226.

Ferguson G, Funck-Brentano C, Fischer T, Darken P, Troy

S, Compton C, et al.Cardiovascular safety of salmeterol in patients with COPD. *American Journal of Respiratory and Critical Care Medicine* 2002;**165(Suppl 8)**:A228. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. *Chest* 2003;**123**(6):1817–24.

GlaxoSmithKline. A multicentre, randomised, doubleblind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUSTM/ACCUHALERTM, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. SFCB3024. http://www.gskclinicalstudyregister.com/ (accessed 14 December 2012). Hunjan MK, Chandler F. Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando, D22 Poster 503. Hunjan MK, Williams DT. Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (seretide) and salmeterol [Abstract]. European Respiratory Journal 2004;24(Suppl 48):291s.

Hunjan MK, Williams DT. Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD [Abstract]. *European Respiratory Journal* 2004;**24(Suppl 48)**:513s.

Jones PW, Edin HM, Anderson J. Salmeterol/fluticasone propionate combination improves health status in COPD patients. *American Journal of Respiratory and Critical Care Medicine* 2002;**165(Suppl 8)**:A111.

Khamis RY, Rajakulasingam RK. Combined salmeterol and fluticasone for COPD. *Lancet* 2003;**361**(9369):1652; author reply 1652-3. [: 0140–6736]

Nitschmann S. Inhalational combination therapy in chronic obstructive lung disease: Tristan study. *Internist* 2004;**45** (6):727–8. [: 0020–9554]

Pauwels RA, Calverley PMA, Vestbo J, Jones P, Pride NB, Gulsvik A, et al.Reduction of exacerbations with salmeterol/ fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1569.

Pauwels RA, Vestbo J, Calverley PMA, Jones PW, Pride NB, Gulsvik A, et al.Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle, D092 Poster 215.

Spencer MD, Karia N, Anderson J. The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. *European Respiratory Journal* 2004;**24(Suppl 48)**:290s. Vestbo J, Calverley PMA, Pauwels R, Jones P, Pride NB, Gulsvik A, et al.Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease [abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1570.

Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. *Thorax* 2005;**60**(4): 301–4. [: 0040–6376]

Vestbo J, Pauwels RA, Calverley PMA, Jones PW, Pride NB, Gulsvik A, et al.Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle, A035 Poster D48. Vestbo J, Soriano JB, Anderson JA, Calverley P, Pauwels R, Jones P. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. *Respiratory Medicine* 2004;**98**(11):1045–50. [: 0954–6111]

Calverley 2007 [TORCH] {published data only}

Allegra L. TORCH study: an invitation to clinical considerations. *Giornale Italiano delle Malattie del Torace* 2007;**61**(1):15–23.

Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PMA, Jones PW, et al.Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. *European Respiratory Journal* 2010;**35**(3):532–9.

Calverley P, Celli B, Anderson J, Ferguson G, Jenkins C, Jones P, et al.Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: ontreatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15-20; San Diego, A6191 (Poster 219).

Calverley P, Celli B, Anderson JA, Ferguson GT, Jenkins C, Jones PW, et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. *Respirology* 2006;**11(Suppl 5)**:A149 [PS-3-8].

Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.Cardiovascular events in patients with COPD: TORCH study results. *Thorax* 2010;**65**(8): 719–25.

Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.. *New England Journal of Medicine* 2007;**356**(8):775–89. Calverley PM, Celli B, Anderson JA, Ferguson GT, Jenkins C, Jones PW, et al.The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years [Abstract]. *Chest* 2006;**130**(4):122s.

* Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.Salmeterol and fluticasone

propionate and survival in chronic obstructive pulmonary disease. *New England Journal of Medicine* 2007;**356**(8): 775–89.

Calverley PMA, Celli B, Andersen JA, Ferguson GT, Jenkins C, Jones PW, et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years [Abstract]. *European Respiratory Journal* 2006;**28** (**Suppl 50**):34s [E311].

Celli B, Calverley PM, Anderson JA, Ferguson GT, Jenkins C, Jones P, et al. The TOwards a Revolution in COPD Health (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]. *Respirology* 2006;**11(Suppl 5)**:A140 [O-9-2].

Celli B, Calverley PM, Anderson JA, Ferguson GT, Jenkins C, Jones PW, et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. *Chest* 2006;**130**(4):177s.

Celli B, Calverley PMA, Anderson JA, Ferguson GT, Jenkins C, Jones PW, et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. *European Respiratory Journal* 2006;**28(Suppl 50)**:34s [E312]. Celli B, Emmett A, Crater G, Kalberg C. Fluticasone

propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19-24; San Diego, A320 Poster 323.

Celli B, Ferguson GT, Anderson JA, Jenkins CR, Jones PW, Vestbo J, et al.Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco, A763.

Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PMA, et al.Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. *American Journal of Respiratory and Critical Care Medicine* 2011;**183** (3):317–22.

Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al.Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. *American Journal of Respiratory and Critical Care Medicine* 2008;**178**(4): 332–8.

Corhay JL, Louis R. Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health). [French]. *Revue Medicale de Liege* 2007;**62**(4):230–4. Ferguson GT, Calverley PM, Anderson JA, Celli B, Jenkins C, Jones PW, et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest 2006;130(4):178s.

Ferguson GT, Calverley PM, Anderson JA, Celli B, Jenkins CR, Jones PW, et al.Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco, A763.

Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Celli B, et al.Prevalence and progression of osteoporosis in patients with COPD: results from the Towards a Revolution in COPD health study. *Chest* 2009;**136**(6):1456–65. [: 0012–3692]

Ferguson GT, Calverley PMA, Anderson JA, Celli B, Jenkins C, Jones PW, et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. *European Respiratory Journal* 2006;**28(Suppl 50)**:34s. GlaxoSmithKline. A multi-centre, randomised, doubleblind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. SCO30003. http://www.gsk-clinicalstudyregister.com/ (accessed 10 December 2012).

Glick H, Briggs A, Lozano-Ortega G, Spencer M, Vestbo J, Calverley P. Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco, C97. Jenkins C, Celli B, Anderson J, Ferguson G, Calverley P, Jones P, et al.Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15-20; San Diego, A6186 Poster 213.

Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, et al.Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal 2012;39(1):38-45. Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi-national study [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco, C97. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al.Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebocontrolled TORCH study. Respiratory Research 2009;10:59. Jones PW, Anderson JA, Calverley PM, Celli BR, Ferguson GT, Jenkins C, et al.Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research 2011;12:71. Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson

GT, Jenkins C, et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/ salmeterol improves and sustains health status in COPD over 3 years [Abstract]. *Chest* 2006;**130**(4):177s.

Jones PW, Vestbo J, Anderson JA, Celli B, Ferguson GT, Jenkins CR, et al.Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco, C97.

Keene ON, Vestbo J, Anderson JA, Calverley PMA, Celli B, Ferguson GT, et al.Methods for therapeutic trials in COPD: lessons from the TORCH trial. *European Respiratory Journal* 2009;**34**(5):1018–23.

McDonough C, Blanchard AR. TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. *Hospital Practice* (1995) 2010;**38**(2):92–3.

McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA, Committee TCE. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. *Thorax* 2007;**62**(5):411–5.

Mehta RS, Kathman SJ, Daley-Yates PT, Cahn T, Beerahee M, Kunka RL, et al.Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco, Poster A41.

Sacchetta A. Long term therapy and outcome of chronic obstructive pulmonary disease with or without co-morbidity: the TORCH study. *Italian Journal of Medicine* 2008;**2**(3):11–5.

Vestbo J, Anderson JA, Calverley PMA, Celli B, Ferguson GT, Jenkins C, et al.Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. *Clinical Respiratory Journal* 2011;**5**(1):44–9. Vestbo J, Calverley P, Celli B, Ferguson G, Jenkins C, Jones P, et al.The TORCH (TOwards a Revolution in COPD Health) survival study protocol. *European Respiratory Journal* 2004;**24**(2):206–10. [: 0903–1936]

Campbell 2005 {published data only}

AstraZeneca. A 6-month study to compare the efficacy and safety of 9microg formoterol (Oxis) Turbuhaler b.i.d. with placebo b.i.d. in patients with Chronic Obstructive Pulmonary Disease (COPD). Furthermore to compare formoterol 4.5microg as needed with terbutaline 0.5 mg as needed. SD-037-0709. http:// www.astrazenecaclinicaltrials.com/ (accessed 12 December 2012).

Bogdan M, Eliraz A, McKinnon C, Nihlen U, Radeczky E, Soliman S, et al.Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility [abstract]. European Respiratory Society Annual Congress. 2002 Sep 14–18:

P1578.

* Campbell M, Eliraz A, Johansson G, Tornling G, Nihlen U, Bengtsson T, et al.Formoterol for maintenance and asneeded treatment of chronic obstructive pulmonary disease. *Respiratory Medicine* 2005;**99**(12):1511–20.

Campbell M, Rabe KF, Andersson A. Formoterol turbuhaler for maintenance and as-needed use is effective and well tolerated in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle, B024 Poster 417.

Eliraz A, Bengtsson T, Bogdan M, Coenen PDM, Johanson G, Osmanilev D, et al.Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) [abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1580.

Dahl 2001 {published data only}

Dahl R, Greefhorst AP, Byrne AM. Onset of inhaled formoterol compared to ipratropium bromide in patients with COPD. *European Respiratory Journal* 2000;**16(Suppl 31**):5s.

Dahl R, Greefhorst APM, Nowak D, Nonikov V, Byrne A, Colacchio C, et al.Comparison of the efficacy and safety of inhaled formoterol and ipratropium bromide in patients with COPD. *American Journal of Respiratory and Critical Care Medicine* 2000;**161(Suppl 3)**:A489.

Dahl R, Greefhorst APM, Thomson MH, Till D. Formoterol (Foradil[®]) improves lung function and quality of life (QOL) parameters in patients with reversible or poorly reversible COPD. *American Journal of Respiratory and Critical Care Medicine* 2001;**163(Suppl 5)**:A280.

* Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, et al.Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*. 2001;**164**(5):778–84. [: 1073–449X] Dahl R, Kristufek P, Greefhorst APM, Amgott TR, Della Cioppa G, Thompson MH. The cardiac safety profile of formoterol dry powder is similar to placebo in patients with

COPD. European Respiratory Journal 2000;16(Suppl 31): 51s.

Greefhorst APM, Dahl R, Nowak D, Nonikov V, Byrne A, Colacchio C, et al.Effect of inhaled formoterol and ipratropium bromide on quality of life, "bad days" and exacerbations in patients with COPD. *American Journal of Respiratory and Critical Care Medicine* 2000;**161(Suppl 3)**: A490.

Greefhorst APM, Dahl R, Nowak D, Nonikov V, Colacchio C, Byme AM. Formoterol dry powder improves the quality of life of patients with COPD whereas the effect of ipratropium bromide is similar to placebo. *European Respiratory Journal* 2000;**16(Suppl 31)**:51s. Greefhorst APM, Thomson MH, Byrne A, Till D. The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use. *European Respiratory*

Journal 2001;18(Suppl 33):515s.

Hogan TJ, Geddes R, Gonzalez ER. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. *Clinical Therapeutics* 2003;**25**(1):285–97. [: 0149–2918]

Dahl 2010 {published data only}

* Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al.Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. *Thorax* 2010;**65**(6):473–9.

Dahl R, Kolman P, Jack D, Bleasdale P, Owen R, Higgins M, et al.Bronchodilator therapy with indacaterol oncedaily in COPD: a 52-week comparison with formoterol [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna, E4350.

Jones PW, Mahler DA, Gale R, Owen R, Kramer B. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. *Respiratory Medicine* 2011; **105**(6):892–9.

Magnussen H, Paggiaro P, Jack D, Owen R, Higgins M, Kramer B, et al.Bronchodilator treatment with indacaterol once-daily vs formoterol twice-daily in COPD: a 52-week study [Abstract]. American Thoracic Society International Conference; 2009 May 15-20; San Diego, A6184 Poster 211.

Nonikov V, Verkindre C, Jack D, Bleasdale P, Owen R, Kramer B, et al.Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna, P2024.

Doherty 2012 {published data only}

Doherty D, Tashkin D, Kerwin E, Eduardo Matiz-Bueno C, Shekar T, Banerjee S, et al.Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26-week trials [Abstract]. *Chest* 2011; **140**(4):535A.

Doherty DE, Kerwin E, Tashkin DP, Matiz-Bueno CE, Shekar T, Banerjee S, et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. *Journal of Allergy and Clinical Immunology* 2012;**129(Suppl 2)**:AB75 [283]. [: 0091–6749]

* Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, et al.Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52week phase III trial in subjects with moderate-to-very severe COPD. *International Journal of COPD* 2012;7:57–71.

Kerwin E, Tashkin D, Matiz-Bueno CE, Doherty D, Shekar T, Banerjee S, et al.Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. *Chest*

2011;140(4):558A.

Matiz-Bueno CE, Doherty D, Kerwin E, Tashkin D, Shekar T, Banerjee S, et al. The long-term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1-year multicenter clinical trials [Abstract]. Chest 2011;140(4):548A. Tashkin D, Doherty D, Kerwin E, Matiz-Bueno CE, Shekar T, Banerjee S, et al. The effect of mometasone furoate/ formoterol combination therapy on chronic pbstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. Chest 2011;140(4):549A. Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, et al.Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. International Journal of COPD 2012:7:73-86.

Hanania 2003 {published data only}

Ferguson G, Funck-Brentano C, Fischer T, Darken P, Troy S, Compton C, et al.Cardiovascular safety of salmeterol in patients with COPD. *American Journal of Respiratory and Critical Care Medicine* 2002;**165(Suppl 8)**:A228. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. *Chest* 2003;**123**(6):1817–24.

GlaxoSmithKline. A randomized, double-blind, placebocontrolled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/ fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. SFCA3007. http:/ /www.gsk-clinicalstudyregister.com/ (accessed 14 December 2012).

* Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. *Chest* 2003;**124**(3):834–43.

Hanania NA, Knobil K, Watkins M, Wire P, Yates J, Darken P. Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD. [Abstract]. Chest; 2002 Nov 2-7; San Diego, S129. Hanania NA, Ramsdell J, Payne K, Davis S, Horstman D, Lee B, et al.Improvements in airflow & dyspnea in COPD patients following 24 weeks treatment with salmeterol 50µg & fluticasone propionate 250µg alone or in combination via the diskus®. American Journal of Respiratory and Critical Care Medicine 2001;163(Suppl 5):A279. Horstman D, Darken P, Davis S, Lee B. Improvements in

FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. *European*

Respiratory Journal 2003;**22(Suppl 45)**:Abstract No. P434. Knobil K, Yates J, Horstman D, Darken P, Wire P. Combination of fluticasone and salmeterol (Advair Diskus®) improves cough in patients with chronic obstructive pulmonary disease [Abstract]. Chest; 2002 Nov 2-7; San Diego, P288.

Mahler DA, Darken P, Brown CP, Knobil K. Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; 2003 Nov 14-15; Virginia, Abstract 1081.

Mahler DA, Darken P, Brown CP, Knobil K. Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. *European Respiratory Journal* 2003;**22(Suppl 45)**:Abstract P429. Spencer M, Wire P, Lee B, Chang C, Darken P, Hortsman D. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. *European Respiratory Journal* 2003; **22(Suppl 45)**:Abstract P438.

Spencer MD, Karia N, Anderson J. The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. *European Respiratory Journal* 2004;**24(Suppl 48)**:290s.

Hanrahan 2008 {published data only}

Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA,
Sciarappa K, Hanrahan JP. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and activecontrolled trial. *Clinical Therapeutics* 2007;**29**(2):261–78.
Grogan DR, Hanrahan JP, Morganroth J, Cheng H, Baumgartner RA. Arrythmias in COPD: Holter monitoring results from 2 arformoterol pivotal trials [Abstract].
American Thoracic Society International Conference; 2007 May 18-23; San Francisco, Poster 413.
Hanrahan JP, Grogan DR, Baumgartner RA, Wilson A,

Cheng H, Zimetbaum PJ, et al.Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled longacting beta2-agonists arformoterol and salmeterol. *Medicine* 2008;**87**(6):319–28.

* Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. *Journal of Chronic Obstructive Pulmonary Disease* 2008;5(1):25–34.

Hanrahan JP, Kerwin E, Cheng H, Grogan DR, Baumgartner RA. Arformoterol in COPD safety results from two pooled phase 3 trials [Abstract]. *European Respiratory Journal* 2006;**28(Suppl 50)**:428s [P2500]. Hanrahan JP, Sahn SA, Busse WW, Sciarappa K, Baumgartner RA. Efficacy of nebulized arformoterol: a long acting B2 adrenergic bronchodilator in patients with COPD [abstract]. *European Respiratory Journal* 2006;**28** (**Suppl 50**):215s [P1276].

Hanrahan JP, Sahn SA, Fogarty CM, Sciarappa K, Baumgartner RA. Efficacy and safety of arformoterol in

COPD: a prospective phase 3 clinical trial [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19-24; San Diego, A847 Poster 509.

Hanrahan JP, Smith WB, Sciarappa K, McVicar WK, Baumgartner RA. Efficacy and safety of nebulized arformoterol in COPD: a prospective, phase III clinical trial [Abstract]. *Chest* 2006;**130**(4):181s.

Sciurba FC, Baumgartner RA, Sciarappa K, Benzo RP, Hanrahan JP. Degree of exercise limitation in COPD impact on 6 minute walk in response to long acting b agonist (LABA) treatment [Abstract]. *European Respiratory Journal* 2007;**30**(**Suppl 51**):76s [P596].

Sepracor. A double-blind, double-dummy, randomized, placebo- and active-controlled, multicenter, parallel group study of (R,R)-formoterol in the treatment of subjects with chronic obstructive pulmonary disease. NCT00064402 and NCT00064415. www.clinicaltrials.gov (accessed 20 November 2012).

Kornmann 2011 {published data only}

* Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al.Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. *European Respiratory Journal* 2011;**37**(2):273–9. Kornmann O, Luthra A, Owen R, Lassen C, Kramer B. Once-daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive COPD: a 26-week placebo-controlled study. *Chest* 2009;**136**(4): 152S.

Mahler 1999 {published data only}

Ferguson G, Funck-Brentano C, Fischer T, Darken P, Troy S, Compton C, et al.Cardiovascular safety of salmeterol in patients with COPD. *American Journal of Respiratory and Critical Care Medicine* 2002;**165(Suppl 8)**:A228. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. *Chest* 2003;**123**(6):1817–24.

GlaxoSmithKline. A randomized, double-blind, doubledummy, comparative clinical trial of 12-week courses of salmeterol xinafoate versus ipratropium bromide versus placebo (PRN Ventolin) in subjects with chronic obstructive pulmonary disease. SLGA4005. www.gskclinicalstudyregister.com (accessed 20 December 2012). * Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al.Efficacy of salmeterol xinafoate in the treatment of COPD. *Chest* 1999;**115**(4): 957–65.

Mahler 2002 {published data only}

Ferguson G, Funck-Brentano C, Fischer T, Darken P, Troy S, Compton C, et al.Cardiovascular safety of salmeterol in patients with COPD. *American Journal of Respiratory and Critical Care Medicine* 2002;**165(Suppl 8)**:A228. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. *Chest* 2003;**123**(6):1817–24.

GlaxoSmithKline. A randomized, double-blind, placebocontrolled, parallel-group trial evaluating the safety and

efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/ fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. SFCA3006. www.gsk-clinicalstudyregister.com (accessed 10 December 2012).

Littner M, Yates J, Fischer T, Horstman D, Wire P. Improvements in FEV1 and symptoms in poorly-reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the DiskusTM inhaler. *European Respiratory Journal* 2001;**18(Suppl 33)**:176s.

* Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al.Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 2002;**166**(8):1084–91. [: 1073–449X]

Mahler DA, Wong E, Giessel G, Clifford D, Chang C, Yates J, et al.Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/ fluticasone propionate 500 combination. *American Journal of Respiratory and Critical Care Medicine* 2001;**163(Suppl 5)**:A279.

Spencer M, Wire P, Lee B, Chang C, Darken P, Hortsman D. Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life [Abstract]. *European Respiratory Journal* 2003; **22(Suppl 45)**:Abstract P438.

Spencer MD, Anderson JA. Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society International Conference; 2005 May 20-25; San Diego, B93 Poster 308.

Spencer MD, Karia N, Anderson J. The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD [Abstract]. *European Respiratory Journal* 2004;**24(Suppl 48)**:290s.

Nelson 2007 {published data only}

Gross NJ, Lapidus R, Dunn LJ, Lynn LD, Denis-Mize K, Rinehart M. Nebulized formoterol is an effective bronchodilator and improves the quality of life for COPD patients [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco, Poster A10.

Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. *Respiratory Medicine* 2008;**102**(2):189–97.

Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K, et al.Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. *Clinical Therapeutics* 2007;**29**(10): 2167–78.

* Nelson HS, Gross NJ, Rinehart M, Denis-Mize K.

Cardiovascular safety of nebulized formoterol in COPD patients: a double-blind, placebo-controlled study. *Chest* 2007;**132**(4):529b–530.

Nelson HS, ZuWallack R, Levine B, Kerwin EM, Denis-Mize K, Rinehart M. Safety profile of formoterol fumarate delivered by nebulization to COPD patients [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco, Poster A11.

Rennard 2001 {published data only}

Ferguson G, Funck-Brentano C, Fischer T, Darken P, Troy S, Compton C, et al.Cardiovascular safety of salmeterol in patients with COPD. *American Journal of Respiratory and Critical Care Medicine* 2002;**165(Suppl 8)**:A228. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. *Chest* 2003;**123**(6):1817–24.

GlaxoSmithKline. A randomized, double-blind, doubledummy, comparative clinical trial of 12-week courses of salmeterol xinafoate versus ipratropium bromide versus placebo (PRN Ventolin[®]) in subjects with chronic obstructive pulmonary disease. SLGA4004. www.gskclinicalstudyregister.com (accessed 7 December 2012).

* Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 2001;**163** (5):1087–92.

Rennard 2009 {published data only}

Bleecker ER, Meyers DA, Bailey WC, Sims AM, Bujac SR, Goldman M, et al.ADRB2 polymorphisms and budesonide/ formoterol responses in COPD. *Chest* 2012;**142**(2):320–8. [1931–3543: (Electronic)]

Celli BR, Tashkin DP, Rennard SI, McElhattan J, Martin UJ. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. *Respiratory Medicine* 2011;**105**(8):1176–88.

Laties A, Rennard SI, Tashkin DP, Suchower LJ, Martin UJ. Effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pMDI) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1-year, randomized, controlled clinical trial [Abstract]. *Chest* 2010;**138**(4):468A. Nelson HS, Tashkin DP, Rennard SI, Martin P, Goldman M, Silkoff PE. Onset of bronchodilation with budesonide and formoterol administered in one pressurized metereddose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. *Chest* 2008;**134** (4):105002s.

* Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, et al.Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. *Drugs* 2009;**69**(5): 549–65. [: 0012–6667] Rennard SI, Tashkin DP, McElhattan J, Goldman M, Silkoff

PE. Long-term tolerability of budesonide and formoterol administered in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. *Chest* 2008;**134**(4):103003s. Rennard SI, Tashkin DP, Suchower LJ, Martin UJ. Effect of budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1-year, randomized, controlled clinical trial [Abstract]. *Chest* 2010;**138**(4):863A.

Rossi 2002 {published data only}

Amgott TR, Kristufek P, Levine B, Byrne A, Till D. Effect of inhaled formoterol and oral slow-release theophylline on peak expiratory flow and symptoms in patients with COPD. *American Journal of Respiratory and Critical Care Medicine* 2000;**161(Suppl 3)**:A582.

Kristufek P, Amgott TR, Levine B, Byrne A, Colacchio C. Comparison of the efficacy and safety of inhaled formoterol dry powder and oral slow-release theophylline in patients with COPD. *American Journal of Respiratory and Critical Care Medicine* 2000;**161(Suppl 3)**:A489.

Kristufek P, Levine B, Della Cioppa G, Byrne A, Till D. Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use. *European Respiratory Journal* 2001;**18(Suppl 33)**:514s.

Kristufek P, Levine B, Till D, Byrne A. Inhaled formoterol (Foradil[®]) improves lung function in patients with both reversible and poorly reversible COPD. *American Journal of Respiratory and Critical Care Medicine* 2001;**163(Suppl 5)**: A280.

* Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, et al.Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. *Chest* 2002;**121** (4):1058–69. [: 0012–3692]

SLMF4010 2005 {published data only}

* GlaxoSmithKline. Multicentre, randomised, parallel group, placebo-controlled, double-blind study, stratified on tobacco status at enrolment, evaluating during 6 months the efficacy of salmeterol powder for inhalation, 50µg two times per day for the reduction of thoracic distension in subjects with chronic obstructive pulmonary disease (COPD). SLMF4010. www.gsk-clinicalstudyregister.com (accessed 9 December 2012).

Szafranski 2003 {published data only}

Anderson P. Budesonide/formoterol in a single inhaler (Symbicort[®]) provides early and sustained improvement in lung function in moderate to severe COPD. *Thorax* 2002; **57(Suppl 3)**:iii43.

AstraZeneca SD. A placebo-controlled 12 month efficacy study of the fixed combination budesonide/ formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). SD-039-CR-0629. http:// www.astrazenecaclinicaltrials.com/ (accessed 25 November 2012).

Borgstrom L, Asking L, Olsson H, Peterson S. Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando, C22 Poster 505. Calverley P, Pauwels Dagger R, Lofdahl CG, Svensson K, Higenbottam T, Carlsson LG, et al.Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. *European Respiratory Journal* 2005; **26**(3):406–13. [: 0903–1936]

Calverley PM, Szafranski W, Andersson. Budesonide/ formoterol is a well-tolerated long term maintenance therapy for COPD [Abstract]. *European Respiratory Journal* 2005;**26(Suppl 49)**:Abstract 1917.

Calverley PMA. Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. *Thorax* 2002;**57(Suppl 3)**:iii44.

Calverley PMA, Thompson NC, Olsson H. Budesonide/ formoterol in a single inhaler sustains lung function improvements in COPD[Abstract]. *European Respiratory Journal* 2003;22(Suppl 45):Abstract P435.

Campbell LM, Szafranski W. Budesonide/formoterol in a single inhaler (Symbicort[®]) provides sustained relief from symptoms in moderate to severe COPD. *Thorax* 2002;**57** (**Suppl 3**):iii43.

Dahl R, Cukier A, Olsson H. Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD [abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1575.

Egede F, Menga G. Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and nighttime awakenings in moderate to severe COPD: results from a 1-year study [abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1574.

Halpin D, Stahl E, Lundback B, Anderson F, Peterson S. Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando, D22 Poster 525. Jones PW, Stahl E, Svensson K. Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler [abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1613.

Korsgaard J, Sansores R. Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD [abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1577.

Lange P, Saenz C. Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study [abstract]. European Respiratory

Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1573.

Lofdahl CG. Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. *European Respiratory Review* 2004;**13**(88):14–21.

Milanowski J, Nahabedian S. Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD [abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1576.

* Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al.Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. *European Respiratory Journal* 2003;**21** (1):74–81. [: 0903–1936]

Szafranski W, Ramirez A, Peterson S. Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P2453.

Tashkin 2008 [SHINE] {published data only}

AstraZeneca. A 6-month double-blind, double-dummy, randomized, parallel group, multicenter efficacy & safety study of SYMBICORT[®] pMDI 2 x 160/4.5mg & 80/ 4.5mg bid compared to formoterol TBH, budesonide pMDI (& the combination) & placebo in COPD patients. D5899C00002. http://www.astrazenecaclinicaltrials.com/ (accessed23 November 2012).

Bleecker ER, Meyers DA, Bailey WC, Sims AM, Bujac SR, Goldman M, et al.Effect of β 2-adrenergic receptor gene polymorphism Gly16Arg on response to budesonide/ formoterol pressurized metered-dose inhaler in chronic obstructive pulmonary disease [Abstract]. *American Journal of Respiratory and Critical Care Medicine* 2011;**183**:A4086. Celli BR, Tashkin DP, Rennard SI, McElhattan J, Martin UJ. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. *Respiratory Medicine* 2011;**105**(8):1176–88.

Nelson HS, Tashkin DP, Rennard SI, Martin P, Goldman M, Silkoff PE. Onset of bronchodilation with budesonide and formoterol administered in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. *Chest* 2008;**134** (4):105002s.

Tashkin DP, Rennard SI, Martin P, Goldman M, Silkoff PE. Efficacy of budesonide/formoterol administered via one pressurized metered-dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. *Chest* 2008;**134**(4):105001s.

* Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, et al.Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6-month randomized clinical trial. *Drugs* 2008;**68**(14):1975–2000. [0012–6667: (Print)]

Tashkin 2012 {published data only}

Doherty D, Tashkin D, Kerwin E, Eduardo Matiz-Bueno C, Shekar T, Banerjee S, et al.Efficacy and safety of mometasone furoate/formoterol in subjects with moderate to very severe chronic obstructive pulmonary disease: results from two phase three 26-week trials [Abstract]. *Chest* 2011; **140**(4):535A.

Kerwin E, Tashkin D, Matiz-Bueno CE, Doherty D, Shekar T, Banerjee S, et al. Quality of life following 26 weeks of mometasone furoate/formoterol therapy: results from two phase three trials in subjects with moderate to very severe chronic obstructive pulmonary disease [Abstract]. *Chest* 2011;**140**(4):558A.

Matiz-Bueno CE, Doherty D, Kerwin E, Tashkin D, Shekar T, Banerjee S, et al. The long-term safety characteristics of mometasone furoate/formoterol for the treatment of moderate to very severe chronic obstructive pulmonary disease: pooled findings from two 1-year multicenter clinical trials [Abstract]. *Chest* 2011;**140**(4):548A.

Tashkin D, Doherty D, Kerwin E, Matiz-Bueno CE, Shekar T, Banerjee S, et al. The effect of mometasone furoate/ formoterol combination therapy on chronic obstructive pulmonary disease (COPD) exacerbations: results from two phase three trials in subjects with moderate to very severe COPD [Abstract]. *Chest* 2011;**140**(4):549A.

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, et al.Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. *International Journal of COPD* 2012;7:73–86.

* Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, et al.Efficacy and safety of a fixeddose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week phase III trial. *International Journal* of COPD 2012;7:43–55.

Vogelmeier 2008 {published data only}

Arievich H, Potena A, Fonay K, Vogelmeier CF, Overend T, Smith J, et al.Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. *European Respiratory Journal* 2006;**28(Suppl 50)**:440s [P2514].

* Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. *Respiratory Medicine* 2008;**102**(11):1511–20.

Vogelmeier CF, Harari SA, Fonay K, Beier J, Overend T, Till D, et al.Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. *European Respiratory Journal* 2006;28(Suppl 50):429s [P2506].

Wadbo 2002 {published data only}

* Wadbo M, Lofdahl CG, Larsson K, Skoogh BE, Tornling G, Arwestrom E, et al.Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study.

European Respiratory Journal 2002;**20**(5):1138–46. [: 0903–1936]

Watkins 2002 {published data only}

* Watkins M, Wire P, Yates J, Fischer T, Chang C, Horstman D, et al.Sustained Fev increases in COPD patients induced by Salmeterol 50 mcg twice daily via the diskus inhaler. *American Journal of Respiratory and Critical Care Medicine* 2002;**165(Suppl 8)**:A228.

References to studies excluded from this review

Boyd 1995 {published data only}

Boyd G, Crawford C. Salmeterol (SALM) for treatment of patients with chronic obstructive pulmonary disease (COPD). *European Respiratory Journal* 1995;**8(Suppl 19)**: 1675.

Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) [published erratum appears in European Respiratory Journal 1997 Jul; 10(7):1696]. *European Respiratory Journal* 1997;**10**(4): 815–21.

GlaxoSmithKline. A multicentre, randomised, doubleblind, parallel group study to compare the efficacy and safety of inhaled salmeterol xinafoate 50 microg bd and inhaled salmeterol xinafoate 100 microg bd with placebo, all administered via the metered-dose inhaler, in the treatment of patients with chronic obstructive pulmonary disease. www.gsk-clinicalstudyregister.com (accessed 11 December 2012).

Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. *American Journal of Respiratory and Critical Care Medicine* 1997;**155**(4):1283–9. Jones PW, Wilson K, Sondhi S. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: An economic evaluation. *Respiratory Medicine* 2003;**97**(1):20–6. [: 0954–6111]

Jones PW, Wilson KK, Sondhi S. Economic evaluation of salmeterol xinafoate in chronic obstructive pulmonary disease (COPD) demonstrating improved outcomes and health. *European Respiratory Journal* 2000;**16(Suppl 31)**: 56s.

Celli 2003 {published data only}

Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). *Respiratory Medicine* 2003;**97(Suppl A)**:S35–43. [: 0954–6111]

Chapman 2002 {published data only}

Chapman K, Kuipers AF, Goldstein R, James MH. The addition of salmeterol 50mcg bid to anticholinergic treatment in COPD [Abstract]. *American Journal of Respiratory and Critical Care Medicine* 1999;**159**(3):A523. Chapman KR, Arvidsson P, Chuchalin AG, Dhillon DP, Faurschou P, Goldstein RS, et al. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. *Canadian Respiratory Journal* 2002;**9**(3):178–85. [: 1198–2241] GlaxoSmithKline. A multi-centre, double-blind, parallel group study to evaluate the efficacy of SEREVENT 50 microg BID versus placebo BID all administered via the multi dose powder inhaler (DISKUS/ACCUHALER) in terms of symptoms in the treatment of patients with chronic obstructive pulmonary disease. www.gskclinicalstudyregister.com (accessed 15 December 2012).

Dal Negro 2003 {published data only}

Dal Negro R, Micheletto C, Trevisan F, Tognella S, Pomari C. Salmeterol & fluticasone 50 µg/250 µg bid vs salmeterol 50µg bid and vs placebo in the long-term treatment of COPD. *American Journal of Respiratory and Critical Care Medicine* 2002;**165(Suppl 8)**:A228.

Dal Negro RW, Pomari C, Tognella S, Micheletto C. Salmeterol & fluticasone 50 mug/250 mug bid in combination provides a better long-term control than salmeterol 50 mug bid alone and placebo in COPD patients already treated with theophylline. *Pulmonary Pharmacology and Therapeutics* 2003;**16**(4):241–6.

Rutten-van Molken 1999 {published data only}

GlaxoSmithKline. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. www.gskclinicalstudyregister.com (accessed 8 December 2012). Rutten-van Molken M, Roos B, Van Noord JA. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. *Thorax* 1999;**54**(11):995–1003.

Stahl E, Wadbo M, Bengtsson T, Strom K, Lofdahl CG. Health-related quality of life, symptoms, exercise capacity and lung function during treatment for moderate to severe COPD. *Journal of Outcomes Research* 2001;**5**:11–24. van Noord JA, de Munck D, Bantje TA, Hop WCJ, Bommer AM. Efficacy and safety of salmeterol (SLM) and ipratropium bromide (IPB) in patients with chronic obstructive pulmonary disease (COPD). *American Journal of Respiratory and Critical Care Medicine* 1998;**157**(**Suppl 3**):A799.

van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. *European Respiratory Journal* 2000;**15**(5):878–85.

Steffensen 1996 {published data only}

Steffensen I, Faurschou P, Riska H, Rostrup J, Wegener T. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. *Allergy* 1995;**50**(8):657–63. [0105–4538: (Print)]

Steffensen IE, Faurschou P. Formoterol as inhalation powder in the treatment of patients with reversible obstructive lung diseases. A 3-month placebo-controlled comparison of the

effects of formoterol and salbutamol, followed by a 12month period with formoterol alone. *Ugeskr-Laeger* 1996; **158**(49):7092–6.

Stockley 2006 {published data only}

GlaxoSmithKline. A multi-centre, randomised, doubleblind, placebo-controlled, parallel-group study to investigate the effect of 12 months treatment with salmeterol (50mcg bd), delivered via the DISKUS* inhaler, on the incidence of moderate and severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD) when added to their usual treatment regimen. www.gsk-clinicalstudyregister.com (accessed 8 December 2012).

Stockley R, Davis EA, Sondhi S, Rice L. [Salmeterol provides sustained health status improvement over 12 months in patients with COPD [abstract]]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1567.

Stockley R, Rice L, Chopra N. [Salmeterol added to usual therapy gives a rapid improvement in lung function that is sustained at 6 and 12 months in patients with COPD [abstract]]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle, A035 Poster D71. Stockley R, Rice L, Chopra N. [Salmeterol added to usual therapy significantly reduces the frequency of moderate/ severe exacerbations in patients with COPD [abstract]]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle, A108 Poster C51. Stockley RA, Chopra N. [Salmeterol, added to usual therapy, is an effective bronchodilator over 12 months of treatment in chronic obstructive pulmonary disease (COPD) [abstract]]. European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Abstract P1568. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006;61(2):122-8.

References to studies awaiting assessment

Fattore 2005 {published data only}

Fattore G, Torbica A, Mangone M. Cost-analysis of four treatment strategies in the management of moderate-to-severe COPD: an application of non-parametric bootstrap. [Italian]. Pharmacoeconomics Italian Research Articles 2005; Vol. 7, issue 2:135–43. [: 1590–9158]

References to ongoing studies

NCT01437397 {unpublished data only}

NCT01437397. Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov (accessed 30 July 2013).

NCT01572792 {unpublished data only}

NCT01572792. Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28-weeks treatment in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov (accessed 30 July 2013).

Additional references

Appleton 2006

Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MMK, et al.Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. *Cochrane Database* of *Systematic Reviews* 2006, Issue 3. [DOI: 10.1002/ 14651858.CD001104.pub2]

AstraZeneca

AstraZeneca. AstraZeneca clinical trials. http:// www.astrazenecaclinicaltrials.com/ (accessed 15 November 2012).

ATS/ERS 2011

Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al.Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. *Annals of Internal Medicine* 2011;**155**(3):179–91.

Beeh 2010

Beeh KM, Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. *Advances in Therapy* 2010; **27**(3):150–9.

Berger 2008

Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. *Respiratory Medicine* 2008;**102**(2):173–88.

BNF 2009

British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. *British National Formulary.* 8th Edition. UK: BMJ Publishing Group, 2009.

Calverley 2003

Calverley PMA, Spencer S, Willits L, Burge S, Jones P. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. *Chest* 2003;**124**:1350–6.

Cheyne 2012

Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2012, Issue 1. [DOI: 10.1002/14651858.CD009552]

Chong 2011

Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2011, Issue 5. [DOI: 10.1002/14651858.CD002309.pub3]

Chong 2012

Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2]

Effing 2007

Effing T, Monninkhof EEM, van der Valk PPDLPM, Zielhuis GGA, Walters EH, van der Palen JJ, et al.Selfmanagement education for patients with chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2007, Issue 4. [DOI: 10.1002/ 14651858.CD002990.pub2]

Geake 2012

Geake JB, Dabscheck EJ, Wood-Baker R. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta-agonists or placebo for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2012, Issue 10. [DOI: 10.1002/14651858.CD010139]

GlaxoSmithKline

GlaxoSmithKline. GSK clinical study register. http:// www.gsk-clinicalstudyregister.com/ (accessed 15 November 2012).

GOLD 2013

Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http:// www.goldcopd.com (accessed 9/10/13).

Higgins 2009

Higgins JPT, Green S, editors. *Cochrane Handbook* for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, www.cochrane-handbook.org, 2009.

Hutchinson 2010

Hutchinson A, Brand C, Irving L, Roberts C, Thompson P, Campbell D. Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. *Internal Medicine Journal* 2010; **40**(5):364–71.

Karner 2011

Karner C, Cates CJ. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2011, Issue 9. [DOI: 10.1002/14651858.CD009039.pub2]

Karner 2011a

Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2011, Issue 3. [DOI: 10.1002/ 14651858.CD008532.pub2]

Karner 2012

Karner C, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2agonist alone for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2012, Issue 4. [DOI: 10.1002/14651858.CD008989.pub2]

Karner 2012a

Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. *Cochrane Database* of *Systematic Reviews* 2012, Issue 7. [DOI: 10.1002/ 14651858.CD009285.pub2]

Karner 2012b

Karner C, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2012, Issue 9. [DOI: 10.1002/14651858.CD010115]

Kliber 2010

Kliber A, Lynd LD, Sin DD. The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. *Respiratory Research* 2010;**11**(1):56–69.

Lacasse 2006

Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2006, Issue 4. [DOI: 10.1002/14651858.CD003793.pub2]

Nannini 2010

Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2010, Issue 1. [DOI: 10.1002/14651858.CD006826]

Nannini 2010a

Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2010, Issue 1. [DOI: 10.1002/14651858.CD003794.pub3]

Nannini 2012

Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus longacting beta2-agonists for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2]

NICE 2010

National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, Costing report, Implementing NICE guidance. http:// guidance.nice.org.uk/CG101/CostingReport/pdf/English (accessed 17 December 2012).

NICE 2011

National Institute for Health and Clinical Excellence. CG101 Chronic obstructive pulmonary disease (update): NICE guideline. http://guidance.nice.org.uk/CG101/ NICEGuidance/pdf/English (accessed 17 November 2012).

Puhan 2011

Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2011, Issue 10. [DOI: 10.1002/14651858.CD005305.pub3]

Rodrigo 2008

Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting β -agonists in stable COPD: a systematic review. *Chest* 2008;**133**(5):1079–87.

Song 2010

Song F, Parekh S, Hooper L, Loke Y, Ryder J, Sutton A, et al.Dissemination and publication of research findings: an updated review of related biases. *Health Technology Assessment* 2010;**iii, ix-xi**:1–193. [DOI: 10.3310/ hta14080]

Spencer 2011

Spencer S, Karner C, Cates CJ, Evans DJ. Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease. *Cochrane Database* of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/ 14651858.CD007033.pub3]

Stockley 2006a

Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. *Respiratory Research* 2006;7:147. [1465–993X: (Electronic)]

van der Meer 2001

van der Meer RM, Wagena E, Ostelo RWJG, Jacobs AJE,

van Schayck OP. Smoking cessation for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2001, Issue 1. [DOI: 10.1002/14651858.CD002999]

Wang 2012

Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting betaagonists on the frequency of COPD exacerbations: a metaanalysis. *Journal of Clinical Pharmacy and Therapeutics* 2012;**37**(2):204–11. [1365–2710: (Electronic)]

Welsh 2011

Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. *Cochrane Database* of *Systematic Reviews* 2011, Issue 7. [DOI: 10.1002/ 14651858.CD007891.pub2]

wно

World Health Organization. Chronic respiratory diseases. www.who.int (accessed 20 November 2012).

Yang 2012

Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Aalbers 2002

Methods	 Design: randomised, multi-centre, double-blind, parallel-group study Duration: 3 months (+ 2 weeks run-in period) Location: The study took place in 86 centres in nine countries (Australia, Belgium, Denmark, Germany, Hungary, The Netherlands, Norway, Poland and UK) 	
Participants	Population : 516 participants were randomly assigned to formoterol 12 μ g twice daily (166), formoterol 24 μ g twice daily (177) and placebo (173) Baseline characteristics : Mean age (years): formoterol 12 μ g, 63.3; formoterol 24 μ g, 61.9; placebo, 61.8 % Male: formoterol 12 μ g, 71.7; formoterol 24 μ g, 69.5; placebo, 65.3 % Reversibility: formoterol 12 μ g, 5.8; formoterol 24 μ g, 6.5; placebo, 6.7 % FEV ₁ predicted: formoterol 12 μ g, 54.5; formoterol 24 μ g, 54.7; placebo, 53.8 Inclusion criteria : male or female current or former smokers with a history of at least 10 pack-years and a clinical diagnosis of COPD Prebronchodilator FEV ₁ had to be > 0.7 L and 40% to 70% of predicted, FEV ₁ /forced vital capacity (FVC) ratio < 89% pred normal for females and < 88% for males and the total symptom score had to be 2 or greater on at least 7 days of the run-in period Exclusion criteria : history of asthma or seasonal rhinitis before age 40; current respira- tory tract disorder other than COPD; significant or unstable heart disease; other signif- icant gastro, hepatic, renal or endocrine disease	
Interventions	 Formoterol 12 μg twice daily Formoterol 24 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: terbutaline (0.5 mg), prednisolone (10 mg), methylprednisolone (8 mg) and betamethasone (1 mg) were allowed during the study period. Excluded medications included inhaled and oral beta ₂ -agonists, inhaled anticholinergics, xanthine derivatives, leukotriene antagonists, ephedrine and parenteral glucocorticosteroids	
Outcomes	Lung function: FEV ₁ , FVC and dyspnoea (TDI) Adverse events: non-fatal serious adverse events Other: withdrawal, symptom scores and % of symptom-free days, shuttle walking test, use of relief medication	
Notes	Funding : AstraZeneca Study number : unknown Definitions : none (exacerbations not reported)	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Random sequence generation (selection bias)	Low risk	Participants were randomly assigned to the four treatments in balanced blocks using a computer-generated schedule after com- pleting the run-in period
Allocation concealment (selection bias)	Low risk	Individually sealed treatment codes indi- cating the allocated treatment for each par- ticipant were available at each clinic for emergency situations
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind study-all inhalers used in the study were of identical appearance, and active and placebo inhalers were indistin- guishable in taste
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment were found
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawal rates were similar and below 20% in each group (formoterol 12 μ g 18. 1%, formoterol 24 μ g 15.3%, placebo 15. 6%)
Selective reporting (reporting bias)	High risk	Results for all specified outcomes were re- ported, but key outcomes expected for COPD were omitted (HRQoL, exacerba- tions, mortality)

Bogdan 2011

Methods	Design : randomised, double-blind, placebo-controlled, parallel-group, multinational phase III study Duration : 3 months (+ 2 weeks run-in period) Location : 65 centres in Japan, Romania, Russia and Ukraine
Participants	Population : 407 participants were randomly assigned to formoterol 12 μ g twice daily (199) and placebo (208) Baseline characteristics : Mean age (years): formoterol 12 μ g, 66.7; formoterol 24 μ g, 67.2; placebo, 66.3 % Male: formoterol 12 μ g, 85.4; placebo, 89.4 % White: formoterol 12 μ g, 45.7; placebo, 47.1 % Reversibility: formoterol 12 μ g, 46.5; placebo, 47.4 % FEV ₁ predicted: 50.4; formoterol 12 μ g, 51.5; placebo, 52.5 Inclusion criteria : > 40 years old; clinical diagnosis of COPD (postbronchodilator FEV ₁ < 80% predicted, and postbronchodilator FEV ₁ /FVC < 70%); history of at least 10 pack-years; symptom score of at least 2 points on at least 6 of the last 10 days of the run-

Bogdan 2011 (Continued)

	in period Exclusion criteria : history of asthma; history of clinical diagnosis of atopic disease such as allergic rhinitis; significant or unstable ischaemic heart disease or other cardiovascular conditions, other respiratory tract disorders or significant disease
Interventions	 Formoterol 12 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: salbutamol (100 μg pMDI) and short-acting anticholinergics were allowed as rescue medication. Excluded medication included long-acting anticholinergics and glucocorticoid treatment (including inhaled corticosteroids)
Outcomes	 HRQoL: St George's Respiratory Questionnaire (SGRQ) COPD exacerbations: number requiring hospitalisation and/or a course of antibiotics and/or systemic steroid therapy Lung function: change (ratio) from baseline to end of treatment period in FEV1 60 minutes postdose, FVC 60 minutes postdose, FEV1 and FVC predose and 5 minutes postdose Adverse events: all-cause mortality and non-fatal serious adverse events Other: withdrawal, use of salbutamol as reliever medication (measured as inhalations/ day), COPD symptom scores (night-time awakenings due to symptoms, breathlessness and cough)
Notes	Funding : AstraZeneca Study number : AstraZeneca ID D5122C00001; registration NCT00628862 Definitions : Exacerbations were defined as requiring hospitalisation and/or a course of antibiotics and/or systemic steroid therapy

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned to treatment. No details of sequence gener- ation methods but assumed to adhere to usual AstraZeneca methods
Allocation concealment (selection bias)	Unclear risk	No details reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Trial registration states masking was dou- ble-blind for subject, caregiver and investi- gator
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment

Bogdan 2011 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Dropout was uneven but relatively low in all groups (formoterol 12, 8.5%; placebo, 10.6%)
Selective reporting (reporting bias)	Low risk	Checked paper against protocol. Results for all specified outcomes were reported and could be included
Brusasco 2003		
Methods	 Design: pooled results from two randomised, double-blind, double-dummy, parallel-group design studies Duration: 6 months (+ 2 weeks run-in period) Location: The studies were performed in 18 countries The only difference in the two studies was the duration of serial spirometry in the clinic (12 hours in one study, 3 hours in the second) 	
Participants	 (405) and placebo (400) Baseline characteristics: Mean age (years): salmeterol, 64.1; placebo % Male: salmeterol, 75.1; placebo, 76.3 Pack-years: salmeterol, 44.8; placebo, 42.4 % FEV₁ predicted: salmeterol, 37.7; placebo Inclusion criteria: Participants were require with FEV₁ < 65% of predicted normal and smoking history of > 10 pack-years Exclusion criteria: Patients with a history an increased total eosinophil count were use of supplemental oxygen or an upper before screening. Patients with a significant Significant disease was defined as a disease total eosinophil count were significant disease was defined as a disease total eosinophil count were significant disease was defined as a disease total eosinophil count were significant disease was defined as a disease total eosinophil eosinophil count were significant disease was defined as a disease total eosinophil eos	
Interventions	inhaled steroids or regular oral steroids, not	opium placebos d to continue previously prescribed regular exceeding a dose equivalent to approximately participants taking these medications during
Outcomes	by at least 4 units COPD exacerbations : number of exacerbations age of participants with at least one COP	ne SGRQ and number whose score decreased ations, number of exacerbation days, percent- D exacerbation, time to first COPD exacer- n and for an exacerbation, days hospitalised,

Brusasco 2003 (Continued)

	 percentage of participants with at least one hospital admission for a COPD exacerbation, time to first hospital admission due to a COPD exacerbation Lung function: FEV₁, FVC, dyspnoea (evaluated using the Baseline Dyspnoea Index (BDI) and the TDI) Adverse events: all-cause mortality Other: withdrawal, non-scheduled contacts with physicians and other healthcare providers (use of the intensive care unit), disability days (days unable to perform daily activities) and employment status
Notes	 Funding: Boehringer Ingelheim Study number: Boehringer Ingelheim 205.130/205.137 Definitions: Exacerbations were defined as a complex of respiratory symptoms (new onset or an increase in at least one of cough, sputum, dyspnoea, wheeze or chest discomfort) lasting at least 3 days and usually associated with a therapeutic intervention

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The randomisation list was generated by Boehringer Ingelheim with the use of a val- idated system, which involved a pseudo- random number generator, so that the re- sulting treatment sequence was both repro- ducible and non-predictable
Allocation concealment (selection bias)	Low risk	All investigational medication for each par- ticipant was identified by a unique med- ication number. Each eligible participant was assigned the lowest medication num- ber available to the investigator at the time of randomisation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Boehringer Ingelheim was responsible for preparing and coding study medication in a blinded fashion (Boehringer Ingelheim study drug and control were indistinguish- able). Participants, investigators and study personnel remained blinded with regard to treatment assignments up to database lock. Double-dummy technique was used to blind different application devices
Blinding of outcome assessment (detection bias) All outcomes	Low risk	In all studies, a selection of standard respi- ratory endpoints, such as pulmonary func- tion, SGRQ, TDI, treadmill, exacerba- tions, etc., were used. Outcome assessors remained blinded with regard to treatment assignments up to database lock

Brusasco 2003 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawal rates were relatively even be- tween groups (salmeterol, 18.8%, placebo, 25.8%)
Selective reporting (reporting bias)	High risk	FEV_1 [secondary outcome] was not reported in a way that could be included in the qualitative synthesis, and no data were reported for serious adverse events
Calverley 2003a		
Methods	Design : randomised, double-blind, placebo-controlled, parallel-group study Duration : 12 months (+ 2 weeks run-in period) Location : 109 centres in 15 countries or regions	
Participants	Population : 511 participants were randomly assigned to formoterol 12 μ g twice daily (255) and placebo (256) Baseline characteristics : Mean age (years): formoterol 12 μ g, 63; placebo, 65 % Male: formoterol 12 μ g, 75; placebo, 75 % Reversibilty: formoterol 12 μ g, 60; placebo, 6.0 Pack-years: formoterol 12 μ g, 38; placebo, 39 % FEV ₁ predicted: formoterol 12 μ g, 36; placebo, 36 % taking ICS: formoterol 12 μ g, 0; placebo, 0 Inclusion criteria : Males and females > 40 years old; history of at least 10 pack-years; COPD for at least 2 years; < 70% FEV ₁ /FVC, FEV ₁ < 50% predicted; 1+ COPD exacerbations requiring medication in previous 2 to 12 months Exclusion criteria : history of asthma or seasonal allergic rhinitis before age 40; any relevant cardiovascular disorders or other disease	
Interventions	costeroids and antibiotics were allowed in t and/or nebulised treatment were allowed at ing the study period were oxygen therapy; b	eeded; maximum 3-week course of oral corti- he event of exacerbations; parenteral steroids emergency visits. Medications excluded dur- beta-blocking agents; inhaled corticosteroids; nists or 5-lipoxygenase inhibitors; other bron- ns containing ephedrine
Outcomes	and mild exacerbations Lung function : FEV ₁ , FVC, morning and Adverse events : all-cause mortality and no Other : withdrawal, diary cards, rescue mo	xacerbations, time to first severe exacerbation l evening PEF

Calverley 2003a (Continued)

Notes	Funding: AstraZeneca
	Study number: AZ study ID SD-039-0670
	Definitions: 'Severe' exacerbations were defined as intake of a course of oral steroids
	and/or antibiotics and/or hospitalisation due to respiratory symptoms (coded as severe
	and moderate in the review); 'mild' exacerbations were described as the number of days
	with intake of 4 or more puffs of rescue medication

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned to treatment. No details of sequence gener- ation methods but assumed to adhere to usual AstraZeneca methods
Allocation concealment (selection bias)	Unclear risk	No details reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Study reported as double-blind (participants and investigators)
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawal even but high in both groups (formoterol, 43.5%; placebo, 41.4%). An intention-to-treat analysis was used for all hypothesis testing
Selective reporting (reporting bias)	Low risk	All relevant outcomes were reported and could be included. Only an inexact P-value was given for quality of life [primary out- come], which was included as an approxi- mation in the analysis

Calverley 2003b [TRISTAN]

Methods	Design: randomised, double-blind, placebo-controlled, parallel-group design
	Duration: 12 months (+ 2 weeks run-in period)
	Location: 196 centres in 25 countries (Australia, Austria, Belgium, Canada, Czech Re-
	public, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Italy,
	Lithuania, The Netherlands, New Zealand, Norway, Poland, Russia, South Africa, Spain,
	Sweden, Switzerland and United Kingdom)

Participants	Population : 733 participants were randomly assigned to salmeterol 50 μ g twice daily (372) and placebo (361) Baseline characteristics : Mean age (years): salmeterol, 63.2; placebo 63.4 % Male: salmeterol, 70; placebo, 75 % Reversibilty: salmeterol, 3.7; placebo, 4.0 % White: salmeterol, 99; placebo, 98 Pack-years: salmeterol, 43.7; placebo, 43.4 % FEV ₁ predicted: salmeterol, 44.3; placebo, 44.2 Inclusion criteria : \geq 10-Pack-year history of cigarette smoking; a history of cough productive of sputum on most days for at least 3 months of the year, for at least 2 years; documented history of COPD exacerbations each year for the previous 3 years, including at least one exacerbation in the last year that required oral corticosteroids and/or antibiotics; a baseline (pre-bronchodilator) FEV ₁ \geq 25% to \leq 70% of predicted normal FEV ₁ value 30 minutes after inhalation of 400 μ g salbutamol) and FEV ₁ /forced vital capacity (FVC) ratio \leq 70% Exclusion criteria : respiratory disorders other than COPD. Patients were also excluded if they had received systemic corticosteroids, high doses of inhaled corticosteroids or antibiotics in the 4 weeks before the 2 weeks run-in	
Interventions	 Salmeterol 50 µg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Inhaled salbutamol was used as relief medication throughout the study, and regular treatment with anticholinergics, mucolytics and theophylline was allowed. Medications not allowed during the study period were inhaled corticosteroids and LABAs 	
Outcomes	 HRQoL: Health status was assessed with St George's Respiratory Questionnaire COPD exacerbations: acute exacerbations (see notes) Lung function: FEV1 (at least 6 hours after medication), pretreatment FVC and postbronchodilator FEV1 and FVC, morning PEF Adverse events: any adverse event, non-fatal serious adverse event and all-cause mortality Other: withdrawal, diary cards recording use of relief medication, symptom scores and night-time awakenings 	
Notes	Funding : GlaxoSmithKline Study number : GSK identifier SFCB3024 Definitions : Exacerbations were defined as worsening of COPD symptoms that required treatment with antibiotics, oral corticosteroids or both (coded as moderate for this re- view). Episodes that required corticosteroid treatment or hospital admission were noted separately	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Random sequence generation (selection bias)	Low risk	We used a randomisation schedule gener- ated by the Patient Allocation for Clinical Trials (PACT) programme to assign partic- ipants to study treatment groups
Allocation concealment (selection bias)	Low risk	Every participating centre was supplied with a list of participant numbers (assigned to participants at their first visit) and a list of treatment numbers. Participants who sat- isfied eligibility criteria were assigned the next sequential treatment number from the list
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Study drugs were labelled to ensure that both the participant and the investigator were unaware of the allocated treatment
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Withdrawal relatively even but high in both groups (salmeterol, 32.0%, placebo, 38. 8%); the intent-to-treat (ITT) population, consisting of all participants who were ran- domly assigned to treatment and received at least one dose of the study medication, was used for all analyses of efficacy and sa- fety. Unclear what method of imputation was used for each outcome
Selective reporting (reporting bias)	Low risk	All outcomes stated in the protocol were reported in detail and could be included in the meta-analysis

Methods	 Design: a multi-centre, randomised, double-blind, parallel-group, placebo-controlled study Duration: 36 months (+ 3 weeks run-in period) Location: 466 centres in 42 countries comprising 190 centres in USA, 134 centres in Western Europe (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom), 46 centres in Eastern Europe (Bulgaria, Croatia, Czech Republic, Hungary, Estonia, Latvia, Lithuania, Poland, Romania, Russia, Slovakia, Ukraine), 37 centres in Asia Pacific (China, Hong Kong, Malaysia, Philippines, Singapore, Taiwan, Thailand) and 59 centres in other regions (Australia, New Zealand, South Africa, Canada, Argentina, Brazil, Chile, Mexico)
Participants	 Population: 3087 participants were randomly assigned to salmeterol 50 μg twice daily (1542) and placebo (1545) Baseline characteristics: Mean age (years): salmeterol, 65.1; placebo, 65.0 % Male: salmeterol, 76.3; placebo, 76.3 % White: salmeterol, 82; placebo, 82 Pack-years: salmeterol, 49.3; placebo, 48.6 % FEV1 predicted: salmeterol, 43.6; placebo, 44.1 Inclusion criteria: male or female current or former smokers; history of at least 10 pack-years; clinical diagnosis of COPD; aged 40 to 80 years inclusive, with pre-bronchodilator FEV1 < 60% predicted at entry to the study Exclusion criteria: current diagnosis of asthma; current respiratory disorders other than COPD; lung volume reduction surgery and/or transplant; serious uncontrolled disease; evidence of alcohol, drug or solvent abuse, hypersensitivity to ICS, bronchodilators or lactose; deficiency of alpha1-antitrypsin; exacerbation during run-in period
Interventions	 Salmeterol 50 µg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Ventolin as relief, inhaled long-acting bronchodilators and long-term oral corticosteroids (theophyllines long- and short-acting, SABAs and short-acting anticholinergic agents allowed). Medications not allowed during the study period were inhaled corticosteroids, inhaled long-acting bronchodilators, long-term oral corticosteroids and long-term oxygen therapy
Outcomes	HRQoL: assessed by St. George's Respiratory Questionnaire COPD exacerbations: rates of moderate and severe COPD exacerbations Lung function: adjusted mean change FEV ₁ Adverse events: all-cause mortality, non-fatal serious adverse events Other: withdrawal
Notes	Funding : GlaxoSmithKline Study number : GSK identifier SCO30003; trial registration NCT00268216 Definitions : Exacerbations were defined as symptomatic deterioration requiring treat- ment with antibiotic agents, systemic corticosteroids, hospitalisation or a combination of these
Risk of bias	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	[From protocol] "Subjects will be assigned to study treatment in accordance with the randomisation schedule, which will be generated using the GW computer pro- gram Patient Allocation for Clinical Trials (PACT)"
Allocation concealment (selection bias)	Low risk	[From protocol] "Subjects will be centrally randomised to one of the four treatment groups via the System for Central Alloca- tion of Drug (SCAD) and will be stratified by smoking status" ['central' interpreted as being masked from individual study cen- tres]
Blinding of participants and personnel (performance bias) All outcomes	Low risk	[From protocol] "Once the database has been frozen, the treatment allocations will be unblinded and all of the analyses detailed in this document will be performed. The treatment allocations will be unblinded us- ing standard GSK systems. The database will be frozen by BDS Respiratory Data Management, GSK"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	An independent clinical end point com- mittee, whose members were unaware of the treatment assignments, determined the primary cause of death and whether death was related to COPD. Unclear for other outcomes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawal rates quite similar but both high by the end of the 36-month treatment period. Acceptable methods of imputation used in all cases. For any participant who withdraws prematurely from the study, all available data up to the time of discontin- uation were included in the analyses. Mor- tality data were collected for participants who withdrew early
Selective reporting (reporting bias)	Low risk	All relevant outcomes stated in the protocol were reported in detail. Exacerbation data could not be included with the rest of the data, as they were given only as rate per patient-year

Campbell 2005

Methods	Design : randomised, double-blind, placebo Duration : 6 months (+ 3 weeks run-in peri Location : 73 centres in eight countries (B Romania, Spain, Sweden and the UK)	lod)
Participants	Population : 432 participants were randomly assigned to formoterol 12 μ g twice daily (215) and placebo (217) Baseline characteristics : Mean age (years): formoterol, 60; placebo, 60 % Male: formoterol, 61; placebo, 73 % Reversibilty: formoterol, 5.1; placebo, 4.7 Pack-years: formoterol, 37; placebo, 37 % FEV ₁ predicted: formoterol, 53.0; placebo, 54.1 % taking ICS: formoterol, 47; placebo, 44 Inclusion criteria : older than 40 years of age; clinical diagnosis of COPD with at least 2 years of symptoms, FEV ₁ 40% to 70% predicted, FEV ₁ /slow VC < 70%; history of at least 10 pack-years Exclusion criteria : history of asthma or seasonal allergic rhinitis; onset before age 40; inhaled corticosteroid dose change; oral steroid use or significant COPD exacerbation in the past month	
Interventions	 Formoterol 12 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Allowed medications were terbutaline (0.5 mg) used as reliever [in the two arms used in the review]; inhaled and nasal corticosteroids without modification of dosage or frequency of administration. Disallowed medications included domiciliary oxygen; disodium cromoglycate; ephedrine; antihistamines; beta-blockers and bronchodilators other than the study medication 	
Outcomes	 HRQoL: assessed using St George's Respiratory Questionnaire (SGRQ) COPD exacerbations: time to first severe exacerbation; number of participants with at least one exacerbation Lung function: FEV₁ % change, morning PEF, slow VC Adverse events: non-fatal serious adverse events and all-cause mortality Other: combined symptom score (CSS), reliever medication use 	
Notes	Funding: AstraZeneca Study number: unknown Definitions: Exacerbations were defined as the need for oral steroids, change in dose of inhaled corticosteroids or the need for antibiotics or hospitalisation [coded as moderate and severe in the present review]	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Campbell 2005 (Continued)

Random sequence generation (selection bias)	Low risk	Treatment was randomly assigned in bal- anced blocks using a computer-generated scheme
Allocation concealment (selection bias)	Low risk	Randomisation scheme was provided in coded envelopes
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind treatment period (participants and investigators)
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	An intention-to-treat approach was used throughout. Unclear how data were im- puted, but withdrawal rates were simi- lar and below 20% in both groups (for- moterol, 14.0%, placebo, 18.0%)
Selective reporting (reporting bias)	Unclear risk	No trial protocol could be located against which to check all preregistered outcomes as reported

Dahl 2001

Methods	 Design: multicenter, double-blind, randomised, parallel-group, placebo-controlled study Duration: 6 months (+ 2 weeks run-in period) Location: Denmark, Netherlands, Poland, Russia, UK
Participants	 Population: 586 participants were randomly assigned to formoterol 12 μg twice daily (194), formoterol 24 μg twice daily (192) and placebo (200) Baseline characteristics: Mean age (years): formoterol 12, 64.3; formoterol 24, 63.5; placebo, 63.4 % Male: formoterol 12, 74.2; formoterol 24, 75.6; placebo, 78.5 Pack-years: formoterol 12, 46.0; formoterol 24, 42.2; placebo, 42.5 % FEV₁ predicted: formoterol 12, 46.0; formoterol 24, 53; placebo, 54 Inclusion criteria: males and females aged 40 and older; history of at least 10 pack-years; clinical diagnosis of COPD Exclusion criteria: history of asthma; respiratory tract infection in the past month; need for long-term oxygen therapy
Interventions	 Formoterol 12 μg twice daily Formoterol 24 μg twice daily Placebo

	Inhaler device : dry powder inhaler Co-medication : Salbutamol was provided as rescue; inhaled corticosteroids (ICS) were allowed if stable; short courses of antibiotics, oral corticosteroids and/or oxygen could be used in case of exacerbation or infection. Initiation or discontinuation of ICS or recent change in dose was not allowed; neither were parenteral or oral corticosteroids, theophylline, anticholinergics or other LABAs
Outcomes	 HRQoL: assessed with St George's Respiratory Questionnaire (SGRQ) COPD exacerbations: frequency of level 1, 2 and 3 exacerbations (definitions below) Lung function: FEV₁ area under the curve over 12 hours and at individual time points, morning PEF Adverse events: non-fatal serious adverse events and all-cause mortality Other: withdrawal, vital signs, electrocardiograms and clinical laboratory evaluations, number of puffs of rescue medication, daily total symptom scores
Notes	Funding : Novartis Study number : unknown Definitions : First level of exacerbation was defined as days with at least two individual symptom scores of 2 or greater and/or a reduction in PEF from baseline of greater than 20%; second level of exacerbation: course of additional therapy (corticosteroids, antibiotics or oxygen) [coded as moderate for this review]; third level: COPD-related hospitalisations [coded as severe for this review]

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	, <u> </u>	Randomly assigned to receive one of the following four regimens [no other details given but industry sponsored]
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding was obtained by double-dummy dosing [assumed participants and investi- gators]
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Statistical analysis was carried out accord- ing to the intent-to-treat principle. [Un- clear how data were imputed across out- comes. Dropout higher in placebo group but considered low overall in all three groups (formoterol 12, 6.7%; formoterol 24, 6.8%, placebo, 14.5%)]

Dahl 2001 (Continued)

Selective reporting (reporting bias)	Unclear risk	Moderate exacerbation rates not reported for each group, but all other outcomes could be included in the meta-analysis. Trial protocol could not be located against which to check all preregistered outcomes as reported
Dahl 2010		
Methods	Design : randomised double-blind double- Duration : 12 months (+ 2 weeks run-in p Location : Denmark, UK, Germany, Russi	eriod)
Participants	 (435) and placebo (432) Baseline characteristics: Mean age (years): formoterol, 64; placebo, % Male: formoterol, 80.2; placebo, 81.5 % Reversibility: formoterol, 10.1; placebo, Pack-years: formoterol, 40; placebo, 43 % FEV₁ predicted: formoterol, 52.5; place % taking ICS: formoterol, 50.9; placebo, 5 Inclusion criteria: males and females aged to severe COPD; history of at least 20 pack 	 10.8 bo, 52.0 51.9 40 and older; clinical diagnosis of moderate k-years ent respiratory tract infection or hospitalisa-
Interventions	were replaced by monotherapy ICS at an e as needed. Participants receiving ICS mono	of inhaled corticosteroids (ICS) plus LABA equivalent dose and regimen plus salbutamol otherapy continued treatment at a stable dose s were not allowed, or a change in ICS was
Outcomes	scores) Adverse events: any adverse events and all	rbations (definition below) and PEF, dyspnoea (baseline and transition -cause mortality ion, change in concomitant medications, 6-
Notes		s onset or worsening of more than one respi- based on diary cards or participants' reports

of their health since the previous visit) plus documented proof of intensified treatment (e.g. systemic steroids, antibiotics or oxygen) and/or hospitalisation or emergency room visit [coded as moderate and severe]

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly assigned to treatment (1:1:1:1) with stratification for smoking status (cur- rent/ex-smoker) using an automated inter- active system
Allocation concealment (selection bias)	Low risk	Using an automated interactive system [concealment assumed by automatisation]
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind double-dummy trial
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Protocol states double-blind for partici- pant, caregiver, investigator and outcomes assessor (http://www.clinicaltrials.gov/ct2/ show/NCT00393458)
Incomplete outcome data (attrition bias) All outcomes	High risk	Efficacy results are presented for the mod- ified intention-to-treat (ITT) population, including all randomly assigned partici- pants who received at least one dose of study drug, but excluding patients from six sites owing to non-conformance with good clinical practice. Withdrawal rela- tively high in both groups (formoterol, 25. 7; placebo, 31.7)
Selective reporting (reporting bias)	Low risk	Checked paper against protocol. All out- comes stated in the protocol were reported

Doherty 2012

Methods	Design : randomised, double-blind, placebo-controlled trial Duration : 6 months (+ 2 weeks run-in period) Location : 164 centres in North, Central and South America, Europe, Africa and Asia
Participants	Population : 479 participants were randomly assigned to formoterol 10 μ g twice daily (243) and placebo (236) Baseline characteristics : Mean age (years): formoterol, 59.7; placebo, 58.8

Long-acting beta₂-agonists for chronic obstructive pulmonary disease (Review)

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Doherty 2012 (Continued)

	 % Male: formoterol, 74.9; placebo, 75.4 % White: formoterol, 68.7; placebo, 65.7 % Reversibility: formoterol, 10.4; placebo, 9.5 Pack-years: formoterol, 45.9; placebo, 43.5 % FEV1 predicted: formoterol, 38.2; placebo, 38.0 Inclusion criteria: males and females aged 40 and older; FEV1/FVC < 70%; PFEV 25% to 60%; COPD symptoms for at least 24 months; history of at least 10 pack-years Exclusion criteria: current diagnosis of asthma; marked bronchodilator reversibility; recent COPD exacerbation; history of lung cancer/surgery; other significant medical illness
Interventions	 Formoterol 10 μg twice daily Placebo Inhaler device: metered dose inhaler Co-medication: open-label, short-acting beta₂-agonist (SABA)/short-acting anticholinergic combination was allowed. All long-acting COPD treatments (LABA, inhaled corticosteroids, LABA/ICS FDC or long-acting anticholinergics) were disallowed
Outcomes	 HRQoL: assessed with St George's Respiratory Questionnaire (including number reaching a minimally clinically important difference) COPD exacerbations: time to first mild, moderate or severe exacerbation. Number of people with exacerbations Lung function: FEV₁ area under the curve from 0 to 12 hours postdose (at weeks 13 and 26 LOCF); trough FEV₁ (not for LABA placebo comparison) Adverse events: all-cause mortality and non-fatal serious adverse events Other: withdrawal, COPD symptom-free nights
Notes	 Funding: Merck & Co Study number: NCT00383721 Definitions: A mild exacerbation was defined as a clinically judged deterioration of COPD symptoms (managed with increased short-acting bronchodilator use: 12+ inhalations/day of SABA/short-acting anticholinergic, or 2+ nebulised treatments/day of 2.5 mg SABA/short-acting anticholinergic) on any two consecutive days. A moderate exacerbation was defined as a clinically judged deterioration of COPD with an acute change in symptoms that required antibiotic and/or oral steroid treatment for lower airway disease. A severe exacerbation was defined as a deterioration of COPD that resulted in emergency treatment or hospitalisation because of COPD

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned in a 1: 1:1:1:1 ratio [industry sponsored]
Allocation concealment (selection bias)	Unclear risk	Participants who discontinued early were not replaced [no other details given]

Doherty 2012 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy. Protocol states participants and investigators were blind
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Protocol and paper do not provide details about blinding of outcome assessors
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawal rates were quite different (for- moterol, 20.6%; placebo, 28.4%), but ef- ficacy analyses and safety summaries were based on the intent-to-treat principle for all randomly assigned participants
Selective reporting (reporting bias)	High risk	Quality of life [primary outcome] was not reported in a way that could be analysed for the comparison in question. All other stated and expected outcomes were reported and analysed
Hanania 2003		
Methods	 Design: randomised, double-blind, placebo-controlled, parallel-group, 24-week clinical trial Duration: 6 months (+ 2 weeks run-in period) Location: 75 centres in the USA, one in Puerto Rico 	
Participants	 Population: 362 participants were randomly assigned to salmeterol 50 μg twice daily (177) and placebo (185) Baseline characteristics: Mean age (years): salmeterol, 64.2; placebo, 64.8 % Male: salmeterol, 57.6; placebo, 68.1 % White: salmeterol, 93.2; placebo, 93.5 Pack-years (median): salmeterol, 57; placebo, 56 % FEV1 predicted: salmeterol, 42; placebo, 42 Inclusion criteria: males and females aged 40 and older; clinical diagnosis of COPD; history of at least 20 pack-years and cough productive of sputum on most days for at least 3 months of the year for at least 2 years; FEV1/FVC ratio < 70% and baseline FEV1 < 65% predicted but > 0.70 L Exclusion criteria: current diagnosis of asthma; abnormal clinically significant ECG; moderate or severe exacerbation during the run-in period; any significant medical disorder 	
Interventions	 Salmeterol 50 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Stable regimens of theophylline were allowed (no change in dose for 1 month before screening) [only 11% were taking these medications]. Disallowed medica- 	

Hanania 2003 (Continued)

	tions included oral corticosteroids within the past 6 weeks and long-term oxygen therapy, and participants discontinued the use of corticosteroids and bronchodilators
Outcomes	 HRQoL: assessed with the Chronic Respiratory Disease Questionnaire (CRQ). Clinically meaningful difference of 10 points COPD exacerbations: See 'definitions' Lung function: morning predose and 2-hour postdose FEV₁, morning peak expiratory flow (PEF), dyspnoea (as assessed by the transition dyspnoea index [TDI]) Adverse events: Other: withdrawal, supplemental albuterol use, symptoms of chronic bronchitis (as assessed by the Chronic Bronchitis Symptom Questionnaire [CBSQ])
Notes	Funding : GlaxoSmithKline Study number : GSK identifier SFCA3007 Definitions : Exacerbations were defined by treatment, with moderate exacerbations requiring treatment with antibiotics and/or corticosteroids, and severe exacerbations requiring hospitalisation

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was stratified by reversibil- ity (defined as a 12% and 200-mL increase in FEV ₁ from baseline after administration of 400 g albuterol) and investigative site [se- quence generation not described but study was industry sponsored]
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as double-blind [presumed par- ticipant and investigator]
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment
Incomplete outcome data (attrition bias) All outcomes	High risk	Withdrawal high and even between groups (formoterol, 31.7%, placebo, 31.9%). To account for participant withdrawals, end point was used as the primary time point and was defined as the last on-treat- ment post-baseline assessment excluding any data from the discontinuation visit

Hanania 2003 (Continued)

Selective reporting (reporting bias)	Low risk	All expected and stated outcomes were re- ported. Quality of life data were not in- cluded, as QOL was measured on the CRQ rather than the SGRQ	
Hanrahan 2008			
Methods	blind, double-dummy, place domised trials [Baumgartne Duration : 3 months (+ 2 v	 Design: Pooled results from two identically designed phase III multicentre double-blind, double-dummy, placebo- and active-controlled, parallel-group, multiple-dose randomised trials [Baumgartner 2007 and NCT00064402] Duration: 3 months (+ 2 weeks run-in period) Location: 60 sites in the first study and 64 sites in the second study (all in the United States) 	
Participants	 (290) and placebo (293) Baseline characteristics: Mean age (years): salmetered % Male: salmeterol, 58.6; p % White: salmeterol, 93.4; % FEV1 predicted: salmeterol, 24.1 % FEV1 predicted: salmeterol, 24.1 Inclusion criteria: males at agnosis; FEV1 < 65% predistreat hessness severity on d Exclusion criteria: life-three 	placebo, 60.4 placebo, 96.6 rrol, 40.9; placebo, 41.3 28.6; placebo, 23.9 und females aged 35 and older; primary clinical COPD di- dicted and > 0.70 L; FEV ₁ /FVC < 70%; > 15 pack-years; yspnoea scale > 2 extening/unstable respiratory status within 30 days; asthma or rase other than COPD; lung resection > 1 full lobe; clinically	
Interventions	and supplemental medicat had been stable for 14 day		
Outcomes	exacerbations Lung function: % change curve	portion of participants experiencing protocol-defined COPD in trough FEV1 from baseline and average area under the nortality and non-fatal serious adverse events nd Holter monitoring	
Notes	Funding: Sepracor Study number: NCT0006 Definitions: Exacerbation	4402 and NCT00064415 was defined as an increase in symptoms leading to any change	

Hanrahan 2008 (Continued)

in baseline medication or additional medical attention (e.g. hospitalisation, emergency room visit)

Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned to LABA treatment or placebo [industry sponsored]
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Protocols state participant, investigator and outcomes assessor were blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	Among 1465 randomly assigned partici- pants, 1456 took at least 1 dose of double- blind study medication (ITT participants) . Withdrawal higher in placebo group (sal- meterol, 14.5%, placebo, 21.8%)
Selective reporting (reporting bias)	High risk	SGRQ [primary outcome] named in pro- tocol but not reported. All other outcome data provided
Kornmann 2011		

Methods	Design : randomised, double-blind, placebo-controlled trial Duration : 6 months (+ 2 weeks run-in period) Location : 142 centres in 15 countries (Brazil, Canada, Colombia, Czech Republic, Denmark, Germany, Hungary, Iceland, India, Italy, Norway, Peru, Russia, Slovakia, Taiwan and Finland)
Participants	Population : 669 participants were randomly assigned to salmeterol 50 μg twice daily (334) and placebo (335) Baseline characteristics : Mean age (years): salmeterol, 63; placebo, 64 % Male: salmeterol, 75; placebo, 77 % Reversibility: salmeterol, 11; placebo, 13 Pack-years: salmeterol, 40; placebo, 41 % FEV ₁ predicted: salmeterol, 53; placebo, 53 % taking ICS: salmeterol, 46; placebo, 40

Kornmann 2011 (Continued)

	 Inclusion criteria: Males and females aged 40 and older; diagnosis of moderate to severe COPD; history of at least 20 pack-years; < 80% and > 30% predicted FEV1; FEV1/FVC < 0.70 Exclusion criteria: history of asthma; hospitalisation for COPD exacerbation in the 6 weeks before Visit 1 or during run-in; requiring oxygen therapy; respiratory tract infection within 6 weeks before Visit 1 and during the run-in period; concomitant pulmonary disease; history of long QTc syndrome or QTc interval > 450 ms for males and > 470 ms for females; clinically significant condition
Interventions	 Salmeterol 50 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Concomitant medication with inhaled corticosteroids was allowed if stable for 1 month before screening and remained stable throughout the study; salbutamol was provided for relief. Participants previously taking fixed combinations of ICS and LABA were switched to equivalent ICS monotherapy
Outcomes	 HRQoL: assessed with St George's Respiratory Questionnaire (including proportion meeting minimal clinically important difference) COPD exacerbations: not reported Lung function: trough FEV₁, transition dyspnoea index, morning and evening PEF Adverse events: all-cause mortality and non-fatal serious adverse events Other: withdrawal, use of relief medication, days of poor COPD control, vital signs and ECGs
Notes	Funding : Novartis Study number : NCT00567996 Definitions : Trough FEV ₁ was defined as average of the 23 hour 10 minute and 23 hour 45 minute postdose FEV ₁ readings

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly allocated to treatment in a 1:1:1 ratio (with stratifi- cation for smoking status) using an auto- mated system
Allocation concealment (selection bias)	Low risk	Using an automated system [concealment assumed by automatisation]
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participant, investigator, outcomes asses- sor all blind [from protocol]. Blinding was maintained from randomisation until database lock unless any participant emer- gencies arose

Kornmann 2011 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participant, investigator, outcomes asses- sor all blind [from protocol]. Blinding was maintained from randomisation until database lock unless any participant emer- gencies arose
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawal somewhat higher in placebo group (salmeterol, 15%; placebo, 20.1%). Efficacy data were analysed for the inten- tion-to-treat (ITT) population, comprising all randomly assigned participants who re- ceived at least one dose of the study drug. The population for the safety analysis com- prised all participants who received at least one dose of the study drug
Selective reporting (reporting bias)	High risk	FEV ₁ data given only in graphical form. No exacerbation data provided. SGRQ re- ported only as a dichotomous outcome

Mahler 1999

Methods	 Design: Stratified, randomised, double-blind, double-dummy, placebo-controlled, parallel-group clinical trial Duration: 3 months (+ 2 to 3 weeks run-in period) Location: multiple sites at clinics and university medical centres throughout the United States
Participants	Population: 278 participants were randomly assigned to salmeterol 42 μg twice daily(135) and placebo (143)Baseline characteristics:Mean age (years): salmeterol, 63.2; placebo, 63.2% Male: salmeterol, 71.9; placebo, 76.2% White: salmeterol, 91.9; placebo, 90.9Pack-years: salmeterol, 60.2; placebo, 60.2% FEV1 predicted: salmeterol, 42.1; placebo, 40.8Inclusion criteria: males and females aged 35 and older; history of at least 10 pack-years; diagnosis of COPD; FEV1 > 0.7 L and < 65% predicted normal; FEV1/FVC < 70%
Interventions	 Salmeterol 42 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Albuterol was allowed for acute symptomatic relief; participants receiving a stable regimen of oral (< 10 mg prednisone per day) or inhaled corticosteroids

Mahler 1999 (Continued)

	continued these treatments. Oxygen therapy other than nocturnal use was disallowed, as were changes in medications for COPD within 4 weeks before the screening visit and inability to discontinue treatment with theophylline, ipratropium or oral B-agoing therapy
Outcomes	 HRQoL: assessed by the Chronic Respiratory Disease Questionnaire (CDRQ), including the proportion of participants meeting minimal clinically important difference from baseline COPD exacerbations: time to first COPD exacerbation; percentage of participants experiencing one or more exacerbations Lung function: spirometric measures over 12 hours (FEV₁, FVC), area under the 12-hour curve for FEV₁, dyspnoea severity on the transition dyspnoea index Adverse events: adverse events, vital signs and all-cause mortality Other: six-minute walk test (6MW) within 4 hours of the morning dose of study medication, participant-rated intensity of breathlessness on the Borg dyspnoea scale before and after the 6MW, participant self-rating of symptoms, night-time awakenings, supplemental albuterol use, ECG
Notes	Funding : GlaxoSmithKline Study number : GSK identifier SLGA4005 Definitions : Exacerbations were not defined

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Stratified, randomised trial [GSK spon- sored]
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy [assumed participant and investigator]
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment
Incomplete outcome data (attrition bias) All outcomes	High risk	Withdrawal more than twice as high in the placebo group (salmeterol, 6.7%, placebo, 16.1%). Analyses were performed on three groups of participants: all participants, re- sponsive and non-responsive strata [no mention of intention-to-treat principle or imputation]

Mahler 1999 (Continued)

Selective reporting (reporting bias)	High risk	Different FEV1 outcome from other stud- ies, cannot be included. No serious adverse event data
Mahler 2002		
Methods	Design : randomised, double-bl Duration : 6 months (+ 2 week Location : 65 centres in the Un	
Participants	 Population: 341 participants were randomly assigned to salmeterol 50 μg twice daily (160) and placebo (181) Baseline characteristics: Mean age (years): salmeterol, 63.5; placebo, 64.0 % Male: salmeterol, 64.4; placebo, 75.1 % White: salmeterol, 95.0; placebo, 91.7 Pack-years (median): salmeterol, 52.5; placebo, 60 % FEV1 predicted: salmeterol, 40; placebo, 41 Inclusion criteria: males and females aged 40 and older; history of at least 20 pack-years; diagnosis of COPD; FEV1 < 65% of predicted but > 0.70 L, FEV1/FVC ratio < 70%; daily cough productive of sputum for 3 months of the year for 2 consecutive years and dyspnoea Exclusion criteria: current diagnosis of asthma; abnormal clinically significant ECG; moderate or severe exacerbation during the run-in period; any significant medical disorder 	
Interventions	 Salmeterol 50 µg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Albuterol was allowed as needed, as were stable regimens of theophylline. Disallowed medications included oral corticosteroid use in the past 6 weeks, long-term oxygen therapy, corticosteroids and all bronchodilators 	
Outcomes	 HRQoL: assessed on the CRQ COPD exacerbations: time to exacerbation and proportions of participants experiencing at least one moderate/severe COPD exacerbation Lung function: AM predose and 2-hour postdose FEV₁, serial FEV₁ over 12 hours, morning (AM) peak expiratory flow rate (PEFR) Adverse events: non-fatal serious adverse events and all-cause mortality Other: Chronic Bronchitis Symptoms Questionnaire (CBSQ), supplemental albuterol (MDI or nebules), night-time awakenings requiring the use of albuterol 	
Notes		r SFCA3006 bations were defined as those requiring treatment with ids, and severe exacerbations were those requiring hospi-

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was stratified by reversibil- ity and investigative site to ensure a balance between treatment groups at each site and in terms of the numbers of reversible par- ticipants [no other details, industry spon- sored]
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind [participant and investiga- tor]
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment
Incomplete outcome data (attrition bias) All outcomes	High risk	Withdrawal high and uneven between groups (salmeterol, 28%, placebo, 38%). Analyses based on the intent-to-treat (ITT) population consisted of all randomly as- signed participants who had taken at least one dose of double-blind study drug
Selective reporting (reporting bias)	Low risk	All stated and expected outcomes were re- ported in detail and were included, except quality of life, because the study used a dif- ferent measure than was used in the other studies
Nelson 2007		
Methods	Design : randomised, double-bli Duration : 3 months (+ 4 to 14 Location : 38 centres across the	
Participants	Population: 228 participants were randomly assigned to formoterol 12 μ g twice daily (114) and placebo (114) Baseline characteristics: Mean age (years): formoterol, 63.0; placebo, 63.5 % Male: formoterol, 53.5; placebo, 57.0 % White formoterol, 23.3; placebo, 57.0	

% White: formoterol, 83.3; placebo, 86.0

% taking other COPD med: formoterol, 33.3; placebo, 37.7

Inclusion criteria: males and females aged 40 and older; diagnosis of COPD; history

Long-acting beta₂-agonists for chronic obstructive pulmonary disease (Review)

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Nelson 2007 (Continued)

	of at least 10 pack-years; FEV ₁ 30% to < 70% predicted; FEV ₁ /FVC ration < 70% Exclusion criteria : current or past diagnosis of asthma; respiratory tract infection or acute exacerbation of COPD within the previous month; other significant disease
Interventions	 Formoterol 12 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Albuterol was allowed as rescue medication and the use of inhaled or oral steroids was permitted if the corticosteroid dose was stable for 1 month. Disallowed medications included oxygen therapy, non-selective beta-blockers, MAOIs and other bronchodilators
Outcomes	HRQoL: not reported COPD exacerbations: number of participants experiencing at least one exacerbation during the study Lung function: not reported Adverse events: cardiac adverse events, all-cause mortality and non-fatal serious adverse events Other: withdrawal, Holter monitoring, ECG
Notes	Funding : Dey Pharma Study number : NCT00215436 Definitions : Exacerbations were not defined in the paper

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly assigned in a 1:1:1 ratio [no other details, industry sponsored]
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinded electronic ECG and Holter mon- itor data were assessed by a central labo- ratory (Quintiles Transnational Corpora- tion, Mumbai, India) to look for clinically significant abnormalities according to pre- determined criteria. Blinded investigators rated the intensity of each AE and cate- gorised each for potential relationship to study medication

Nelson 2007 (Continued)

Incomplete outcome data (attrition bias) All outcomes	High risk	Withdrawal twice as high in placebo group as in drug group [formoterol, 10.5%, placebo, 20.2%]. The safety population consisted of all participants who received \geq 1 dose of study medication [not given for efficacy population]
Selective reporting (reporting bias)	High risk	HRQoL, severe exacerbations [primary outcomes] and FEV1 [secondary] were not reported
Rennard 2001		
Methods	Design : randomised, double-blind, place Duration : 3 months (+ run-in period of Location : 27 clinical centres in the Unite	unknown length)
Participants	Population : 267 participants were randomly assigned to salmeterol 42 μ g twice daily (132) and placebo (135) Baseline characteristics : Mean age (years): salmeterol, 63.9; placebo, 63.7 % Male: salmeterol, 61.4; placebo, 64.4 % White: salmeterol, 93.2; placebo, 97.0 Inclusion criteria : males and females aged 35 and older; diagnosis of COPD; FEV ₁ > 0.7 L and < 65% predicted normal; FEV ₁ /FVC < 70% Exclusion criteria : pulmonary infection within 4 weeks before the study; significant cardiovascular disease; history of malignancy within the previous two years; significantly abnormal ECG or lab results; history of hypersensitivity to any beta-agonist or anti-cholinergic compound	
Interventions	 Salmeterol 42 μg twice daily Placebo Inhaler device: metered-dose inhaler Co-medication: up to 14-day courses of oral corticosteroids for exacerbations; participants using ICS at entry must have maintained a stable regimen for the duration of the study. Participants were required to discontinue the use of theophylline, ipratropium and oral beta-agonists for the duration of the study; participants requiring oral corticosteroid therapy > 10 mg prednisone or continuous oxygen therapy were excluded 	
Outcomes	 HRQoL: Quality of life (QOL) was measured using the Chronic Respiratory Disease Questionnaire (CRQ) and the Pittsburgh Sleep Quality Index (PSQI) COPD exacerbations: COPD exacerbations Lung function: FEV₁, forced vital capacity (FVC), forced expiratory flow in the middle half of FVC (FEF25% to 75%) assessments, peak expiratory flow, Transitional Dyspnea Index (TDI) score, FEV₁ area under the curve (AUC) calculated from 12-hour serial pulmonary function tests (PFTs) Adverse events: Other: 6-Minute walk, Borg dyspnoea score, participant self-rating of symptoms, night- 	

Rennard 2001 (Continued)

	time awakenings, supplemental albuterol use	
Notes	Funding : GlaxoSmithKline Study number : GSK identifier SLGA4004 Definitions : Exacerbations were defined as worsening symptoms of COPD requiring a change in drug therapy [coded as moderate for this review]	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly assigned to receive 1 of the 3 treatments [no other details provided, in- dustry sponsored]
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, double-dummy
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided, included outcomes might be subject to detection bias [self- rated quality of life, exacerbations, all-cause mortality, serious adverse events and with- drawal]
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawal quite similar between groups (salmeterol, 16.7%, placebo, 21.2). Last observation carried forward (LOCF) analy- ses were performed on all efficacy measure- ments to investigate the impact of drop- outs, and LOCF analyses (data not shown) were entirely consistent with those pre- sented here
Selective reporting (reporting bias)	Low risk	All stated and expected outcomes were re- ported in a way that could be included in the meta-analysis

Rennard 2009

Methods

Design: randomised, double-blind, double-dummy, parallel-group, active- and placebo-controlled, multi-centre study
Duration: 12 months (+ 2 weeks run-in period)
Location: 237 sites in the USA, Europe and Mexico

Participants	 Population: 976 participants were randomly assigned to formoterol 12 μg twice daily (495) and placebo (481) Baseline characteristics: Mean age (years): formoterol, 62.9; placebo, 62.9 % Male: formoterol, 65.3; placebo, 65.3 % White: formoterol, 92.3; placebo, 91.7 % Reversibility: formoterol, 16.9; placebo, 19.5 Pack-years (median): formoterol, 40; placebo, 40 % FEV1 predicted: formoterol, 39.3; placebo, 40.8 Inclusion criteria: Males and females aged 40 and older; moderate to severe COPD for 2+ years; history of at least 10 pack-years Exclusion criteria: history of asthma or seasonal rhinitis before age 40; significant/unstable cardiovascular disorder; significant respiratory tract disorder other than COPD; homozygous alpha1-antitrypsin deficiency or other clinically significant co-morbidities precluding participation
Interventions	 Formoterol 12 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Salbutamol was allowed as relief medication. Previous inhaled corticosteroids were discontinued, and disallowed medication included long-acting anticholinergics; inhaled LABAs or SABAs (other than salbutamol); oral beta-adrenoreceptor agonists; ephedrine; leukotriene receptor agonists; xanthine derivatives except for short-term use
Outcomes	 HRQoL: assessed with St George's Respiratory Questionnaire (SGRQ) COPD exacerbations: time to first exacerbation and number per participant-treatment year Lung function: predose FEV₁, one hour postdose FEV₁, morning and evening REF Adverse events: all-cause mortality and non-fatal serious adverse events Other: withdrawal, participant-rated symptom scores
Notes	Funding: AstraZeneca Study number: NCT00206167 Definitions: Exacerbations were defined as worsening of COPD requiring an oral cor- ticosteroid or hospitalisation [coded as moderate and severe for this review]

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Designed to conform with the Declaration of Helsinki, and consistent with the In- ternational Conference on Harmonisation and Good Clinical Practice and applicable regulatory requirements

Rennard 2009 (Continued)

Allocation concealment (selection bias)	Low risk	Designed to conform with the Declaration of Helsinki, and consistent with the In- ternational Conference on Harmonisation and Good Clinical Practice and applicable regulatory requirements
Blinding of participants and personnel (performance bias) All outcomes	Low risk	To maintain blinding, participants received both a pressurised metered dose inhaler (pMDI) and a dry powder inhaler (DPI) containing active treatment or double- dummy placebo (PL), as appropriate
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided. Outcomes could be affected by detection bias
Incomplete outcome data (attrition bias) All outcomes	High risk	Withdrawal even but high in both groups [formoterol 31.7%, placebo, 36.4%]. The efficacy analysis set (i.e. intent-to-treat pop- ulation) included all randomly assigned participants who received at least one dose of randomly assigned study medication and contributed sufficient data for at least one co-primary or secondary efficacy end point to be calculated during the randomly as- signed treatment period. The safety analysis population included all randomly assigned participants who received at least one dose of randomly assigned study medication and from whom any postrandom assignment data were available
Selective reporting (reporting bias)	High risk	Serial spirometry was reported only for a subset. Exacerbations not reported in a way that could be included in the meta-analysis

Rossi 2002

Methods	Design : multi-centre, randomised, parallel-group, placebo-controlled study Duration : 12 months (+ 10 to 21 days run-in period) Location : 81 centres worldwide
Participants	Population : 645 participants were randomly assigned to formoterol 12 μ g twice daily (211), 24 μ g twice daily (214) and placebo (220) Baseline characteristics : Mean age (years): formoterol 12 μ g, 63; formoterol 24 μ g, 62; placebo, 63 % Male: formoterol 12 μ g, 87.2; formoterol 24 μ g, 83.2; placebo, 79.5 % on ICS: formoterol 12 μ g, 47; formoterol 24 μ g, 47; placebo, 49

	Inclusion criteria : males and females aged 40 and older; diagnosis of COPD; history of at least 10 pack-years; FEV ₁ < 70% predicted; FEV ₁ /FVC ration < 0.89 Exclusion criteria : history of asthma; respiratory tract infection in the past month; need for long-term oxygen therapy
Interventions	 Formoterol 12 μg twice daily Formoterol 24 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Stable participants receiving inhaled corticosteroid treatment were instructed to remain on that treatment throughout the study; Salbutamol (up to 8 puffs/d) was allowed as the rescue medication. Short courses of antibiotics, oral corticosteroids and/or oxygen were permitted in case of exacerbation or respiratory infection up to two times during the study. All other bronchodilating medications were discontinued
Outcomes	 HRQoL: assessed with St George's Respiratory Questionnaire (SGRQ) COPD exacerbations: frequency of exacerbations, see definitions below Lung function: standardised AUC for FVC, absolute FEV₁ values at all time points, predose FEV₁, morning PEF Adverse events: all-cause mortality and non-fatal serious adverse events Other: withdrawal, daily total symptom score, vital signs, ECG
Notes	Funding : Novartis Study number : unknown Definitions : Mild exacerbation = "bad days," defined as days with at least two individ- ual symptom scores of 2 and/or a reduction in PEF from baseline of 20%; moderate exacerbation = undergo a course of additional therapy (i.e. corticosteroids, antibiotics or oxygen); severe exacerbation = COPD-related hospitalisations

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised, parallel-group study [no spe- cific details, industry sponsored]
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	F12, F24 and PL were administered in a double-blind manner
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided, unclear whether out- comes included in the meta-analysis were subject to detection bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawal rates were relatively similar across the three groups (formoterol 12, 24. 6%, formoterol 24, 18.7%, placebo, 26.

Rossi 2002 (Continued)

		8%). The statistical analysis was carried out according to the intent-to-treat principle
Selective reporting (reporting bias)	Unclear risk	Key expected outcomes were reported (ex- cept FEV ₁ [secondary] as AUC outcome) . No preregistered protocol was available against which to check all outcomes as re- ported

SLMF4010 2005

Methods	 Design: multicentre, randomised, parallel-group, placebo-controlled, double-blind study Duration: 6 months (run-in not defined) Location: 9 centres in France
Participants	Population : 34 participants were randomly assigned to salmeterol 50 μ g twice daily (17) and placebo (17) Baseline characteristics : Mean age (years): salmeterol, 62.9; placebo, 64.6 % Male: salmeterol, 94.1; placebo, 82.4 % White: salmeterol, 100; placebo, 100 Inclusion criteria : males and females aged 40 and older; history of at least 20 pack- years; diagnosis of COPD; FEV ₁ > 60% of theoretical value, FEV ₁ /TLC ratio > 75% in absolute value and > 85% of theoretical value, FEV ₁ reversibility > 12% and > 200 mL 20 minutes after 400 μ g of salbutamol Exclusion criteria : history of asthma or allergy including non-respiratory signs (bronchial cancer, thoracic surgery, etc.); severe cardiovascular disease; exacerbation and/ or other acute respiratory disease within 4 weeks before enrolment
Interventions	 Salmeterol 50 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Disallowed medications included long-term oxygen therapy; inhaled or systemic corticosteroids and LABAs or theophyllines within 4 weeks of enrolment
Outcomes	 HRQoL: change in St George's Respiratory Questionnaire (SGRQ) from visit 1 to 4 and from visit 4 to 6 COPD exacerbations: number experiencing exacerbations during the study period, and length of hospital stay Lung function: variations in IC, FRC, FEV₁, FIV₁ and total lung capacity (post-salbutamol - pre-salbutamol) Adverse events: non-fatal serious adverse events and all-cause mortality Other: withdrawal, exercise capacity, use of rescue medication, tobacco status
Notes	Funding : GlaxoSmithKline Study number : GSK identifier SLMF 4010 Definitions : Exacerbations were not well defined but included those leading to hospi-

SLMF4010 2005 (Continued)

talisation [coded as moderate and severe for this review]

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly assigned and stratified on to- bacco status [no other details, industry sponsored]
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind [participant and investiga- tor]
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment
Incomplete outcome data (attrition bias) All outcomes	High risk	Withdrawal very high in both groups [41. 2% each]. ITT population included all ran- domly assigned participants who had re- ceived at least one dose of study medication and for whom the assessment data for at least one assessment criterion were available and were analysed on the basis of treatment allocated. Safety population consisted of all randomly assigned participants who had re- ceived at least one dose of study medication and were analysed on the basis of treatment really received
Selective reporting (reporting bias)	Low risk	All stated and expected outcomes could be included in the analyses

Szafranski 2003

Methods	Design : randomised, double-blind, placebo-controlled, parallel-group, multi-centre study
	Duration : 12 months (+ 2 weeks run-in period)
	Location: 89 centres from 11 countries (Årgentina, Brazil, Denmark, Finland, UK, Italy,
	Mexico, Poland, Portugal, South Africa and Spain)
Participants	Population : 406 participants were randomly assigned to formoterol 12 μ g twice daily (201) and placebo (205) Baseline characteristics : Mean age (years): formoterol, 63; placebo, 65

Szafranski 2003 (Continued)

	% Male: formoterol, 76; placebo, 83 % Reversibility: formoterol, 6; placebo, 5 Pack-years: formoterol, 45; placebo, 45 % FEV ₁ predicted: formoterol, 36; placebo, 36 Inclusion criteria : males and females aged 40 and older; symptoms for 2+ years; history of at least 10 pack-years Exclusion criteria : history of asthma or seasonal rhinitis before 40 years of age; relevant cardiovascular disorders; use of beta-blockers; current respiratory tract disorders other than COPD or any other significant diseases or disorders; requiring regular use of oxygen therapy; exacerbation during run-in
Interventions	 Formoterol 12 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: terbutaline (0.5 mg) as reliever. Disallowed medication included parenteral steroids, oral steroids, antibiotics and nebulised treatment from 4 weeks before; inhaled steroids from 2 weeks before; inhaled long-acting beta2-agonists from 48 hours before; inhaled short-acting beta2-agonists from 6 hours before; other bronchodilators from 6 to 48 hours before
Outcomes	 HRQoL: assessed with St George's Respiratory Questionnaire (SGRQ) COPD exacerbations: number of severe exacerbations Lung function: FEV₁, vital capacity, morning and evening PEF Adverse events: all-cause mortality and non-fatal serious adverse events Other: withdrawal, diary card data, short-acting beta₂-agonist use (rescue medication) , use of antitussives and other COPD medication, COPD symptom scores, night-time awakenings due to COPD symptoms, health care contacts and sick leave related to COPD symptoms
Notes	Funding : AstraZeneca Study number : AZ identifier SD-039-CR-0629 Definitions : Exacerbations were defined as intake of a course of oral steroids and/or antibiotics and/or hospitalisation due to respiratory symptoms [coded as moderate and severe in this review]

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A total of 812 participants were randomly assigned [no other details, industry spon- sored]
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind [presumed participant and investigator]

Szafranski 2003 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment
Incomplete outcome data (attrition bias) All outcomes	High risk	Withdrawal high and uneven between groups (formoterol, 31.8%, placebo, 43. 9%). An intention-to-treat analysis was performed
Selective reporting (reporting bias)	Unclear risk	Quality of life [primary] stated as outcome but not reported in enough detail to be in- clude in the meta-analysis. Other outcomes included

Tashkin 2008 [SHINE]

Methods	 Design: randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multicentre study Duration: 6 months (+ 2 weeks run-in period) Location: 194 centres in the USA, Czech Republic, the Netherlands, Poland and South Africa
Participants	 Population: 584 participants were randomly assigned to formoterol 12 μg twice daily (284) and placebo (300) Baseline characteristics: Mean age (years): formoterol, 63.5; placebo, 63.2 % Male: formoterol, 65.5; placebo, 69.0 % White: formoterol, 92.3; placebo, 94.7 Pack-years (median): formoterol, 40; placebo, 40 % FEV₁ predicted: formoterol, 39.6; placebo,41.3 Inclusion criteria: male and female current or former smokers; history of at least 10 pack-years; clinical diagnosis of COPD; 40+ years; symptoms for longer than 2 years; at least one exacerbation treated with oral corticosteroids and/or antibacterials within 1 to 12 months before screening Exclusion criteria: history of asthma or seasonal rhinitis before age 40; significant/ unstable cardiovascular disorder; significant respiratory tract disorder other than COPD; homozygous alpha₁-antitrypsin deficiency or other clinically significant co-morbidities precluding participation
Interventions	 Formoterol 12 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: Allowed medications were ephedrine-free antitussives and mucolytics; nasal corticosteroids; stable-dose non-nebulised ipratropium; cardioselective beta-adrenoceptor antagonists; salbutamol as rescue; oral steroids, xanthines, inhaled beta-agonists and ipratropium as medication for exacerbations. Medications disallowed during the study period were long-acting anticholinergics; inhaled LABAs or SABAs (other than salbutamol); oral beta-adrenoreceptor agonists; ephedrine; leukotriene receptor agonists

Tashkin 2008 [SHINE] (Continued)

	and xanthine derivatives except for short-term use	
Outcomes	 HRQoL: assessed with St George's Respiratory Questionnaire (SGRQ) including number of people reaching threshold for minimal clinically important difference from baseline (4 units) COPD exacerbations: number per participant-treatment year Lung function: predose forced expiratory volume in 1 second (FEV₁) and 1-hour postdose FEV₁, dyspnoea, morning and evening PEF Adverse events: non-fatal serious adverse events and all-cause mortality Other: withdrawal, breathlessness diary 	
Notes	Funding : AstraZeneca Study number : AZ identifier D5899C00002; trial registration NCT00206154 Definitions : Exacerbations were defined as requiring treatment with oral corticosteroids and/or hospitalisation [coded as moderate and severe in this review]	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Eligable participants were randomly as- signed in balanced blocks according to a computer-generated randomisation scheme at each site
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	To maintain blinding, participants received both a pressurised metered dose inhaler (pMDI) and a dry powder inhaler (DPI) containing active treatment or placebo (PL) , or combinations of active treatment and placebo, as appropriate
Blinding of outcome assessment (detection bias) All outcomes	Low risk	ECG results were evaluated by a cardiolo- gist in a blinded fashion through an inde- pendent ECG service provider
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawal rates were similar (21.5% for- moterol, 25.7% placebo), and 'the efficacy analysis set included all randomised pa- tients who received at least one dose of study medication and contributed suffi- cient data for at least one co-primary or sec- ondary efficacy endpoint'
Selective reporting (reporting bias)	Low risk	All stated and expected outcomes were re- ported in full and were included in the quantitative synthesis

Tashkin 2012

Methods	Design : randomised, double-blind, placebo-controlled trial Duration : 6 months (+ 2 weeks run-in period) Location : 131 centres located in South America, Asia, Africa, Europe and North America	
Participants	Population : 421 participants were randomly assigned to formoterol 10 μ g twice daily (209) and placebo (212) Baseline characteristics : Mean age (years): formoterol, 59.6; placebo, 58.8 % Male: formoterol, 72.7; placebo, 80.2 % White: formoterol, 77.0; placebo, 73.1 Pack-years: formoterol, 40.3; placebo, 40.29 Inclusion criteria : males and females aged 40 and older; history of at least 10 pack- years; moderate to severe COPD for at least 2 years; predicted FEV ₁ between 25% and 60% normal Exclusion criteria : exacerbation in the four weeks before randomisation; significant medical illness; diagnosis of asthma, lung cancer or alpha ₁ -antitrypsin deficiency, lobec- tomy, pneumonectomy, lung volume reduction surgery or ocular problems	
Interventions	 Formoterol 10 μg twice daily Placebo Inhaler device: metered dose inhaler Co-medication: Participants were given open-label, short-acting beta₂-agonist (SABA)/ short-acting anticholinergic fixed-dose combination to use as relief medication throughout the study. All long-acting COPD treatments (LABA, ICS, LABA/ICS FDC or long-acting anticholinergics), supplemental oxygen and beta-blocking agents were not allowed during the study period 	
Outcomes	 HRQoL: assessed with St George's Respiratory Questionnaire (SQRQ), reported as both final scores and the number of people experiencing a MCID (improvement or worsening by 4 units) COPD exacerbations: rates of moderate or severe exacerbations Lung function: serial FEV₁ postdose, standardised FEV₁ area under the curve Adverse events: non-fatal serious adverse events and all-cause mortality Other: withdrawal, systemic and ocular effects 	
Notes	Funding : Merck & Co/Schering-Plough Study number : NCT00383435 Definitions : If COPD exacerbation met criteria for a severe AE (e.g. was life-threatening, required hospitalisation or required prolonged hospitalisation), it was recorded as an adverse event (therefore, exacerbation data were coded as moderate in this review)	
Risk of bias		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The sponsor's statistician produced a com- puter-generated randomisation schedule with treatment codes in blocks using SAS.

Tashkin 2012 (Continued)

		Randomisation was stratified according to the participant's smoking status at the time of randomisation
Allocation concealment (selection bias)	Low risk	Randomly assigned treatment was pro- vided to the investigative site by means of an interactive voice response system at the time participants were randomly assigned
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Protocol describes the study masking
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Protocol describes the study masking
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawal rates 17.7% in formoterol group and 25% in placebo group. ITT used
Selective reporting (reporting bias)	Unclear risk	Moderate exacerbations were not reported for the comparison of interest in this review [stated in protocol]

Vogelmeier 2008

Methods	 Design: randomised, partially blinded, placebo-controlled trial Duration: 6 months (+ 2 weeks run-in) Location: outpatient and specialist clinics at 86 centres in Germany (30), Italy (19), Netherlands (9), Russian Federation (9), Poland (7), Czech Republic (4), Spain (4) and Hungary (4)
Participants	Population : 419 participants were randomly assigned to formoterol 10 μg twice daily (210) and placebo (209) Baseline characteristics : Mean age (years): formoterol, 61.8; placebo, 62.5 % Male: formoterol, 75.7; placebo, 77.5 % Reversibility: formoterol, 11.4; placebo, 11.4 Pack-years: formoterol, 35.4; placebo, 40.1 % FEV ₁ predicted: formoterol, 51.6; placebo, 51.1 % taking ICS: 40.6 to 43.9 across groups Inclusion criteria : males and females aged 40 and older; history of at least 10 pack- years; FEV ₁ < 70% predicted normal; FEV ₁ /FVC < 70% Exclusion criteria : respiratory tract infection or hospitalised for an acute exacerbation within the month before screening; clinically significant condition other than COPD such as ischaemic heart disease

Vogelmeier 2008 (Continued)

Interventions	 Formoterol 10 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: salbutamol as rescue (but not in the 8 hours before a study visit); inhaled corticosteroids (ICS) were allowed at a stable daily dose. Any participants receiving fixed combinations of ICS and beta₂-agonists were switched to receive the same dose of ICS and on-demand salbutamol
Outcomes	 HRQoL: assessed with St Geoge's Respiratory Questionnaire (SGRQ) COPD exacerbations: rates of moderate and severe exacerbations Lung function: FEV₁ and FEV measured at 5 minutes, 2 hours and 3 hours postdose, PEF Adverse events: all-cause mortality Other: withdrawal, 6-minute walk test, haematology, blood chemistry, ECG, daily diary card recoding symptoms, rescue salbutamol use
Notes	Funding : Novartis Study number : NCT00134979 Definitions : Moderate exacerbation was defined as requiring additional treatment; severe exacerbations were those leading to hospitalisation

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random assignment was not stratified [no other information given but assumed to fol- low conventional Novartis sequence gener- ation methods]
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The study was double-blind for the treat- ment comparison used in this review
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No specific details regarding blinded out- come assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Dropout low and even between groups (formoterol, 11.9%, placebo, 14.4%). In- tent-to-treat (ITT) population consisted of all randomly assigned participants who re- ceived at least one dose of study medica- tion. This population was used for efficacy and safety analyses

Vogelmeier 2008 (Continued)

Selective reporting (reporting bias)	High risk	FEV1 and SGRQ outcomes provided only in graphical form with inexact P-values	
Wadbo 2002			
Methods	Design : randomised, double- Duration : 3 months (+ 2 wee Location : 14 centres in Swed	eks run-in period)	
Participants	Population : 121 participants were randomly assigned to formoterol 24 μ g twice of (61) and placebo (60) Baseline characteristics : Mean age (years): formoterol, 63.6; placebo, 63.6 % Male: formoterol, 54.1; placebo, 50.0 % Reversibility: formoterol, 5.8; placebo, 6.0 % FEV ₁ predicted: formoterol, 33.3; placebo, 32.6 Inclusion criteria : males and females aged 40 to 75 years; history of at least 10 p years; diagnosis of COPD; history of reduced exercise capacity due to dyspnoea exertion; FEV ₁ < 60% predicted normal and FEV ₁ /FVC < 70% Exclusion criteria : adult asthma		
Interventions	 Formoterol 24 μg twice daily Placebo Inhaler device: dry powder inhaler Co-medication: inhaled short-acting beta₂-agonists allowed as relief medication, and haled glucocorticoids and mucolytics allowed at a constant dose. No other bronchod tor medication permitted during the study, and participants requiring long-term oxy; therapy excluded 		
Outcomes	COPD exacerbations : not ret Lung function : FEV ₁ and FV Adverse events : non-fatal seri	C, walking and evening PEF, dyspnoea	
Notes	Funding: Lund Study number: unknown		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants with a walking distance < 300 m were sequentially assigned the lowest randomisation number, and participants with a walking distance > 300 m were sequentially assigned the highest available

Wadbo 2002 (Continued)

		randomisation number
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	Double-blind study desi and investigators]	
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Investigator- and participant-rated out- comes [both blind]
Incomplete outcome data (attrition bias) All outcomes	Low risk	Dropout was relatively high but even be- tween groups (formoterol, 27.9%; placebo, 26.7%). All analyses were performed ac- cording to the intention-to-treat approach
Selective reporting (reporting bias)	High risk	Key expected outcomes not reported (mor- tality and exacerbation rates), and no vari- ance given for FEV1 outcome

Watkins 2002

Methods	Design : randomised, double-blind trial Duration : 3 months
Participants	 Population: 182 participants were randomly assigned to salmeterol 50 g twice daily (87) and placebo (95) Baseline characteristics: no baseline data reported Inclusion criteria: no information Exclusion criteria: no information
Interventions	 Salmeterol 50 g twice daily Placebo Inhaler device: dry powder inhaler Co-medication: no information
Outcomes	HRQoL: no information COPD exacerbations: no information Lung function: FEV ₁ area under the curve Adverse events: no information Other: no information
Notes	Funding: GlaxoSmithKline Study number: unknown Only a conference abstract was available for this report, so no data could be included in the meta-analysis
Risk of bias	

Watkins 2002 (Continued)

Bias	Authors' judgement	Support for judgement	
Random sequence generation (selection bias)	Unclear risk	No information provided	
Allocation concealment (selection bias)	Unclear risk	No information provided	
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as double-blind [assumed inves- tigator and participant]	
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided, but no outcomes could be included	
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information provided regarding with- drawal rates or method of imputation	
Selective reporting (reporting bias)	High risk	No full-text paper-only information from conference abstract. No outcomes could be included	

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Boyd 1995	More than 50% taking other COPD medications [84% in total-including ICS, oral CS, methylxanthines, anticholinergics and beta ₂ -agonists]
Celli 2003	More than 50% taking other COPD medications [55% SABA, 54% ICS/oral CS, 33% anticholinergics, 25% LABAs, 22% xanthines]
Chapman 2002	More than 50% taking other COPD medications [placebo 55% and LABA 68% taking ICS; placebo 17% and LABA 24% taking theophylline]
Dal Negro 2003	More than 50% taking other COPD medications [all treated with theophylline]
Rutten-van Molken 1999	More than 50% taking other COPD medications [81% of salmeterol group and 76% of placebo group taking ICS, and all maintenance drugs other than the study medication continued at constant dosage]
Steffensen 1996	Entry criteria specified reversible obstructive airways disease, including asthma. Subgroups not reported
Stockley 2006	More than 50% taking other COPD medications [LABA 86% and placebo 89% in total-including ICS, anticholinergics and xanthines]

Characteristics of studies awaiting assessment [ordered by study ID]

Fattore 2005

Methods	Design : cost-analysis data were collected alongside a 12-month, multinational, randomised, double-blind, placebo- controlled trial Location : Italian National Health Service
Participants	272 participants (mean age = 65.27 years) equally distributed in four treatment groups [two of which received formoterol and placebo]
Interventions	Formoterol (? dose)Placebo
Outcomes	Average total cost per participant per year
Notes	Unclear which 12-month trial this ran alongside

Characteristics of ongoing studies [ordered by study ID]

NCT01437397

Trial name or title	Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAC)
Methods	Design : randomised, double-blind, parallel-group, efficacy study Conducted at 208 study centres in four countries (Australia, Canada, New Zealand and the United States)
Participants	Inclusion criteria: current or former cigarette smokers at least 40 years of age with a cigarette smoking history of at least 10 pack-years; a diagnosis of stable moderate to severe COPD and stable airway obstruction as defined by the GOLD guidelines Exclusion criteria: patients who had been hospitalised for an acute COPD exacerbation within three months before visit 1; also, patients with any respiratory tract infection or COPD exacerbation in the 6 weeks before visit 1; any clinically significant respiratory conditions other than COPD; clinical history that suggests that the patient has asthma as opposed to COPD; long-term use of oxygen therapy > 15 hours/d; clinically significant cardiovascular condition; history of hypersensitivity reaction to inhaled anticholinergics
Interventions	 Formoterol 12 μg twice daily Placebo twice daily The study also randomly assigned people to three aclidinium groups that were not relevant to the review
Outcomes	Primary : morning predose (trough) forced expiratory volume in one second (FEV ₁) at week 24; time frame: change from baseline (week 0) to 24 weeks. Morning one-hour postdose FEV ₁ at week 24; time frame: change from baseline (Week 0) to 24 weeks Secondary : change from baseline in St George's Respiratory Questionnaire (SGRQ) total score, improvement in Transition Dyspnea Index (TDI) score
Starting date	First received on clinicaltrials.gov September 19, 2011

NCT01437397 (Continued)

Contact information	Funded by Forest Laboratories, no contact information listed			
Notes	Completed but no results posted. Final data collection for primary outcome in February 2013			
NCT01572792				
Trial name or title	Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fu- marate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)			
Methods	Design : randomised, double-blind, parallel-group, safety/efficacy study Conducted at 208 study centres in four countries (Australia, Canada, New Zealand and the United States)			
Participants	To be included in the extension phase, participants had to complete the treatment phase of the lead-in study (LAC-MD-31/NCT01437397) and provide written informed consent			
Interventions	 All participants remained in the same treatment group as for the lead-in study (NCT01437397) and continued on one of the four treatment arms or placebo Formoterol 12 μg twice daily Placebo twice daily The study also randomly assigned people to three aclidinium groups that were not relevant to the review 			
Outcomes	Primary : adverse events, clinical laboratory parameters, vital sign measurement, and electrocardiogram parameters			
Starting date	First received on clinicaltrials.gov April 4, 2012			
Contact information	Funded by Forest Laboratories, no contact information listed			
Notes	Completed but no results posted. Final data collection for primary outcome in June 2013			

DATA AND ANALYSES

Comparison 1. All LABA versus placebo [subgrouped by drug]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Quality of life (SGRQ total score)	17	11397	Mean Difference (IV, Random, 95% CI)	-2.32 [-3.09, -1.54]
1.1 Formoterol 12 μ g twice daily	11	5587	Mean Difference (IV, Random, 95% CI)	-2.66 [-3.84, -1.48]
1.2 Formoterol 24 μ g twice daily	3	627	Mean Difference (IV, Random, 95% CI)	-2.51 [-4.51, -0.51]
1.3 Salmeterol 50 μ g twice daily	5	5183	Mean Difference (IV, Random, 95% CI)	-1.64 [-2.78, -0.50]
2 Quality of life (number of people achieving the MCID on the SGRQ)	3	1871	Odds Ratio (M-H, Fixed, 95% CI)	1.58 [1.32, 1.90]
2.1 Formoterol 12 μ g twice daily	1	397	Odds Ratio (M-H, Fixed, 95% CI)	3.11 [2.06, 4.70]
2.2 Salmeterol 50 μ g twice daily	2	1474	Odds Ratio (M-H, Fixed, 95% CI)	1.33 [1.08, 1.64]
3 Quality of life (CRQ)	4	1193	Mean Difference (IV, Fixed, 95% CI)	3.10 [1.22, 4.98]
3.1 Salmeterol 50 μ g twice daily	4	1193	Mean Difference (IV, Fixed, 95% CI)	3.10 [1.22, 4.98]
4 Severe exacerbations (hospitalisations)	7	3804	Odds Ratio (M-H, Fixed, 95% CI)	0.73 [0.56, 0.95]
4.1 Formoterol 12 μ g twice daily	6	2418	Odds Ratio (M-H, Fixed, 95% CI)	0.75 [0.55, 1.02]
4.2 Formoterol 24 μ g twice daily	2	581	Odds Ratio (M-H, Fixed, 95% CI)	0.28 [0.11, 0.73]
4.3 Salmeterol 50 μ g twice daily	1	805	Odds Ratio (M-H, Fixed, 95% CI)	0.99 [0.52, 1.86]
5 Severe/moderate exacerbations (hospitalisation <i>or</i> course of meds <i>or</i> ER visit	7	3968	Odds Ratio (M-H, Fixed, 95% CI)	0.88 [0.76, 1.02]
5.1 Formoterol 12 μ g twice daily	4	2682	Odds Ratio (M-H, Fixed, 95% CI)	0.87 [0.73, 1.04]
5.2 Salmeterol 50 μ g twice daily	3	1286	Odds Ratio (M-H, Fixed, 95% CI)	0.90 [0.69, 1.16]
6 Moderate exacerbations (course of antibiotics and/or steroids)	7	3375	Odds Ratio (M-H, Fixed, 95% CI)	0.73 [0.61, 0.87]
6.1 Formoterol 12 μ g twice daily	3	968	Odds Ratio (M-H, Fixed, 95% CI)	0.74 [0.51, 1.05]
6.2 Formoterol 24 μ g twice daily	1	324	Odds Ratio (M-H, Fixed, 95% CI)	0.59 [0.35, 0.97]
6.3 Salmeterol 50 μ g twice daily	4	2083	Odds Ratio (M-H, Fixed, 95% CI)	0.75 [0.60, 0.94]
7 Mortality (all-cause)	23	14079	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.90 [0.75, 1.08]

7.1 Formoterol 12 μ g twice	13	6343	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.41 [0.87, 2.30]
daily				
7.2 Formoterol 24 μ g twice	2	615	Peto Odds Ratio (Peto, Fixed, 95% CI)	4.54 [0.07, 285.14]
daily				
7.3 Salmeterol 50 μ g twice	10	7121	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.83 [0.69, 1.01]
daily				
8 People with one or more	20	12446	Odds Ratio (M-H, Random, 95% CI)	0.97 [0.83, 1.14]
non-fatal serious adverse event				
8.1 Formoterol 12 μ g twice	10	4829	Odds Ratio (M-H, Random, 95% CI)	1.20 [0.99, 1.45]
daily				
8.2 Formoterol 24 μ g twice	3	737	Odds Ratio (M-H, Random, 95% CI)	0.42 [0.23, 0.77]
daily				
8.3 Salmeterol 50 μ g twice	9	6880	Odds Ratio (M-H, Random, 95% CI)	0.93 [0.78, 1.10]
daily		0000		0.99 [0., 0, 1110]
9 Predose FEV ₁ (mL)	13	6125	Mean Difference (IV, Random, 95% CI)	72.92 [48.02, 97.82]
9.1 Formoterol 12 μ g twice	6	3222	Mean Difference (IV, Random, 95% CI)	44.68 [29.39, 59.97]
daily	Ũ	5222		1100 [20.000, 00.007]
9.2 Salmeterol 50 μ g twice	7	2903	Mean Difference (IV, Random, 95% CI)	101.01 [59.84, 142.
daily	/	2905	Wear Difference (17, Randolli, 7970 Cl)	18]
10 Withdrawal	25	14763	Odds Ratio (M-H, Fixed, 95% CI)	0.74 [0.69, 0.80]
10.1 Formoterol 12 μ g twice	14	6597	Odds Ratio (M-H, Fixed, 95% CI)	0.76 [0.68, 0.86]
daily	11	0,777		0.70 [0.00, 0.00]
10.2 Formoterol 24 μ g twice	4	1001	Odds Ratio (M-H, Fixed, 95% CI)	0.81 [0.58, 1.14]
daily	т	1001	Ouds Natio (W-11, 11xcu, 7)/0 Ci)	0.01 [0.00, 1.14]
	10	7165	Odds Datis (M H Eined 0504 CI)	0.72 [0.65 0.80]
10.3 Salmeterol 50 μ g twice	10	7165	Odds Ratio (M-H, Fixed, 95% CI)	0.72 [0.65, 0.80]
daily				

Comparison 2. Formoterol 12 μ g versus placebo [subgrouped by trial duration]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Quality of life (SGRQ)	11		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 3 months	3	1627	Mean Difference (IV, Random, 95% CI)	-3.86 [-5.25, -2.46]
1.2 6 months	5	2427	Mean Difference (IV, Random, 95% CI)	-1.14 [-2.51, 0.23]
1.3 12 months	5	3079	Mean Difference (IV, Random, 95% CI)	-3.24 [-4.77, -1.71]
2 Severe exacerbations	6	2614	Odds Ratio (M-H, Fixed, 95% CI)	0.73 [0.54, 0.98]
(hospitalisations)				
2.1 3 months	1	353	Odds Ratio (M-H, Fixed, 95% CI)	0.47 [0.08, 2.60]
2.2 6 months	3	1319	Odds Ratio (M-H, Fixed, 95% CI)	0.53 [0.26, 1.08]
2.3 12 months	2	942	Odds Ratio (M-H, Fixed, 95% CI)	0.80 [0.57, 1.12]
3 Moderate exacerbations (course	3	1078	Odds Ratio (M-H, Fixed, 95% CI)	0.78 [0.56, 1.07]
of antibiotics and/or steroids)				
3.1 3 months	1	228	Odds Ratio (M-H, Fixed, 95% CI)	0.76 [0.27, 2.12]
3.2 6 months	1	419	Odds Ratio (M-H, Fixed, 95% CI)	0.53 [0.28, 0.99]
3.3 12 months	1	431	Odds Ratio (M-H, Fixed, 95% CI)	0.92 [0.62, 1.37]
4 Mortality (all-cause)	13	6553	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.45 [0.89, 2.37]
4.1 3 months	5	1927	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.22 [0.64, 7.70]
4.2 6 months	4	1946	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.25 [0.98, 5.16]

4.3 12 months	4	2680	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.94 [0.47, 1.88]
5 Patients with one or more serious	10	5039	Odds Ratio (M-H, Fixed, 95% CI)	1.20 [1.00, 1.43]
adverse event				
5.1 3 months	2	799	Odds Ratio (M-H, Fixed, 95% CI)	1.21 [0.57, 2.58]
5.2 6 months	4	1916	Odds Ratio (M-H, Fixed, 95% CI)	1.10 [0.78, 1.55]
5.3 12 months	4	2324	Odds Ratio (M-H, Fixed, 95% CI)	1.23 [1.00, 1.52]
6 Predose FEV ₁ (mL)	6	3222	Mean Difference (IV, Fixed, 95% CI)	44.68 [29.39, 59.97]
6.1 3 months	1	407	Mean Difference (IV, Fixed, 95% CI)	40.0 [16.29, 63.71]
6.2 6 months	3	1437	Mean Difference (IV, Fixed, 95% CI)	44.41 [18.63, 70.18]
6.3 12 months	2	1378	Mean Difference (IV, Fixed, 95% CI)	53.46 [21.74, 85.17]
7 Withdrawal	14	6894	Odds Ratio (M-H, Fixed, 95% CI)	0.77 [0.69, 0.86]
7.1 3 months	4	1368	Odds Ratio (M-H, Fixed, 95% CI)	0.69 [0.50, 0.94]
7.2 6 months	5	2335	Odds Ratio (M-H, Fixed, 95% CI)	0.72 [0.59, 0.89]
7.3 12 months	5	3191	Odds Ratio (M-H, Fixed, 95% CI)	0.81 [0.70, 0.94]

Comparison 3. Formoterol 24 μ g versus placebo [subgrouped by trial duration]

Outcome or subgroup title	No. of Itcome or subgroup title studies par		Statistical method	Effect size
1 Quality of life (SGRQ)	3	707	Mean Difference (IV, Fixed, 95% CI)	-2.32 [-4.52, -0.13]
1.1 3 months	2	376	Mean Difference (IV, Fixed, 95% CI)	-2.04 [-4.65, 0.56]
1.2 12 months	1	331	Mean Difference (IV, Fixed, 95% CI)	-3.0 [-7.06, 1.06]
2 Severe exacerbations	2	777	Odds Ratio (M-H, Fixed, 95% CI)	0.28 [0.12, 0.67]
(hospitalisations)				
2.1 3 months	1	343	Odds Ratio (M-H, Fixed, 95% CI)	0.50 [0.09, 2.75]
2.2 12 months	1	434	Odds Ratio (M-H, Fixed, 95% CI)	0.24 [0.09, 0.65]
3 Moderate exacerbations (course	1		Odds Ratio (M-H, Fixed, 95% CI)	Totals not selected
of antibiotics and/or steroids)				
3.1 12 months	1		Odds Ratio (M-H, Fixed, 95% CI)	$0.0 \ [0.0, 0.0]$
4 Mortality (all-cause)	2	825	Peto Odds Ratio (Peto, Fixed, 95% CI)	7.60 [0.15, 383.12]
4.1 3 months	1	391	Peto Odds Ratio (Peto, Fixed, 95% CI)	$0.0 \ [0.0, 0.0]$
4.2 12 months	1	434	Peto Odds Ratio (Peto, Fixed, 95% CI)	7.60 [0.15, 383.12]
5 People with one or more	3	947	Odds Ratio (M-H, Fixed, 95% CI)	0.53 [0.36, 0.79]
non-fatal serious adverse events				
5.1 3 months	2	513	Odds Ratio (M-H, Fixed, 95% CI)	0.36 [0.14, 0.94]
5.2 12 months	1	434	Odds Ratio (M-H, Fixed, 95% CI)	0.58 [0.38, 0.89]
6 Withdrawal	4	1297	Odds Ratio (M-H, Fixed, 95% CI)	0.79 [0.59, 1.05]
6.1 3 months	3	863	Odds Ratio (M-H, Fixed, 95% CI)	0.92 [0.64, 1.33]
6.2 12 months	1	434	Odds Ratio (M-H, Fixed, 95% CI)	0.63 [0.40, 0.99]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Quality of life (SGRQ)	5	5183	Mean Difference (IV, Random, 95% CI)	-1.64 [-2.78, -0.50]
1.1 6 months	3	1405	Mean Difference (IV, Random, 95% CI)	-3.10 [-6.03, -0.17]
1.2 12 months	1	733	Mean Difference (IV, Random, 95% CI)	-1.10 [-2.35, 0.15]
1.3 36 months	1	3045	Mean Difference (IV, Random, 95% CI)	-1.0 [-2.00, 2.14]
2 Severe exacerbations	1		Odds Ratio (M-H, Fixed, 95% CI)	Totals not selected
(hospitalisations)				
2.1 6 months	1		Odds Ratio (M-H, Fixed, 95% CI)	$0.0 \ [0.0, \ 0.0]$
3 Moderate exacerbations (course	4	2083	Odds Ratio (M-H, Fixed, 95% CI)	0.75 [0.60, 0.94]
of antibiotics and/or steroids)				
3.1 3 months	2	545	Odds Ratio (M-H, Fixed, 95% CI)	0.71 [0.49, 1.03]
3.2 6 months	1	805	Odds Ratio (M-H, Fixed, 95% CI)	0.84 [0.63, 1.12]
3.3 12 months	1	733	Odds Ratio (M-H, Fixed, 95% CI)	0.40 [0.17, 0.92]
4 Mortality (all-cause)	10	7121	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.83 [0.69, 1.01]
4.1 3 months	3	1132	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.14 [0.00, 6.98]
4.2 6 months	5	2211	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.56 [0.22, 1.46]
4.3 12 months	1	733	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.43 [0.12, 1.50]
4.4 36 months	1	3045	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.87 [0.71, 1.06]
5 People with one or more	9	6880	Odds Ratio (M-H, Fixed, 95% CI)	0.94 [0.83, 1.06]
non-fatal serious adverse events				
5.1 3 months	2	850	Odds Ratio (M-H, Fixed, 95% CI)	0.81 [0.45, 1.46]
5.2 6 months	5	2211	Odds Ratio (M-H, Fixed, 95% CI)	0.74 [0.55, 1.01]
5.3 12 months	1	733	Odds Ratio (M-H, Fixed, 95% CI)	1.29 [0.88, 1.91]
5.4 36 months	1	3086	Odds Ratio (M-H, Fixed, 95% CI)	0.96 [0.83, 1.11]
6 Predose FEV ₁ (mL)	7	2903	Mean Difference (IV, Random, 95% CI)	101.01 [59.84, 142. 18]
6.1 3 months	2	765	Mean Difference (IV, Random, 95% CI)	146.86 [114.38, 179.34]
6.2 6 months	4	1405	Mean Difference (IV, Random, 95% CI)	87.93 [39.05, 136. 80]
6.3 12 months	1	733	Mean Difference (IV, Random, 95% CI)	59.0 [28.52, 89.48]
7 Withdrawal	10	7165	Odds Ratio (M-H, Fixed, 95% CI)	0.72 [0.65, 0.80]
7.1 3 months	3	1132	Odds Ratio (M-H, Fixed, 95% CI)	0.60 [0.44, 0.83]
7.2 6 months	5	2211	Odds Ratio (M-H, Fixed, 95% CI)	0.72 [0.59, 0.88]
7.3 12 months	1	733	Odds Ratio (M-H, Fixed, 95% CI)	0.74 [0.55, 1.01]
7.4 36 months	1	3089	Odds Ratio (M-H, Fixed, 95% CI)	0.74 [0.64, 0.86]

Comparison 4. Salmeterol 50 μ g versus placebo [subgrouped by trial duration]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Quality of life (SGRQ)	12	8520	Mean Difference (IV, Fixed, 95% CI)	-1.53 [-2.08, -0.98]
1.1 Formoterol 12 μ g twice daily	7	3782	Mean Difference (IV, Fixed, 95% CI)	-2.16 [-3.04, -1.27]
1.2 Formoterol 24 μ g twice daily	1	121	Mean Difference (IV, Fixed, 95% CI)	-1.50 [-4.62, 1.62]
1.3 Salmeterol 50 μ g twice daily	4	4617	Mean Difference (IV, Fixed, 95% CI)	-1.12 [-1.84, -0.39]
2 Severe exacerbations (hospitalisations)	3	1795	Odds Ratio (M-H, Fixed, 95% CI)	0.85 [0.62, 1.16]
2.1 Formoterol 12 μ g twice daily	2	990	Odds Ratio (M-H, Fixed, 95% CI)	0.81 [0.57, 1.15]
2.2 Salmeterol 50 μ g twice daily	1	805	Odds Ratio (M-H, Fixed, 95% CI)	0.99 [0.52, 1.86]

Comparison 5. [Sensitivity analysis-ICS use] All LABA versus placebo

Comparison 6. [Sensitivity analysis-attrition] All LABA versus placebo

Outcome or subgroup title	No. of ome or subgroup title studies		Statistical method	Effect size
1 Quality of life (SGRQ)	13	9114	Mean Difference (IV, Fixed, 95% CI)	-1.60 [-2.15, -1.05]
1.1 Formoterol 12 μ g twice	8	3338	Mean Difference (IV, Fixed, 95% CI)	-2.07 [-3.06, -1.08]
daily				
1.2 Formoterol 24 μ g twice	3	627	Mean Difference (IV, Fixed, 95% CI)	-2.25 [-4.56, 0.06]
daily				
1.3 Salmeterol 50 μ g twice	4	5149	Mean Difference (IV, Fixed, 95% CI)	-1.31 [-2.01, -0.61]
daily				

Analysis I.I. Comparison I All LABA versus placebo [subgrouped by drug], Outcome I Quality of life (SGRQ total score).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: I All LABA versus placebo [subgrouped by drug]

Outcome: I Quality of life (SGRQ total score)

Study or subgroup	laba N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI
I Formoterol 12 $_{\mu}$ g twice daily							
Bogdan 2011 (1)	199	38.2 (14.5)	206	42.9 (14.5)		4.7 %	-4.70 [-7.52, -1.88]
Calverley 2003a	255	0.8 (17)	256	4.7 (17)		4.5 %	-3.90 [-6.85, -0.95]
Campbell 2005	215	-3.81 (13.5737)	217	-4.61 (13.5737)		5.3 %	0.80 [-1.76, 3.36]
Dahl 2001 (2)	181	41.7 (11.8)	86	46.8 (11.8)		4.3 %	-5.10 [-8.13, -2.07]
Dahl 2010	435	-5.7 (15.0231)	432	-1.7 (15.0231)		6.8 %	-4.00 [-6.00, -2.00]
Doherty 2012 (3)	243	-4.93 (14.5)	236	-2.88 (14.5)		5.2 %	-2.05 [-4.65, 0.55]
Rennard 2009	495	-2.9 (13.3)	481	-1.5 (12.7)		8.0 %	-1.40 [-3.03, 0.23]
Rossi 2002	159	40.9 (17.8)	80	45.3 (18.7)		2.1 %	-4.40 [-9.34, 0.54]
Szafranski 2003	201	-3.6 (15)	205	-0.03 (15)		4.5 %	-3.57 [-6.49, -0.65]
Tashkin 2008 [SHINE]	284	-1.24 (11.35)	300	-1.02 (12.41)		7.0 %	-0.22 [-2.15, 1.71]
Tashkin 2012	209	-6.19 (15.2)	212	-2.88 (15.2)		4.5 %	-3.31 [-6.21, -0.41]
	209 2876	-6.19 (15.2)	212 2711	-2.88 (15.2)	•		-3.31 [-6.21, -0.41] -2.66 [-3.84, -1.48]
Tashkin 2012 Subtotal (95% CI) Heterogeneity: Tau ² = 2.12; Chi ² = Test for overall effect: Z = 4.44 (P	2876	= 10 (P = 0.01); I	2711	-2.88 (15.2)	•		
Subtotal (95% CI) Heterogeneity: Tau ² = 2.12; Chi ² = Test for overall effect: Z = 4.44 (P • 2 Formoterol 24 µ g twice daily	2876 = 23.11, df < 0.00001	T = 10 (P = 0.01); 1	2711 ¹² =57%		→	57.0 %	
Subtotal (95% CI) Heterogeneity: Tau ² = 2.12; Chi ² = Test for overall effect: Z = 4.44 (P < 2 Formoterol 24 μ g twice daily Dahl 2001	2876 = 23.11, df < 0.00001 169	= 10 (P = 0.01); 1) 43.5 (11.8)	2711 ¹² =57% 86	46.8 (11.8)	• •	57.0 % 4.2 %	- 2.66 [- 3.84 , - 1.48] -3.30 [-6.36, -0.24]
Subtotal (95% CI) Heterogeneity: Tau ² = 2.12; Chi ² = Test for overall effect: Z = 4.44 (P • 2 Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002	2876 = 23.11, df < 0.00001 169 171	² = 10 (P = 0.01); 1) 43.5 (11.8) 42.3 (19)	2711 ¹² =57% 86 80	46.8 (11.8) 45.3 (18.7)	• •	57.0 % 4.2 % 2.0 %	-2.66 [-3.84, -1.48] -3.30 [-6.36, -0.24] -3.00 [-7.99, 1.99]
Subtotal (95% CI) Heterogeneity: Tau ² = 2.12; Chi ² = Test for overall effect: Z = 4.44 (P < 2 Formoterol 24 μ g twice daily Dahl 2001	2876 = 23.11, df < 0.00001 169	= 10 (P = 0.01); 1) 43.5 (11.8)	2711 ¹² =57% 86	46.8 (11.8)	• •	57.0 % 4.2 %	-2.66 [-3.84, -1.48] -3.30 [-6.36, -0.24] -3.00 [-7.99, 1.99]
Subtotal (95% CI) Heterogeneity: Tau ² = 2.12; Chi ² = Test for overall effect: Z = 4.44 (P • 2 Formoterol 24 µ g twice daily Dahl 2001 Rossi 2002	2876 = 23.11, df < 0.00001 169 171 61 401 0.70, df =	<pre>F = 10 (P = 0.01); I) 43.5 (11.8) 42.3 (19) 0 (8.59)</pre>	2711 ² =57% 86 80 60 226	46.8 (11.8) 45.3 (18.7)		57.0 % 4.2 % 2.0 % 4.1 %	-2.66 [-3.84, -1.48] -3.30 [-6.36, -0.24] -3.00 [-7.99, 1.99] -1.50 [-4.62, 1.62]
Subtotal (95% CI) Heterogeneity: Tau ² = 2.12; Chi ² = Test for overall effect: Z = 4.44 (P < 2 Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002 Wadbo 2002 Subtotal (95% CI) Heterogeneity: Tau ² = 0.0; Chi ² = 0 Test for overall effect: Z = 2.46 (P = 3 Salmeterol 50 μ g twice daily	2876 = 23.11, df < 0.00001 169 171 61 401 0.70, df = = 0.014)	 = 10 (P = 0.01); 1 43.5 (11.8) 42.3 (19) 0 (8.59) 2 (P = 0.71); 1² = 	2711 ² =57% 86 80 60 226 0.0%	46.8 (11.8) 45.3 (18.7) 1.5 (8.9034)		57.0 % 4.2 % 2.0 % 4.1 % 10.4 %	-2.66 [-3.84, -1.48] -3.30 [-6.36, -0.24] -3.00 [-7.99, 1.99] -1.50 [-4.62, 1.62] -2.51 [-4.51, -0.51]
Subtotal (95% CI) Heterogeneity: Tau ² = 2.12; Chi ² = Test for overall effect: $Z = 4.44$ (P · 2 Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002 Wadbo 2002 Subtotal (95% CI) Heterogeneity: Tau ² = 0.0; Chi ² = 0 Test for overall effect: $Z = 2.46$ (P =	2876 = 23.11, df < 0.00001 169 171 61 401 0.70, df =	<pre>F = 10 (P = 0.01); I) 43.5 (11.8) 42.3 (19) 0 (8.59)</pre>	2711 ² =57% 86 80 60 226	46.8 (11.8) 45.3 (18.7)		57.0 % 4.2 % 2.0 % 4.1 %	-2.66 [-3.84, -1.48] -3.30 [-6.36, -0.24] -3.00 [-7.99, 1.99] -1.50 [-4.62, 1.62] -2.51 [-4.51, -0.51]
Subtotal (95% CI) Heterogeneity: Tau ² = 2.12; Chi ² = Test for overall effect: Z = 4.44 (P < 2 Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002 Wadbo 2002 Subtotal (95% CI) Heterogeneity: Tau ² = 0.0; Chi ² = 0 Test for overall effect: Z = 2.46 (P = 3 Salmeterol 50 μ g twice daily	2876 = 23.11, df < 0.00001 169 171 61 401 0.70, df = = 0.014) 405	 = 10 (P = 0.01); 1 43.5 (11.8) 42.3 (19) 0 (8.59) 2 (P = 0.71); 1² = 	2711 ² =57% 86 80 60 226 0.0%	46.8 (11.8) 45.3 (18.7) 1.5 (8.9034)		57.0 % 4.2 % 2.0 % 4.1 % 10.4 %	-2.66 [-3.84, -1.48]

Favours LABA Favours placebo

data for Bogdan 2011, Dahl 2001, Rossi 2002, and Calverley 2003b [TRISTAN] are entered as endpoint scores.

(Continued ...)

 $\label{eq:long-acting beta_2-agonists for chronic obstructive pulmonary disease (Review) \\ Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. \\$

86

								(Continued)
Study or subgroup	LABA		Placebo		Diffe	Mean erence	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Rand	om,95% Cl		IV,Random,95% CI
Kornmann 2011	292	-5.6 (15.4)	274	-1.5 (14.9)			5.4 %	-4.10 [-6.60, -1.60]
SLMF4010 2005	17	-7.1 (15.2555)	17	2.7 (16.0801)	•	+	0.5 %	-9.80 [-20.34, 0.74]
Subtotal (95% CI)	2607		2576		•		32.6 %	-1.64 [-2.78, -0.50]
Heterogeneity: Tau ² = 0.73; Chi ²	= 7.76, df =	4 (P = 0.10); I ² =	=48%					
Test for overall effect: $Z = 2.81$ (P = 0.0049)							
Total (95% CI)	5884		5513		+		100.0 %	-2.32 [-3.09, -1.54]
Heterogeneity: Tau ² = 1.27; Chi ²	= 36.00, df	= 18 (P = 0.01); I	² =50%					
Test for overall effect: $Z = 5.83$ (P < 0.00001))						
Test for subgroup differences: Ch	$i^2 = 1.60$, df	= 2 (P = 0.45), I ²	=0.0%					
							1	
				-	10 -5	0 5	10	

Favours LABA Favours placebo

data for Bogdan 2011, Dahl 2001, Rossi 2002, and Calverley 2003b [TRISTAN] are entered as endpoint scores.

(1) Last available score with imputed SD (based on other studies). Change from baseline data and endpoint data were pooled in the analysis. Most studies reported change from baseline but

(2) SDs calculated from ANCOVA confidence intervals

(3) SDs for Doherty 2012 and Szafranski 2003 were imputed based on population variance and that of other arms within the studies

(4) Adjusted mean at endpoint

 $\label{eq:long-acting beta_2-agonists for chronic obstructive pulmonary disease (Review) \\ Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. \\$

87

Analysis 1.2. Comparison I All LABA versus placebo [subgrouped by drug], Outcome 2 Quality of life (number of people achieving the MCID on the SGRQ).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: I All LABA versus placebo [subgrouped by drug]

Outcome: 2 Quality of life (number of people achieving the MCID on the SGRQ)

Study or subgroup	LABA	Placebo		0	dds Ratio		Weight	Odds Ratio
	n/N	n/N		M-H,Fixe	ed,95% C			M-H,Fixed,95% Cl
I Formoterol 12 µ g twice dail	у							
Bogdan 2011	3 / 9	85/206					14.2 %	3.11 [2.06, 4.70]
Subtotal (95% CI)	191	206					14.2 %	3.11 [2.06, 4.70]
Total events: 131 (LABA), 85 (Placebo)							
Heterogeneity: not applicable								
Test for overall effect: $Z = 5.39$	9 (P < 0.00001)							
2 Salmeterol 50 µ g twice daily								
Brusasco 2003	175/405	157/400		+	•		49.6 %	1.18 [0.89, 1.56]
Kornmann 2011	162/334	127/335					36.1 %	1.54 [1.13, 2.10]
Subtotal (95% CI)	739	735			•		85.8 %	1.33 [1.08, 1.64]
Total events: 337 (LABA), 284	(Placebo)							
Heterogeneity: Chi ² = 1.61, df	= I (P = 0.20); I ² =	-38%						
Test for overall effect: $Z = 2.71$	(P = 0.0068)							
Total (95% CI)	930	941			•		100.0 %	1.58 [1.32, 1.90]
Total events: 468 (LABA), 369	(Placebo)							
Heterogeneity: Chi ² = 14.55, c	f = 2 (P = 0.00069)	; I ² =86%						
Test for overall effect: $Z = 4.90$) (P < 0.00001)							
Test for subgroup differences: ($Chi^2 = 12.95, df = 1$	(P = 0.00), I ² =92%						
			0.2	0.5	2	5		

0.2 0.5 Favours placebo

Favours LABA

Analysis I.3. Comparison I All LABA versus placebo [subgrouped by drug], Outcome 3 Quality of life (CRQ).

Review: Long-acting beta₂-agonists for chronic obstructive pulmonary disease

Comparison: I All LABA versus placebo [subgrouped by drug]

Outcome: 3 Quality of life (CRQ)

Study or subgroup	laba N	Mean(SD)	Placebo N	Mean(SD)		Mean ference ed,95% Cl	Weight	Mean Difference IV,Fixed,95% CI
l Salmeterol 50 µ g tw	ice daily							
Hanania 2003 (I)	177	6.4 (18)	185	5 (15)	_	-	30.3 %	1.40 [-2.02, 4.82]
Mahler 1999	135	7.1 (16.2665)	143	2.1 (15.5457)			25.3 %	5.00 [1.26, 8.74]
Mahler 2002 (2)	160	8 (18)	181	5 (15)			28.2 %	3.00 [-0.54, 6.54]
Rennard 2001	109	10.3 (19.7322)	103	6.8 (14.7159)	-		16.3 %	3.50 [-1.17, 8.17]
Total (95% CI)	581		612			•	100.0 %	3.10 [1.22, 4.98]
Heterogeneity: Chi ² =	1.97, df = 3	$B (P = 0.58); I^2 = 0.0\%$	6					
Test for overall effect: 2	Z = 3.23 (P	= 0.0012)						
Test for subgroup differ	rences: Not	applicable						
							1	
					-10 -5	0 5	10	
					Favours placebo	Favours LA	ЪА	

(1) Standard deviations were not reported, and were imputed based on the SDs reported in Mahler 1999 and Rennard 2001

(2) Standard deviations were not reported, and were imputed based on the SDs reported in Mahler 1999 and Rennard 2001

Analysis I.4. Comparison I All LABA versus placebo [subgrouped by drug], Outcome 4 Severe exacerbations (hospitalisations).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: I All LABA versus placebo [subgrouped by drug]

Outcome: 4 Severe exacerbations (hospitalisations)

Study or subgroup	LABA	Placebo	Odds Ratio	Weight	Odds Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
l Formoterol I2 μ g twice dai Vogelmeier 2008	ly 1/210	3/209	←	2.3 %	0.33 [0.03, 3.18]
Doherty 2012	5/243	12/236		9.3 %	0.39 [0.14, 1.13]
Dahl 2001	2/181	2/86		2.1 %	0.47 [0.06, 3.39]
Rossi 2002	10/211	10/110		9.8 %	0.50 [0.20, 1.23]
Tashkin 2012	6/209	7/212		5.3 %	0.87 [0.29, 2.62]
Calverley 2003a	73/255	79/256	-	44.0 %	0.90 [0.61, 1.31]
Subtotal (95% CI) Total events: 97 (LABA), 113 Heterogeneity: Chi ² = 3.88, d Test for overall effect: Z = 1.8	$f = 5 (P = 0.57); I^2 =$	1109	•	72.9 %	0.75 [0.55, 1.02]
2 Formoterol 24 μ g twice dai Rossi 2002	ly 5/214	10/110		10.1 %	0.24 [0.08, 0.72]
Dahl 2001	2/171	2/86		2.1 %	0.50 [0.07, 3.59]
Subtotal (95% CI)	385	196	-	12.2 %	0.28 [0.11, 0.73]
Total events: 7 (LABA), 12 (Pla Heterogeneity: $Chi^2 = 0.40$, d Test for overall effect: $Z = 2.60$	$f = (P = 0.53); ^2$	=0.0%			
3 Salmeterol 50 µ g twice daily	ý				
Brusasco 2003	20/405	20/400		15.0 %	0.99 [0.52, 1.86]
Subtotal (95% CI) Total events: 20 (LABA), 20 (F Heterogeneity: not applicable Test for overall effect: Z = 0.0	,	400	-	15.0 %	0.99 [0.52, 1.86]
Total (95% CI)	2099	1705	•	100.0 %	0.73 [0.56, 0.95]
Total events: 124 (LABA), 145 Heterogeneity: Chi ² = 8.88, d Test for overall effect: $Z = 2.3$ Test for subgroup differences:	f = 8 (P = 0.35); I ² 6 (P = 0.018)	=10%		2000 /2	
			0.05 0.2 I 5 20 Favours LABA Favours placebo		

Analysis 1.5. Comparison I All LABA versus placebo [subgrouped by drug], Outcome 5 Severe/moderate exacerbations (hospitalisation or course of meds or ER visit.

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: I All LABA versus placebo [subgrouped by drug]

Outcome: 5 Severe/moderate exacerbations (hospitalisation or course of meds or ER visit

Study or subgroup	LABA	Placebo	Odds Ratio	Weight	Odds Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Formoterol 2 μ g twice dai	ly				
Bogdan 2011	8/199	17/208		4.1 %	0.47 [0.20, 1.12]
Campbell 2005	35/215	34/217		7.3 %	1.05 [0.63, 1.75]
Dahl 2010	126/435	145/432		26.8 %	0.81 [0.61, 1.08]
Rennard 2009	177/495	179/481		30.2 %	0.94 [0.72, 1.22]
Subtotal (95% CI)	1344	1338	•	68.5 %	0.87 [0.73, 1.04]
Total events: 346 (LABA), 375 Heterogeneity: $Chi^2 = 3.03$, df Test for overall effect: $Z = 1.5$	$f = 3 (P = 0.39); I^2 =$	=1%			
2 Salmeterol 50 µ g twice daily	y				
Hanrahan 2008	41/290	44/293		9.7 %	0.93 [0.59, 1.48
Mahler 2002	100/160	8/ 8		10.8 %	0.89 [0.57, 1.39]
Hanania 2003	55/177	63/185		11.0 %	0.87 [0.56, 1.36]
Subtotal (95% CI)	627	659	•	31.5 %	0.90 [0.69, 1.16]
Total events: 196 (LABA), 225	(Placebo)				
Heterogeneity: $Chi^2 = 0.04$, di	. ,	=0.0%			
Test for overall effect: $Z = 0.83$		100-			
Total (95% CI)	1971	1997	•	100.0 %	0.88 [0.76, 1.02]
Total events: 542 (LABA), 600	· ,				
Heterogeneity: $Chi^2 = 3.10$, d	. ,	=0.0%			
Test for overall effect: $Z = 1.7$	· /				
Test for subgroup differences:	$Chi^2 = 0.03, df = 1$	$(P = 0.85), I^2 = 0.0\%$			
			0.2 0.5 1 2 5		
			Favours LABA Favours placebo		

Analysis 1.6. Comparison I All LABA versus placebo [subgrouped by drug], Outcome 6 Moderate exacerbations (course of antibiotics and/or steroids).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: I All LABA versus placebo [subgrouped by drug]

Outcome: 6 Moderate exacerbations (course of antibiotics and/or steroids)

Study or subgroup	LABA n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% Cl
I Formoterol 12 µ g twice daily Nelson 2007 (1)	7/114	9/114		2.9 %	0.76 [0.27, 2.12]
Vogelmeier 2008	17/210	30/209		9.4 %	0.53 [0.28, 0.99]
0					
Rossi 2002	68/211	38/110		11.5 %	0.90 [0.55, 1.47]
Subtotal (95% CI)	535	433		23.8 %	0.74 [0.51, 1.05]
Total events: 92 (LABA), 77 (Placebo Heterogeneity: Chi ² = 1.77, df = 2 (Test for overall effect: $Z = 1.68$ (P =	$(P = 0.41); I^2 = 0.09$	6			
2 Formoterol 24 µ g twice daily					
Rossi 2002	49/214	37/110		12.8 %	0.59 [0.35, 0.97]
Subtotal (95% CI) Total events: 49 (LABA), 37 (Placebo Heterogeneity: not applicable Test for overall effect: Z = 2.06 (P =		110	-	12.8 %	0.59 [0.35, 0.97]
3 Salmeterol 50 μ g twice daily					
Calverley 2003b [TRISTAN]	8/372	19/361	• •	6.4 %	0.40 [0.17, 0.92]
Rennard 2001	38/132	41/135		9.8 %	0.93 [0.55, 1.57]
Mahler 1999	28/135	47/143		12.3 %	0.53 [0.31, 0.92]
Brusasco 2003	142/405	156/400		34.7 %	0.84 [0.63, 1.12]
Subtotal (95% CI) Total events: 216 (LABA), 263 (Place Heterogeneity: $Chi^2 = 5.01$, df = 3 ($(P = 0.17); I^2 = 40\%$	1039	•	63.3 %	0.75 [0.60, 0.94]
Test for overall effect: Z = 2.56 (P = Total (95% CI)	1793 1793	1582	•	100.0 %	0.73 [0.61, 0.87]
Total events: 357 (LABA), 377 (Place		1902		100.0 /0	0.75[0.01, 0.07]
Heterogeneity: $Chi^2 = 7.59$, $df = 7$ ($(P = 0.37); I^2 = 8\%$				
Test for overall effect: $Z = 3.57$ (P =	,				
Test for subgroup differences: Chi ² =	= 0.78, df = 2 (P =	0.68), l ² =0.0%			
			0.2 0.5 2 5 Favours LABA Favours placebo		

(1) Nelson 2007 and Mahler 1999 did not explicitly define exacerbations. Rates were more in keeping with 'moderate' than 'severe'.

Analysis 1.7. Comparison I All LABA versus placebo [subgrouped by drug], Outcome 7 Mortality (allcause).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: I All LABA versus placebo [subgrouped by drug]

Outcome: 7 Mortality (all-cause)

tudy or subgroup	LABA	Placebo	Peto Odds Ratio	Peto Odds Ratio
	n/N	n/N	Peto,Fixed,95% Cl	Peto,Fixed,95% Cl
oterol 12 μ g twice daily				
dan 2011	0/199	0/208		0.0 [0.0, 0.0]
on 2007	0/114	0/114		0.0 [0.0, 0.0]
1 200 1	0/192	0/100		0.0 [0.0, 0.0]
elmeier 2008	0/210	1/209	·	0.13 [0.00, 6.79]
kin 2008 [SHINE]	1/284	1/300		1.06 [0.07, 16.95]
pbell 2005	2/215	0/217		7.49 [0.47, 120.19]
si 2002	3/211	0/110		4.62 [0.42, 50.53]
kin 2012	3/209	1/212		2.78 [0.39, 19.86]
erty 2012	4/243	2/236		1.90 [0.38, 9.52]
1 2010	3/435	4/432	<u> </u>	0.74 [0.17, 3.29]
nard 2009	4/495	4/481		0.97 [0.24, 3.90]
ranski 2003	6/201	9/205		0.67 [0.24, 1.89]
erley 2003a	13/255	5/256		2.52 [0.98, 6.45]
otal (95% CI)	3263	3080	•	1.41 [0.87, 2.30]
vents: 39 (LABA), 27 (Placebo) geneity: Chi ² = 8.77, df = 9 (P = 0.4 • overall effect: Z = 1.38 (P = 0.17)	6); I ² =0.0%			
oterol 24 µ g twice daily				
1 200 1	0/191	0/100		0.0 [0.0, 0.0]
ii 2002	1/214	0/110		4.54 [0.07, 285.14]
tal (95% CI) vents: (LABA), 0 (Placebo) geneity: $Chi^2 = 0.0$, df = 0 (P = 1.00 · overall effect: Z = 0.72 (P = 0.47)	405); I ² =0.0%	210		4.54 [0.07, 285.14]
eterol 50 μ g twice daily F4010 2005	0/17	0/17		0.0 [0.0, 0.0]
			0.002 0.1 1 10 500	
			Favours LABA Favours placebo	(Continued

Study or subgroup	LABA n/N	Placebo n/N	Peto Odds Ratio Peto,Fixed,95% Cl	(Continued Peto Odds Ratio Peto,Fixed,95% CI
Mahler 1999	0/135	0/143		0.0 [0.0, 0.0]
Hanania 2003	0/177	0/185		0.0 [0.0, 0.0]
Hanrahan 2008	0/293	0/294		0.0 [0.0, 0.0]
Rennard 2001	0/132	1/135	·	0.14 [0.00, 6.98]
Mahler 2002	0/160	3/181		0.15 [0.02, 1.46]
Kornmann 2011	0/334	3/335		0.13 [0.01, 1.30]
Calverley 2003b [TRISTAN]	3/372	7/361	<u> </u>	0.43 [0.12, 1.50]
Brusasco 2003	6/405	5/400		1.19 [0.36, 3.90]
Calverley 2007 [TORCH]	205/1521	232/1524	•	0.87 [0.71, 1.06]
Subtotal (95% CI) Total events: 214 (LABA), 251 (Placed Heterogeneity: $Chi^2 = 7.03$, df = 5 (F Test for overall effect: Z = 1.82 (P = 1	e = 0.22); l ² =29%	3575	•	0.83 [0.69, 1.01]
Total (95% CI) Total events: 254 (LABA), 278 (Placel Heterogeneity: Chi ² = 20.23, df = 16 Test for overall effect: $Z = 1.15$ (P = 1 Test for subgroup differences: Chi ² =	7214 (P = 0.21); I ² =21% 0.25)	6865 I ² =55%	•	0.90 [0.75, 1.08]

0.002 0.1 1 10 Favours LABA Favours placebo

500

Analysis I.8. Comparison I All LABA versus placebo [subgrouped by drug], Outcome 8 People with one or more non-fatal serious adverse event.

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: I All LABA versus placebo [subgrouped by drug]

Outcome: 8 People with one or more non-fatal serious adverse event

	LABA	Placebo	Odds Ratio M-	Weight	Odds Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95 Cl
Formoterol 12 µ g twice daily					
Bogdan 2011	7/199	4/208	- <u>+</u>	1.5 %	1.86 [0.54, 6.45]
Calverley 2003a	85/255	66/256	-	8.6 %	1.44 [0.98, 2.11]
Campbell 2005	3/2 5	9/217	+	2.8 %	1.49 [0.62, 3.56]
Dahl 2001	8/192	5/100		1.7 %	0.83 [0.26, 2.59]
Doherty 2012	19/243	21/236		4.4 %	0.87 [0.45, 1.66]
Rennard 2009	88/495	58/481	-	9.2 %	1.58 [1.10, 2.26]
Rossi 2002	23/211	17/110		4.2 %	0.67 [0.34, 1.31]
Szafranski 2003	39/201	42/205	-	6.6 %	0.93 [0.57, 1.52]
Tashkin 2008 [SHINE]	23/284	25/300	-	5.1 %	0.97 [0.54, 1.75]
Tashkin 2012	17/209	12/212	+	3.4 %	1.48 [0.69, 3.17]
S = 1 + 1 + 1 + 1 + 050 + CI	2504	2325	•	47.5 %	1.20 [0.99, 1.45]
Total events: 322 (LABA), 259 (Plac Heterogeneity: Tau ² = 0.01; Chi ² =	cebo) : 9.84, df = 9 (P = 0				
Subtotal (95% CI) Total events: 322 (LABA), 259 (Plac Heterogeneity: Tau ² = 0.01; Chi ² = Test for overall effect: Z = 1.81 (P = 2 Formoterol 24 µ g twice daily	cebo) 9.84, df = 9 (P = 0 = 0.070)	36); I ² =9%			
Fotal events: 322 (LABA), 259 (Plac Heterogeneity: Tau ² = 0.01; Chi ² = Test for overall effect: Z = 1.81 (P 2 Formoterol 24 μ g twice daily Dahl 2001	sebo) 9.84, df = 9 (P = 0 = 0.070) 3/192	36); I ² =9% 4/100		1.0 %	0.38 [0.08, 1.74]
otal events: 322 (LABA), 259 (Plac Heterogeneity: Tau ² = 0.01; Chi ² = est for overall effect: Z = 1.81 (P = Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002	eebo) 9.84, df = 9 (P = 0 = 0.070) 3/192 15/214	36); 1 ² =9% 4/100 16/110		1.0 % 3.6 %	0.38 [0.08, 1.74] 0.44 [0.21, 0.93]
Fotal events: 322 (LABA), 259 (Plac Heterogeneity: Tau ² = 0.01; Chi ² = Test for overall effect: Z = 1.81 (P 2 Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002 Wadbo 2002	sebo) 9.84, df = 9 (P = 0 = 0.070) 3/192 15/214 3/61	36); I ² =9% 4/100 16/110 7/60	 	1.0 % 3.6 % 1.2 %	0.38 [0.08, 1.74] 0.44 [0.21, 0.93] 0.39 [0.10, 1.59]
Total events: 322 (LABA), 259 (Plac Heterogeneity: Tau ² = 0.01; Chi ² = Test for overall effect: Z = 1.81 (P = 2 Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002	rebo) 9.84, df = 9 (P = 0 = 0.070) 3/192 15/214 3/61 467 po) 0.04, df = 2 (P = 0.9	36); 1 ² =9% 4/100 16/110 7/60 270		1.0 % 3.6 %	0.38 [0.08, 1.74] 0.44 [0.21, 0.93]
Total events: 322 (LABA), 259 (Place Heterogeneity: Tau ² = 0.01; Chi ² = Test for overall effect: Z = 1.81 (P = 2. Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002 Wadbo 2002 Subtotal (95% CI) Total events: 21 (LABA), 27 (Placeber Heterogeneity: Tau ² = 0.0; Chi ² = 0 Fest for overall effect: Z = 2.79 (P =	rebo) 9.84, df = 9 (P = 0 = 0.070) 3/192 15/214 3/61 467 po) 0.04, df = 2 (P = 0.9	36); 1 ² =9% 4/100 16/110 7/60 270		1.0 % 3.6 % 1.2 %	0.38 [0.08, 1.74] 0.44 [0.21, 0.93] 0.39 [0.10, 1.59]
Total events: 322 (LABA), 259 (Place Heterogeneity: Tau ² = 0.01; Chi ² = Test for overall effect: Z = 1.81 (P = 2. Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002 Wadbo 2002 Subtotal (95% CI) Total events: 21 (LABA), 27 (Placeber Heterogeneity: Tau ² = 0.0; Chi ² = 0 Fest for overall effect: Z = 2.79 (P =	rebo) 9.84, df = 9 (P = 0 = 0.070) 3/192 15/214 3/61 467 po) 0.04, df = 2 (P = 0.9	36); 1 ² =9% 4/100 16/110 7/60 270		1.0 % 3.6 % 1.2 %	0.38 [0.08, 1.74] 0.44 [0.21, 0.93] 0.39 [0.10, 1.59]
Fotal events: 322 (LABA), 259 (Place Heterogeneity: Tau ² = 0.01; Chi ² = Test for overall effect: Z = 1.81 (P = 2 Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002 Wadbo 2002 Subtotal (95% CI) Fotal events: 21 (LABA), 27 (Placeb Heterogeneity: Tau ² = 0.0; Chi ² = 0 Fest for overall effect: Z = 2.79 (P = 3 Salmeterol 50 μ g twice daily	rebo) = 9.84, df = 9 (P = 0 = 0.070) 3/192 15/214 3/61 467 po) 0.04, df = 2 (P = 0.9 = 0.0052)	36); 1 ² =9% 4/100 16/110 7/60 270 8); 1 ² =0.0%		1.0 % 3.6 % 1.2 % 5.8 %	0.38 [0.08, 1.74] 0.44 [0.21, 0.93] 0.39 [0.10, 1.59] 0.42 [0.23, 0.77]
Total events: 322 (LABA), 259 (Place Heterogeneity: Tau ² = 0.01; Chi ² = Test for overall effect: Z = 1.81 (P = 2 Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002 Wadbo 2002 Subtotal (95% CI) Total events: 21 (LABA), 27 (Placeb Heterogeneity: Tau ² = 0.0; Chi ² = 0 Fest for overall effect: Z = 2.79 (P = 8 Salmeterol 50 μ g twice daily Brusasco 2003	rebo) = 9.84, df = 9 (P = 0 = 0.070) 3/192 15/214 3/61 467 po) 0.04, df = 2 (P = 0.9 = 0.0052) 49/405	36); 1 ² =9% 4/100 16/110 7/60 270 8); 1 ² =0.0% 56/400		1.0 % 3.6 % 1.2 % 5.8 % 8.0 %	0.38 [0.08, 1.74] 0.44 [0.21, 0.93] 0.39 [0.10, 1.59] 0.42 [0.23, 0.77] 0.85 [0.56, 1.28]
Total events: 322 (LABA), 259 (Place Heterogeneity: Tau ² = 0.01; Chi ² = Test for overall effect: Z = 1.81 (P = 2 Formoterol 24 μ g twice daily Dahl 2001 Rossi 2002 Wadbo 2002 Subtotal (95% CI) Total events: 21 (LABA), 27 (Placed Heterogeneity: Tau ² = 0.0; Chi ² = 0 Test for overall effect: Z = 2.79 (P = 3 Salmeterol 50 μ g twice daily Brusasco 2003 Calverley 2003b [TRISTAN]	Tebo) 9.84, df = 9 (P = 0) = 0.070) 3/192 15/214 3/61 467 0.04, df = 2 (P = 0.9) = 0.0052) 49/405 69/372	36); 1 ² =9% 4/100 16/110 7/60 270 8); 1 ² =0.0% 56/400 54/361		1.0 % 3.6 % 1.2 % 5.8 % 8.0 % 8.4 %	0.38 [0.08, 1.74] 0.44 [0.21, 0.93] 0.39 [0.10, 1.59] 0.42 [0.23, 0.77] 0.85 [0.56, 1.28] 1.29 [0.88, 1.91]

Study or subgroup	LABA	Placebo	Odds Ratio M- H,Random,95%	Weight	(Continued) Odds Ratio M- H,Random,95%
	n/N	n/N	Cl		CI
Hanania 2003	5/177	11/185		1.9 %	0.46 [0.16, 1.35]
Hanrahan 2008	11/290	19/293		3.5 %	0.57 [0.27, 1.22]
Kornmann 2011	19/334	26/335		4.8 %	0.72 [0.39, 1.32]
Mahler 2002	7/160	/ 8	<u> </u>	2.3 %	0.71 [0.27, 1.87]
Rennard 2001	10/132	7/135		2.2 %	1.50 [0.55, 4.06]
SLMF4010 2005	1/17	3/17		0.4 %	0.29 [0.03, 3.13]
Subtotal (95% CI)	3429	3451	•	46. 7 %	0.93 [0.78, 1.10]
Total events: 788 (LABA), 820 (Pla	acebo)				
Heterogeneity: $Tau^2 = 0.01$; Chi ²	= 9.15, df = 8 (P = 0.3	33); I ² =I 3%			
Test for overall effect: $Z = 0.90$ (P	= 0.37)				
Total (95% CI)	6400	6046	•	100.0 %	0.97 [0.83, 1.14]
Total events: 1131 (LABA), 1106 ((Placebo)				
Heterogeneity: $Tau^2 = 0.04$; Chi ²	= 32.05, df = 21 (P =	0.06); I ² =34%			
Test for overall effect: $Z = 0.35$ (P	= 0.72)				
Test for subgroup differences: Chi ²	² = 11.91, df = 2 (P =	0.00), I ² =83%			
			0.02 0.1 1 10 5	50	

Favours placebo

Favours LABA

Analysis 1.9. Comparison I All LABA versus placebo [subgrouped by drug], Outcome 9 Predose FEVI (mL).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: I All LABA versus placebo [subgrouped by drug]

Outcome: 9 Predose FEV₁ (mL)

Study or subgroup	LABA N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	Mean Difference IV,Random,95% Cl
I Formoterol I2 µ g twice daily							
Bogdan 2011	199	50 (122)	208	10 (122)		11.3 %	40.00 [16.29, 63.71]
Calverley 2003a (1)	255	-97.5 (300)	256	-156.8 (300)		8.1 %	59.30 [7.28, .32]
Campbell 2005	215	72.5 (334.3)	217	-21.7 (334.3)		7.0 %	94.20 [31.15, 157.25]
Dahl 2010 (2)	435	1330 (300.5)	432	1280 (300.5)	— —	9.5 %	50.00 [9.99, 90.01]
Tashkin 2008 [SHINE]	284	50 (190)	300	10 (210)		10.4 %	40.00 [7.55, 72.45]
Tashkin 2012 (3)	209	0 (300)	212	-17 (300)		7.6 %	17.00 [-40.32, 74.32]
Subtotal (95% CI)	1597		1625		•	53.9 %	44.68 [29.39, 59.97]
Heterogeneity: $Tau^2 = 0.0$; Chi ²			² =0.0%				
Test for overall effect: $Z = 5.73$	(P < 0.000	001)					
2 Salmeterol 50 $_{\rm H}$ g twice daily							
Calverley 2003b [TRISTAN]	372	323 (2 2)	361	1264 (209)		10.6 %	59.00 [28.52, 89.48]
Hanania 2003	178	91 (300)	185	I (300)		7.1 %	90.00 [28.27, 151.73]
Hanrahan 2008	276	223. (2 8.2)	275	80.4 (204.1)		10.1 %	42.70 [107.42, 177.98]
Kornmann 2011	333	90 (430)	335	-20 (430)		6.8 %	0.00 [44.78, 75.22]
Mahler 2002	159	107 (460)	181	-4 (460)	·	• 4.3 %	.00 [3.00, 209.00]
Rennard 2001	109	150 (323.65)	105	-20 (297.16)		➡ 5.2 %	170.00 [86.80, 253.20]
SLMF4010 2005	17	-94 (239.1)	17	-30 (235)	· · · · · · · · · · · · · · · · · · ·	2.0 %	-64.00 [-223.37, 95.37]
Subtotal (95% CI)	1444		1459		•	46.1 %	101.01 [59.84, 142.18]
Heterogeneity: Tau ² = 1830.26;	$Chi^2 = 19$	9.57, df = 6 (P =	: 0.003); l ²	=69%			
Test for overall effect: $Z = 4.8$ I	(P < 0.000	001)					
Total (95% CI)	3041		3084		•	100.0 %	72.92 [48.02, 97.82]
Heterogeneity: Tau ² = 1279.35;	$Chi^2 = 4$	1.38, df = 12 (P	= 0.00004)	; l ² =71%			
Test for overall effect: $Z = 5.74$	(P < 0.000	001)					
Test for subgroup differences: C	$hi^2 = 6.32$	$P_{\rm e},{\rm df}=1({\rm P}=0.0)$)), ² =849	%			
				-		200	
				Fa	vours placebo Favours LA	BA	

as endpoint scores.

(1) SD imputed by calculating the mean SD for change reported in the other included studies (mean SD for LABA and placebo were both 0.3))

(2) Change from baseline data and endpoint data were pooled in the analysis. Most studies reported change from baseline but data for Dahl 2010, and Calverley 2003b [TRISTAN] are entered

(3) SD imputed as for Calverley 2003a

Analysis 1.10. Comparison I All LABA versus placebo [subgrouped by drug], Outcome 10 Withdrawal.

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: I All LABA versus placebo [subgrouped by drug]

Outcome: 10 Withdrawal

Study or subgroup	LABA n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% CI
l Formoterol 12 µ g twice daily					,
Aalbers 2002	30/166	I 3/86		0.9 %	1.24 [0.61, 2.52]
Bogdan 2011	17/199	22/208		1.2 %	0.79 [0.41, 1.54]
Calverley 2003a	111/255	106/256	_ 	3.7 %	1.09 [0.77, 1.55]
Campbell 2005	30/215	39/217		2.1 %	0.74 [0.44, 1.24]
Dahl 2001	3/ 94	15/100	•	1.2 %	0.41 [0.19, 0.89]
Dahl 2010	112/435	137/432		6.4 %	0.75 [0.56, 1.00]
Doherty 2012	50/243	67/236		3.4 %	0.65 [0.43, 1.00]
Nelson 2007	16/114	30/114		1.6 %	0.46 [0.23, 0.90]
Rennard 2009	157/495	175/481		7.6 %	0.81 [0.62, 1.06]
Rossi 2002	52/211	30/110		1.9 %	0.87 [0.52, 1.47]
Szafranski 2003	64/201	90/205		3.8 %	0.60 [0.40, 0.90]
Tashkin 2008 [SHINE]	61/284	77/300		3.7 %	0.79 [0.54, 1.16]
Tashkin 2012	37/209	53/212		2.7 %	0.65 [0.40, 1.03]
Vogelmeier 2008	25/210	30/209		1.7 %	0.81 [0.46, 1.42]
Subtotal (95% CI) Total events: 775 (LABA), 884 (Plac Heterogeneity: Chi ² = 13.45, df = 1 Test for overall effect: Z = 4.59 (P <	3 (P = 0.41); $ ^2 = 3\%$	3166	•	41.6 %	0.76 [0.68, 0.86]
2 Formoterol 24 µ g twice daily					
Aalbers 2002	27/177	14/87		1.0 %	0.94 [0.46, 1.90]
Dahl 2001	23/192	14/100		1.0 %	0.84 [0.41, 1.71]
Rossi 2002	40/214	29/110		1.9 %	0.64 [0.37, .]
Wadbo 2002	17/61	I 6/60		0.7 %	1.06 [0.48, 2.37]
Subtotal (95% CI) Total events: 107 (LABA), 73 (Place	644 bo)	357	-	4.7 %	0.81 [0.58, 1.14]
			0.2 0.5 2 5 Favours LABA Favours placebo		

(Continued . . .)

Long-acting beta $_2$ -agonists for chronic obstructive pulmonary disease (Review)

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	LABA	Placebo	Odds Ratio	Weight	(Continued Odds Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Heterogeneity: $Chi^2 = 1.31$, df = 3	()·	6			
Test for overall effect: $Z = 1.22$ (P =	= 0.22)				
3 Salmeterol 50 µ g twice daily					
Brusasco 2003	76/405	103/400		5.2 %	0.67 [0.48, 0.93]
Calverley 2003b [TRISTAN]	119/372	140/361		6.0 %	0.74 [0.55, 1.01]
Calverley 2007 [TORCH]	582/1544	694/1545	+	27.0 %	0.74 [0.64, 0.86]
Hanania 2003	57/177	59/185		2.4 %	1.01 [0.65, 1.58]
Hanrahan 2008	44/293	64/294	<u> </u>	3.4 %	0.64 [0.42, 0.97]
Kornmann 2011	50/334	70/335	i	3.7 %	0.67 [0.45, 0.99]
Mahler 1999	9/135	23/143	•	1.3 %	0.37 [0.17, 0.84]
Mahler 2002	45/160	69/181		2.9 %	0.64 [0.40, 1.00]
Rennard 2001	22/132	29/135		1.5 %	0.73 [0.40, 1.35]
SLMF4010 2005	7/17	7/17		0.3 %	1.00 [0.26, 3.92]
Subtotal (95% CI)	3569	3596	•	53.7 %	0.72 [0.65, 0.80]
Total events: 1011 (LABA), 1258 (P	lacebo)				
Heterogeneity: $Chi^2 = 6.26$, df = 9	$(P = 0.7 I); I^2 = 0.0\%$	6			
Test for overall effect: $Z = 6.24$ (P <	< 0.00001)				
Total (95% CI)	7644	7119	•	100.0 %	0.74 [0.69, 0.80]
Total events: 1893 (LABA), 2215 (P	lacebo)				
Heterogeneity: $Chi^2 = 21.80$, $df = 2$	27 (P = 0.75); $I^2 = 0.$	0%			
Test for overall effect: $Z = 7.80$ (P <	< 0.00001)				
Test for subgroup differences: Chi ²	= 0.83, df = 2 (P =	0.66), l ² =0.0%			

0.2	0.5	1 2	5

Favours LABA Favours placebo

Analysis 2.1. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome I Quality of life (SGRQ).

Review: Long-acting beta₂-agonists for chronic obstructive pulmonary disease

Comparison: 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration]

Outcome: I Quality of life (SGRQ)

	Ν	Mean(SD)	Placebo N	Mean(SD)	Difference IV,Random,95% Cl	Weight	Difference IV,Random,95% C
I 3 months							
Bogdan 2011 (1)	199	38.2 (14.5)	206	42.9 (14.5)		24.5 %	-4.70 [-7.52, -1.88]
Dahl 2001	181	41.7 (16.8)	174	46.8 (17.6)		15.2 %	-5.10 [-8.68, -1.52]
Dahl 2010	435	38.1 (13.5208)	432	41.3 (13.5208)		60.3 %	-3.20 [-5.00, -1.40
Subtotal (95% CI) Heterogeneity: Tau ² = 0.0; Test for overall effect: Z = 1 2 6 months		$(P = 0.52); I^2 = 0.52$	812		•	100.0 %	-3.86 [-5.25, -2.46
Calverley 2003a	255	0.2 (17)	256	2 (17)		16.2 %	-1.80 [-4.75, 1.15
Campbell 2005	215	-3.81 (13.5737)	217	-4.61 (13.5737)		19.8 %	0.80 [-1.76, 3.36]
Doherty 2012	243	-4.93 (14.5)	236	-2.88 (14.5)		19.4 %	-2.05 [-4.65, 0.55
Tashkin 2008 [SHINE]	284	-1.24 (11.35)	300	-1.02 (12.41)		28.2 %	-0.22 [-2.15, 1.71
Tashkin 2012	209	-6.19 (15.2)	212	-2.88 (15.2)	_	16.5 %	-3.31 [-6.21, -0.41
Subtotal (95% CI)	1206		1221		•	100.0 %	-1.14 [-2.51, 0.23
Heterogeneity: Tau ² = 0.78 Test for overall effect: Z = 3 12 months Calverley 2003a		4 (P = 0.21); I ² = 0.8 (17)	32% 256	4.7 (17)		18.2 %	-3.90 [-6.85, -0.95
Dahl 2010	435	-6.7 (22.5346)	432	-1.7 (22.5346)	e	17.7 %	-5.00 [-8.00, -2.00
Rennard 2009	495	-2.9 (13.3)	481	-1.5 (12.7)		34.1 %	-1.40 [-3.03, 0.23
Rossi 2002	159	40.9 (17.8)	160	45.3 (18.7)		11.6 %	-4.40 [-8.41, -0.39
Szafranski 2003	201	-3.6 (15)	205	-0.03 (15)		18.4 %	-3.57 [-6.49, -0.65
Subtotal (95% CI) Heterogeneity: Tau ² = 1.10 Test for overall effect: Z = 4 Test for subgroup difference	4.15 (P = 0.000034)				•	100.0 %	-3.24 [-4.77, -1.71

entered as endpoint scores.

(1) Change from baseline data and endpoint data were pooled in the analysis. Most studies reported change from baseline but data for Bogdan 2011, Dahl 2001, Dahl 2010, and Rossi 2002 are

Analysis 2.2. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 2 Severe exacerbations (hospitalisations).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration]

Outcome: 2 Severe exacerbations (hospitalisations)

Study or subgroup	Formoterol 12µg n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% Cl
I 3 months					
Dahl 2001	2/181	4/172		4.0 %	0.47 [0.08, 2.60]
Subtotal (95% CI)	181	172		4.0 %	0.47 [0.08, 2.60]
Total events: 2 (Formoterol I	2μg), 4 (Placebo)				
Heterogeneity: not applicable	2				
Test for overall effect: $Z = 0.3$	87 (P = 0.39)				
2 6 months					
Vogelmeier 2008	1/210	3/209	· · · · ·	3.0 %	0.33 [0.03, 3.18]
Tashkin 2012	6/209	7/212		6.7 %	0.87 [0.29, 2.62]
Doherty 2012	5/243	12/236		11.8 %	0.39 [0.14, 1.13]
Subtotal (95% CI)	662	657	•	21.5 %	0.53 [0.26, 1.08]
Heterogeneity: Chi ² = 1.23, 4 Test for overall effect: Z = 1. 3 12 months Rossi 2002	· · · · ·	20/220		18.5 %	0.50 [0.23, 1.09
Calverley 2003a	73/255	79/256	_	55.9 %	0.90 [0.61, 1.31
	466	476		74.4 %	-
Subtotal (95% CI) Total events: 83 (Formoterol Heterogeneity: $Chi^2 = 1.77$, (Test for overall effect: $Z = 1$.	2μg), 99 (Placebo) df = (P = 0.18); ² =44%	4/0		/4.4 %	0.80 [0.57, 1.12]
Total (95% CI)	1309	1305	•	100.0 %	0.73 [0.54, 0.98]
Total events: 97 (Formoterol Heterogeneity: $Chi^2 = 4.22$,	df = 5 (P = 0.52); $I^2 = 0.0\%$				
Test for overall effect: $Z = 2.0$	· ,				
Test for subgroup differences	$:: Chi^2 = 1.29, df = 2 (P = 0.5)$	2), l ² =0.0%			
		Favours for	0.05 0.2 1 5 20 moterol 12 µ g Favours placebo	0	

Analysis 2.3. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 3 Moderate exacerbations (course of antibiotics and/or steroids).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration]

Outcome: 3 Moderate exacerbations (course of antibiotics and/or steroids)

Study or subgroup	Formoterol 12μg n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% CI
1 3 months	101 1	101 4			
Nelson 2007	7/114	9/114		9.8 %	0.76 [0.27, 2.12]
Subtotal (95% CI)	114	114		9.8 %	0.76 [0.27, 2.12]
Total events: 7 (Formoterol 12	μ g), 9 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: Z = 0.52	P = (P = 0.60)				
2 6 months			_		
Vogelmeier 2008	17/210	30/209		32.2 %	0.53 [0.28, 0.99]
Subtotal (95% CI)	210	209		32.2 %	0.53 [0.28, 0.99]
Total events: 17 (Formoterol 12	2µg), 30 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: Z = 2.01	(P = 0.045)				
3 12 months					
Rossi 2002	68/211	75/220		58.0 %	0.92 [0.62, 1.37]
Subtotal (95% CI)	211	220	-	58.0 %	0.92 [0.62, 1.37]
Total events: 68 (Formoterol 12	2µg), 75 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: Z = 0.41	(P = 0.68)				
Total (95% CI)	535	543	-	100.0 %	0.78 [0.56, 1.07]
Total events: 92 (Formoterol 12	2µg), 114 (Placebo)				
Heterogeneity: Chi ² = 2.16, df	= 2 (P = 0.34); I ² =7%				
Test for overall effect: Z = 1.55	5 (P = 0.12)				
Test for subgroup differences: (Chi ² = 2.16, df = 2 (P = 0.3	34), l ² =7%			

Favours formoterol 12 µ g

Favours placebo

Long-acting beta $_2$ -agonists for chronic obstructive pulmonary disease (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 2.4. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 4 Mortality (all-cause).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration]

Outcome: 4 Mortality (all-cause)

Pe Odds Rat	Peto Odds Ratio	Placebo	Formoterol 12 μ g	Study or subgroup
Peto,Fixed,95%	Peto,Fixed,95% Cl	n/N	n/N	
				I 3 months
0.0 [0.0, 0.0		0/200	0/192	Dahl 2001
0.0 [0.0, 0.0		0/114	0/114	Nelson 2007
0.0 [0.0, 0.0		0/208	0/199	Bogdan 2011
2.78 [0.39, 19.86		1/212	3/209	Tashkin 2012
1.90 [0.38, 9.52		2/236	4/243	Doherty 2012
2.22 [0.64, 7.70	-	970	957	Subtotal (95% CI)
			(P = 0.77); I ² =0.0%	Total events: 7 (Formoterol 12μ g) Heterogeneity: Chi ² = 0.08, df = 1 Test for overall effect: Z = 1.25 (P = 2.6 months
0.13 [0.00, 6.79	•	1/209	0/210	Vogelmeier 2008
1.06 [0.07, 16.95		1/300	1/284	Tashkin 2008 [SHINE]
7.49 [0.47, 120.19		0/217	2/215	Campbell 2005
2.52 [0.98, 6.45	-	5/256	13/255	Calverley 2003a
2.25 [0.98, 5.16	◆	982	964	Subtotal (95% CI)
7.79 [0.81, 75.27		0/220	$B (P = 0.38); I^2 = I\%$	Total events: 16 (Formoterol 12 µ g Heterogeneity: Chi ² = 3.04, df = 3 Test for overall effect: Z = 1.92 (P = 3 12 months Rossi 2002
0.74 [0.17, 3.29		4/432	3/435	Dahl 2010
0.97 [0.24, 3.90		4/481	4/495	Rennard 2009
0.67 [0.24, 1.89		9/205	6/201	Szafranski 2003
0.94 [0.47, 1.88	•	1338	B (P = 0.28); I ² =22%	Subtotal (95% CI) Total events: 16 (Formoterol 12 μ g Heterogeneity: Chi ² = 3.83, df = 3 Test for overall effect: Z = 0.16 (P =
1.45 [0.89, 2.37	◆	3290	3263	Total (95% CI)

Favours formoterol 12 µ g Favours placebo

(Continued ...)

Study or subgroup	Formoterol 12 µ g n/N	Placebo n/N	Peto Odds Ratio Peto,Fixed,95% Cl			(Continue Peta Odds Ratio Peto,Fixed,95% C	0	
Total events: 39 (Formoterol 1	2 µ g), 27 (Placebo)							
Heterogeneity: $Chi^2 = 9.98$, df	$= 9 (P = 0.35); ^2 = 0\%$							
Test for overall effect: $Z = 1.5$	(P = 0.13)							
Test for subgroup differences: ($Chi^2 = 3.02$, $df = 2$ (P = 0.22), $I^2 = 34$	%						
			0.005	0.1	1 10	200		
		Fav	vours formotero	ll2µg	Favours p	olacebo		

Analysis 2.5. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 5 Patients with one or more serious adverse event.

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration]

Outcome: 5 Patients with one or more serious adverse event

Study or subgroup	Formoterol 12µg n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% Cl
I 3 months					
Bogdan 2011	7/199	4/208		1.7 %	1.86 [0.54, 6.45]
Dahl 2001	8/192	9/200		3.7 %	0.92 [0.35, 2.44]
Subtotal (95% CI)	391	408	-	5.4 %	1.21 [0.57, 2.58]
Total events: 15 (Formotero Heterogeneity: $Chi^2 = 0.76$, Test for overall effect: $Z = 0$	$df = 1 (P = 0.38); l^2 = 0.0\%$				
2 6 months					
Campbell 2005	13/215	9/217		3.7 %	1.49 [0.62, 3.56]
Tashkin 2012	17/209	12/212		4.8 %	1.48 [0.69, 3.17]
Doherty 2012	19/243	21/236		8.6 %	0.87 [0.45, 1.66]
Tashkin 2008 [SHINE]	23/284	25/300	_ _	9.8 %	0.97 [0.54, 1.75]
Subtotal (95% CI)	951	965	•	26.9 %	1.10 [0.78, 1.55]
Total events: 72 (Formotero	ol 12µg), 67 (Placebo)				
		Favours	0.1 0.2 0.5 1 2 5 10 formoterol 12 µ g Favours placebo		(

(Continued . . .)

Long-acting beta _-agonists for chronic obstructive pulmonary disease (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

(... Continued)

Study or subgroup	Formoterol 12 µ g	Placebo	Odds Ratio	Weight	Odds Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Heterogeneity: Chi ² = 1.71,	df = 3 (P = 0.63); I ² =0.0%				
Test for overall effect: $Z = 0$.	53 (P = 0.59)				
3 12 months					
Rossi 2002	23/211	33/220		12.6 %	0.69 [0.39, 1.23]
Szafranski 2003	39/201	42/205		14.7 %	0.93 [0.57, 1.52]
Calverley 2003a	85/255	66/256		19.2 %	1.44 [0.98, 2.11]
Rennard 2009	88/495	58/481		21.2 %	1.58 [1.10, 2.26]
Subtotal (95% CI)	1162	1162	•	67.8 %	1.23 [1.00, 1.52]
Total events: 235 (Formotere	ol 12 µ g), 199 (Placebo)				
Heterogeneity: Chi ² = 7.61,	df = 3 (P = 0.05); I ² =61%				
Test for overall effect: $Z = 1$.	.95 (P = 0.052)				
Total (95% CI)	2504	2535	•	100.0 %	1.20 [1.00, 1.43]
Total events: 322 (Formotere	ol 12 µ g), 279 (Placebo)				
-leterogeneity: Chi ² = 10.41	, df = 9 (P = 0.32); $ ^2 = 4\%$				
Test for overall effect: $Z = 2$.	.00 (P = 0.045)				
Test for subgroup differences	s: Chi ² = 0.32, df = 2 (P = 0.8	85), I ² =0.0%			

0.1 0.2 0.5 1 2 5 10

Favours formoterol 12 µ g Favours placebo

Analysis 2.6. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 6 Predose FEVI (mL).

Review: Long-acting beta₂-agonists for chronic obstructive pulmonary disease

Comparison: 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration]

Outcome: 6 Predose FEV₁ (mL)

noterol I2 µ g		Placebo		Mean Difference	Weight	Mean Difference
N	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI	Ū.	IV,Fixed,95% CI
199	50 (122)	208	10 (122)	-	41.6 %	40.00 [16.29, 63.71]
199		208		•	41.6 %	40.00 [16.29, 63.71]
(P = 0.00094)						
215	72.5 (334.3)	217	-21.7 (334.3)		5.9 %	94.20 [31.15, 157.25]
284	50 (190)	300	10 (210)		22.2 %	40.00 [7.55, 72.45]
209	0 (300)	212	-17 (300)		7.1 %	7.00 [-40.32, 74.32]
708		729		•	35.2 %	44.41 [18.63, 70.18]
= 2 (P = 0.19);	l ² =40%					
(P = 0.00073)						
255	-97.5 (300)	256	-156.8 (300)		8.6 %	59.30 [7.28, 111.32]
435	1330 (300.5)	432	1280 (300.5)		14.6 %	50.00 [9.99, 90.01]
690		688		•	23.2 %	53.46 [21.74, 85.17]
= I (P = 0.78);	² =0.0%					
(P = 0.00095)						
1597		1625		•	100.0 %	44.68 [29.39, 59.97]
= 5 (P = 0.57);	2 =0.0%					
(P < 0.00001)						
hi ² = 0.44, df =	2 (P = 0.80), I ²	=0.0%				
	99 199 $(P = 0.00094)$ 215 284 209 708 $= 2 (P = 0.19);$ $(P = 0.00073)$ 255 435 690 $= 1 (P = 0.78);$ $(P = 0.00095)$ 1597 $= 5 (P = 0.57);$ $(P < 0.0001)$	$199 50 (122)$ 199 $(P = 0.00094)$ $215 72.5 (334.3)$ $284 50 (190)$ $209 0 (300)$ 708 $= 2 (P = 0.19); ^{2} = 40\%$ $(P = 0.00073)$ $255 -97.5 (300)$ $435 330 (300.5)$ 690 $= 1 (P = 0.78); ^{2} = 0.0\%$ $(P = 0.00095)$ 1597 $= 5 (P = 0.57); ^{2} = 0.0\%$ $(P < 0.00001)$	$199 50 (122) 208$ $199 208$ $(P = 0.00094)$ $215 72.5 (334.3) 217$ $284 50 (190) 300$ $209 0 (300) 212$ $708 729$ $= 2 (P = 0.19); I^{2} = 40\%$ $(P = 0.00073)$ $255 -97.5 (300) 256$ $435 1330 (300.5) 432$ $690 688$ $= 1 (P = 0.78); I^{2} = 0.0\%$ $(P = 0.00095)$ $1597 1625$ $= 5 (P = 0.57); I^{2} = 0.0\%$	$\begin{array}{c ccccc} 199 & 50 & (122) & 208 & 10 & (122) \\ \hline 199 & 208 \\ (P = 0.00094) \\ \hline 215 & 72.5 & (334.3) & 217 & -21.7 & (334.3) \\ 284 & 50 & (190) & 300 & 10 & (210) \\ 209 & 0 & (300) & 212 & -17 & (300) \\ \hline 209 & 0 & (300) & 212 & -17 & (300) \\ \hline 708 & 729 \\ = 2 & (P = 0.19); \ l^2 = 40\% \\ (P = 0.00073) \\ \hline 255 & -97.5 & (300) & 256 & -156.8 & (300) \\ 435 & 1330 & (300.5) & 432 & 1280 & (300.5) \\ \hline 690 & 688 \\ = 1 & (P = 0.78); \ l^2 = 0.0\% \\ (P = 0.00095) \\ \hline 1597 & 1625 \\ = 5 & (P = 0.57); \ l^2 = 0.0\% \\ (P < 0.0001) \end{array}$	$199 50 (122) 208 10 (122) \\ 199 208 \\ (P = 0.00094) \\ 215 72.5 (334.3) 217 -21.7 (334.3) \\ 284 50 (190) 300 10 (210) \\ 209 0 (300) 212 -17 (300) \\ \hline 708 \qquad 729 \\ = 2 (P = 0.19); I^2 = 40\% \\ (P = 0.00073) \\ 255 -97.5 (300) 256 -156.8 (300) \\ 435 1330 (300.5) 432 1280 (300.5) \\ 690 \qquad 688 \\ = 1 (P = 0.78); I^2 = 0.0\% \\ (P = 0.00095) \\ 1597 \qquad 1625 \\ = 5 (P = 0.57); I^2 = 0.0\% \\ (P < 0.0001) \\ \end{array}$	199 50 (122) 208 10 (122) \blacksquare 41.6 % 199 208 \checkmark 41.6 % \checkmark 41.6 % (P = 0.00094) 215 72.5 (334.3) 217 -21.7 (334.3) \checkmark 5.9 % 284 50 (190) 300 10 (210) \checkmark 22.2 % 209 0 (300) 212 -17 (300) \checkmark 7.1 % 708 729 \checkmark 35.2 % \checkmark 35.2% = 2 (P = 0.19); l ² =40% (P = 0.00073) \checkmark 14.6% \checkmark 35.2% 41.6% 690 688 \checkmark 23.2% \checkmark 14.6% $(P = 0.00073)$ 1597 1625 \bullet 100.0 % \bullet

Favours placebo Favou

Favours formoterol 12 μ g

Change from baseline data and endpoint data were pooled in the analysis. Only Dahl 2010 were entered as endpoint scores.

(1) Data was also presented for 3 months but omitted in this analysis to avoid double counting. Sensitivity analyses with the study included in both time-points did not change conclusions.

Analysis 2.7. Comparison 2 Formoterol 12 μ g versus placebo [subgrouped by trial duration], Outcome 7 Withdrawal.

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 2 Formoterol 12 µ g versus placebo [subgrouped by trial duration]

Outcome: 7 Withdrawal

Study or subgroup	Formoterol 12 µ g n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% CI
I 3 months					
Bogdan 2011	17/199	22/208		2.8 %	0.79 [0.41, 1.54]
Aalbers 2002	30/166	27/173	 +	3.1 %	1.19 [0.67, 2.11]
Nelson 2007	6/ 4	30/114		3.7 %	0.46 [0.23, 0.90]
Dahl 2001	13/194	29/200		3.8 %	0.42 [0.21, 0.84]
Subtotal (95% CI)	673	695	-	13.5 %	0.69 [0.50, 0.94]
Total events: 76 (Formoterol Heterogeneity: $Chi^2 = 7.08$, c Test for overall effect: $Z = 2.3$	$df = 3 (P = 0.07); I^2 = 58\%$				
2 6 months Vogelmeier 2008	25/210	30/209		3.8 %	0.81 [0.46, 1.42]
Campbell 2005	30/215	39/217		4.8 %	0.74 [0.44, 1.24]
Tashkin 2012	37/209	53/212		6.2 %	0.65 [0.40, 1.03]
Doherty 2012	50/243	67/236		7.7 %	0.65 [0.43, 1.00]
Tashkin 2008 [SHINE]	61/284	77/300		8.4 %	0.79 [0.54, 1.16]
Subtotal (95% CI)	1161	1174	•	31.0 %	0.72 [0.59, 0.89]
Total events: 203 (Formotero Heterogeneity: $Chi^2 = 0.81$, c Test for overall effect: $Z = 3.1$ 3 12 months Rossi 2002	$df = 4 (P = 0.94); I^2 = 0.0\%$	59/220		6.2 %	0.89 [0.58, 1.38]
Calverley 2003a	111/255	106/256		8.6 %	1.09 [0.77, 1.55]
Szafranski 2003	64/201	90/205		8.7 %	0.60 [0.40, 0.90]
Dahl 2010	112/435	137/432		14.6 %	0.75 [0.56, 1.00]
Rennard 2009	157/495	175/481		17.4 %	0.81 [0.62, 1.06]
Subtotal (95% CI) Total events: 496 (Formotero Heterogeneity: $Chi^2 = 5.43$, c Test for overall effect: $Z = 2.7$	$df = 4 (P = 0.25); l^2 = 26\%$	1594	•	55.6 %	0.81 [0.70, 0.94]
			0.2 0.5 1 2 5		
		Favours fo	rmoterol 12 µ g Favours placebo		
					(Continued)

Study or subgroup			Weight	Odds Ratio					
	n/N	n/N		M-H,Fi>	ked,95% Cl			M-H,Fixed,95% CI	
Total (95% CI)	3431	3463		•			100.0 %	0.77 [0.69, 0.86]	
Total events: 775 (Formoter	ol 2 µ g), 941 (Placebo)								
Heterogeneity: $Chi^2 = 14.62$	2, df = 13 (P = 0.33); l ² =11%								
Test for overall effect: $Z = 4$.61 (P < 0.00001)								
Test for subgroup difference	s: Chi ² = 1.40, df = 2 (P = 0.5	0), l ² =0.0%							
			0.2	0.5	1 2	5			
		Favours	formoter	ol I 2 µ g	Favours	olacebo			

Analysis 3.1. Comparison 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration], Outcome I Quality of life (SGRQ).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 3 Formoterol $24 \,\mu$ g versus placebo [subgrouped by trial duration]

Outcome: I Quality of life (SGRQ)

Study or subgroup	Formoterol 24 µ g N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV.Fixed,95% Cl
1.3 months		(ob)		(ob)			
Dahl 2001 (1)	169	43.5 (19.4)	86	46.8 (17.6)		21.5 %	-3.30 [-8.03, 1.43]
Wadbo 2002	61	0 (8.59)	60	1.5 (8.9034)		49.4 %	-1.50 [-4.62, 1.62]
Subtotal (95% CI)	230		146		-	7 0.9 %	-2.04 [-4.65, 0.56]
Heterogeneity: $Chi^2 = 0$.		2 =0.0%					
Test for overall effect: Z =	= 1.54 (P = 0.12)						
2 12 months							
Rossi 2002	171	42.3 (19)	160	45.3 (18.7)		29.1 %	-3.00 [-7.06, 1.06]
Subtotal (95% CI)	171		160			29.1 %	-3.00 [-7.06, 1.06]
Heterogeneity: not applie	cable						
Test for overall effect: Z	= 1.45 (P = 0.15)						
Total (95% CI)	401		306		-	100.0 %	-2.32 [-4.52, -0.13]
Heterogeneity: $Chi^2 = 0$.	54, df = 2 (P = 0.76); I	2 =0.0%					
Test for overall effect: Z	= 2.08 (P = 0.038)						
Test for subgroup differer	nces: $Chi^2 = 0.15$, df =	$ (P = 0.70), ^2$	=0.0%				
						1	
				-10	-5 0 5	10	
				Favours formote	erol 24 µ g Favours p	olacebo	

(1) Dahl 2001 and Rossi 2002 data are endpoint scores, and Wadbo 2002 was presented as change from baseline

Analysis 3.2. Comparison 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration], Outcome 2 Severe exacerbations (hospitalisations).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration]

Outcome: 2 Severe exacerbations (hospitalisations)

Study or subgroup	Formoterol 24 µ g n/N	Placebo n/N		odds Ratio æd,95% Cl	Weight	Odds Ratio M-H,Fixed,95% Cl
I 3 months						
Dahl 2001	2/171	4/172			17.0 %	0.50 [0.09, 2.75]
Subtotal (95% CI)	171	172			17.0 %	0.50 [0.09, 2.75]
Total events: 2 (Formoterol 2	24 µ g), 4 (Placebo)					
Heterogeneity: not applicable	e					
Test for overall effect: $Z = 0$.	.80 (P = 0.42)					
2 12 months						
Rossi 2002	5/214	20/220			83.0 %	0.24 [0.09, 0.65]
Subtotal (95% CI)	214	220	-		83.0 %	0.24 [0.09, 0.65]
Total events: 5 (Formoterol 2	24 µ g), 20 (Placebo)					
Heterogeneity: not applicable	e					
Test for overall effect: $Z = 2$.	.81 (P = 0.0050)					
Total (95% CI)	385	392	•		100.0 %	0.28 [0.12, 0.67]
Total events: 7 (Formoterol 2	24 µ g), 24 (Placebo)					
Heterogeneity: $Chi^2 = 0.53$,	df = 1 (P = 0.47); $ ^2 = 0.0\%$					
Test for overall effect: $Z = 2$.	.89 (P = 0.0038)					
Test for subgroup differences	s: $Chi^2 = 0.52$, $df = 1$ (P = 0.4	47), I ² =0.0%				
			0.05 0.2	5 20		
		Favours fo	ormoterol 24 μ g	Favours placebo		

Analysis 3.3. Comparison 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration], Outcome 3 Moderate exacerbations (course of antibiotics and/or steroids).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 3 Formoterol $24 \,\mu$ g versus placebo [subgrouped by trial duration]

Outcome: 3 Moderate exacerbations (course of antibiotics and/or steroids)

Study or subgroup	Formoterol 24 µ g n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Odds Ratio M-H,Fixed,95% Cl
I I2 months Rossi 2002	49/214	75/220		0.57 [0.38, 0.88]
		Fav	0.2 0.5 I 2 ours formoterol 24 µ g Favours place	5 2bo

Analysis 3.4. Comparison 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration], Outcome 4 Mortality (all-cause).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 3 Formoterol 24 $_{\mu}$ g versus placebo [subgrouped by trial duration]

Outcome: 4 Mortality (all-cause)

Study or subgroup	Formoterol 24 µ g	Placebo	Peto Odds Ratio		Peto Odds Ratio	
	n/N	n/N	Peto,Fixed,95%	CI	Peto,Fixed,95% CI	
3 months						
Dahl 2001	0/191	0/200			0.0 [0.0, 0.0]	
Subtotal (95% CI)	191	200			0.0 [0.0, 0.0]	
Total events: 0 (Formoterol 24	4 µ g), 0 (Placebo)					
Heterogeneity: not applicable						
Test for overall effect: $Z = 0.0$	(P < 0.00001)					
2 12 months						
Rossi 2002	/2 4	0/220			7.60 [0.15, 383.12]	
Subtotal (95% CI)	214	220			7.60 [0.15, 383.12]	
Total events: (Formoterol 24	4 µ g), 0 (Placebo)					
			0.002 0.1 10	500		
		F	avours formoterol 24 µ g Favour	s placebo		
					(Continued)	

Study or subgroup	Formoterol 24 µ g n/N	Placebo n/N		Peto ds Ratio Fixed,95% C		(Continued) Peto Odds Ratio Peto,Fixed,95% Cl
Heterogeneity: not applicable						
Test for overall effect: $Z = 1.01$	I (P = 0.3I)					
Total (95% CI)	405	420				7.60 [0.15, 383.12]
Total events: (Formoterol 24	μ g), 0 (Placebo)					
Heterogeneity: $Chi^2 = 0.0$, df =	= 0 (P = 1.00); I ² =0.0%					
Test for overall effect: $Z = 1.01$	I (P = 0.3I)					
Test for subgroup differences: I	Not applicable					
			0.002 0.1	1 10	500	
		Favou	rs formoterol 24 µ g	Favours	s placebo	

Analysis 3.5. Comparison 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration], Outcome 5 People with one or more non-fatal serious adverse events.

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration]

Outcome: 5 People with one or more non-fatal serious adverse events

Study or subgroup	Formoterol 24 µ g	Placebo	0	dds Ratio	Weight	Odds Ratio	
	n/N	n/N	M-H,Fix	ed,95% Cl		M-H,Fixed,95% CI	
I 3 months							
Wadbo 2002	3/61	7/60		-	9.4 %	0.39 [0.10, 1.59]	
Dahl 2001	3/192	9/200		-	12.2 %	0.34 [0.09, 1.26]	
Subtotal (95% CI)	253	260	-		21.6 %	0.36 [0.14, 0.94]	
Total events: 6 (Formoterol 2	14µg), 16 (Placebo)						
Heterogeneity: Chi ² = 0.02, o	$df = 1 (P = 0.88); I^2 = 0.0\%$						
Test for overall effect: $Z = 2.0$	08 (P = 0.038)						
2 I2 months							
Rossi 2002	48/214	73/220			78.4 %	0.58 [0.38, 0.89]	
Subtotal (95% CI)	214	220	•		78.4 %	0.58 [0.38, 0.89]	
Total events: 48 (Formoterol	24 µ g), 73 (Placebo)						
Heterogeneity: not applicable	2						
			0.05 0.2	5 20			
		Favours	formoterol 24 μ g	Favours placebo			
						(Continued)	

Study or subgroup	Formoterol 24 µ g n/N	Placebo n/N		-	edds Ratio ed,95% Cl		Weight	Odds Ratio M-H,Fixed,95% Cl
Test for overall effect: $Z = 2$.49 (P = 0.013)							
Total (95% CI)	467	480		•			100.0 %	0.53 [0.36, 0.79]
Total events: 54 (Formotero	l 24µg), 89 (Placebo)							
Heterogeneity: $Chi^2 = 0.81$,	df = 2 (P = 0.67); I ² =0.0%							
Test for overall effect: $Z = 3$.16 (P = 0.0016)							
Test for subgroup difference	s: $Chi^2 = 0.80$, $df = 1$ (P = 0.3)	7), I ² =0.0%						
			0.05	0.2	5	20		
		Favours fo	ormotero	124µg	Favours pla	acebo		

Analysis 3.6. Comparison 3 Formoterol 24 μ g versus placebo [subgrouped by trial duration], Outcome 6 Withdrawal.

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 3 Formoterol 24μ g versus placebo [subgrouped by trial duration]

Outcome: 6 Withdrawal

-

-

Study or subgroup	Formoterol 24 µ g n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% Cl
I 3 months					
Wadbo 2002	17/61	I 6/60		10.9 %	1.06 [0.48, 2.37]
Aalbers 2002	27/177	27/173		21.6 %	0.97 [0.54, 1.74]
Dahl 2001	23/192	29/200		23.3 %	0.80 [0.45, 1.44]
Test for overall effect: Z = C 2 12 months	, df = 2 (P = 0.83); l ² =0.0% 0.45 (P = 0.65)	433	-	55.8 %	0.92 [0.64, 1.33]
Rossi 2002	40/214	59/220	-	44.2 %	0.63 [0.40, 0.99]
Subtotal (95% CI) Total events: 40 (Formoterc Heterogeneity: not applicab Test for overall effect: Z = 2	le	220		44.2 %	0.63 [0.40, 0.99]
		Favour	0.2 0.5 2 5 rs formoterol 24 µ g Favours placed		(Continued)

	Formoterol 24 µ g	Placebo	Odds Ratio			Veight	Odds Ratio	
	n/N	n/N	M-H,Fi	M-H,Fixed,95% Cl			M-H,Fixed,95% CI	
Total (95% CI)	644	653	-		100.	0 %	0.79 [0.59, 1.05]	
Total events: 107 (Formoterol	24µg), 3 (Placebo)							
Heterogeneity: Chi ² = 2.01, d	$f = 3 (P = 0.57); I^2 = 0.0\%$							
Test for overall effect: Z = 1.6	2 (P = 0.10)							
Test for subgroup differences:	Chi ² = 1.64, df = 1 (P = 0.2	0), I ² =39%						
					1			
		0.1	2 0.5	2	5			
		Favours forme	oterol 24 µ g	Favours plac	ebo			

Analysis 4.1. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome I Quality of life (SGRQ).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration]

Outcome: I Quality of life (SGRQ)

Study or subgroup	Salmeterol 50 µ g		Placebo		Me Differer	ean nce Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random	95% CI	IV,Random,95% CI
I 6 months							
Brusasco 2003	405	-2.8 (14.087)	400	-1.5 (14)	-	19.9 %	-1.30 [-3.24, 0.64]
Kornmann 2011	292	-5.6 (15.4)	274	-1.5 (14.9)		14.5 %	-4.10 [-6.60, -1.60]
SLMF4010 2005	17	-7.1 (15.2555)	17	2.7 (16.0801)	•	1.1 %	-9.80 [-20.34, 0.74]
Subtotal (95% CI) Heterogeneity: Tau ² = 3.52; Chi ² Test for overall effect: Z = 2.07 (I 2 12 months Calverley 2003b [TRISTAN] (P = 0.038)	0.09); I ² =59% 45.2 (7.7149)	691 361	46.3 (9.5)	•	35.6 % 29.9 %	-3.10 [-6.03, -0.17] -1.10 [-2.35, 0.15]
Subtotal (95% CI) Heterogeneity: not applicable Test for overall effect: $Z = 1.72$ (I 3 36 months	372 P = 0.086)		361		•	29.9 %	-1.10 [-2.35, 0.15]
Calverley 2007 [TORCH]	1521	-0.8 (14.0772)	1524	0.2 (14.0772)	20 -10 0	34.5 %	-1.00 [-2.00, 0.00]
					20 -10 0 eterol 50 µ g	Favours placebo	
				i avoui s sdilli	creioi po h g	avours placebo	(Continued)

(Continued . . .)

Cturk and the second	Coloradoural EQ	Dis estas		Mean		(Continued) Mean Difference
Study or subgroup	Salmeterol 50 µ g N	Placebo Mean(SD) N	Mean(SD)	Difference IV,Random,95% (Weight Cl	IV,Random,95% CI
Subtotal (95% CI)	1521	1524	. ,	•	34.5 %	-1.00 [-2.00, 0.00]
Heterogeneity: not applicable						
Test for overall effect: $Z = 1.96$	(P = 0.050)					
Total (95% CI)	2607	2576		•	100.0 %	-1.64 [-2.78, -0.50]
Heterogeneity: $Tau^2 = 0.73$; Ch	$i^2 = 7.76$, df = 4 (P = 0.1	0); I ² =48%				
Test for overall effect: Z = 2.8 I	(P = 0.0049)					
Test for subgroup differences: C	$Chi^2 = 1.79, df = 2 (P = 0)$	0.41), I ² =0.0%				
			-20	-10 0 10	20	
			Favours salmet	erol 50 µ g Favour	rs placebo	
(1) All data except Calverley 2	003b [TRISTAN] (endpo	int scores) are presente	ed as change from	n baseline		

Analysis 4.2. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 2 Severe exacerbations (hospitalisations).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease Comparison: 4 Salmeterol 50 µ g versus placebo [subgrouped by trial duration] Outcome: 2 Severe exacerbations (hospitalisations) Study or subgroup Salmeterol 50 μ g Placebo Odds Ratio Odds Ratio n/N n/N M-H,Fixed,95% Cl M-H,Fixed,95% CI I 6 months 0.99 [0.52, 1.86] Brusasco 2003 20/405 20/400 0.2 0.5 2 5 Favours salmeterol 50 μ g Favours placebo 114

Long-acting beta2-agonists for chronic obstructive pulmonary disease (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 4.3. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 3 Moderate exacerbations (course of antibiotics and/or steroids).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration]

Outcome: 3 Moderate exacerbations (course of antibiotics and/or steroids)

-

Study or subgroup	Salmeterol 50 µ g n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% Cl
I 3 months					
Rennard 2001	38/132	41/135		15.5 %	0.93 [0.55, 1.57]
Mahler 1999	28/135	47/143		19.5 %	0.53 [0.31, 0.92]
Subtotal (95% CI)	267	278	•	35.0 %	0.71 [0.49, 1.03]
Total events: 66 (Salmeterol 50 μ g) Heterogeneity: Chi ² = 2.04, df = 1 Test for overall effect: Z = 1.80 (P = 2.6 months	$(P = 0.15); I^2 = 51\%$				
Brusasco 2003	142/405	156/400	-	54.8 %	0.84 [0.63, 1.12]
Subtotal (95% CI)	405	400	•	54.8 %	0.84 [0.63, 1.12]
Total events: 142 (Salmeterol 50 µ g Heterogeneity: not applicable Test for overall effect: Z = 1.16 (P = 3 12 months Calverley 2003b [TRISTAN]	,	19/361		10.2 %	0.40 [0.17, 0.92]
Subtotal (95% CI)	372	361	-	10.2 %	0.40 [0.17, 0.92]
Total events: 8 (Salmeterol 50 μ g), Heterogeneity: not applicable Test for overall effect: Z = 2.17 (P =	19 (Placebo)			//	
Total (95% CI)	1044	1039	•	100.0 %	0.75 [0.60, 0.94]
Total events: 216 (Salmeterol 50 μ g Heterogeneity: Chi ² = 5.01, df = 3 Test for overall effect: Z = 2.56 (P = Test for subgroup differences: Chi ² :	(P = 0.17); l ² =40% = 0.010)	l ² =33%			
			0.1 0.2 0.5 2 5 10		
		Favours s	almeterol 50 µ g Favours placebo		

Analysis 4.4. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 4 Mortality (all-cause).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration]

Outcome: 4 Mortality (all-cause)

Study or subgroup	Salmeterol 50 µ g	Placebo	Peto Odds Ratio	Peto Odds Ratio
	n/N	n/N	Peto,Fixed,95% Cl	Peto,Fixed,95% C
I 3 months				
Mahler 1999	0/135	0/143		0.0 [0.0, 0.0]
Hanrahan 2008	0/293	0/294		0.0 [0.0, 0.0]
Rennard 2001	0/132	1/135	·	0.14 [0.00, 6.98]
Subtotal (95% CI)	560	572		0.14 [0.00, 6.98]
Total events: 0 (Salmeterol 50 μ g), 1 Heterogeneity: Chi ² = 0.0, df = 0 (P Test for overall effect: Z = 0.99 (P = 2 6 months	$P = 1.00); I^2 = 0.0\%$			
Hanania 2003	0/177	0/185		0.0 [0.0, 0.0]
SLMF4010 2005	0/17	0/17		0.0 [0.0, 0.0]
Mahler 2002	0/160	3/181		0.15 [0.02, 1.46]
Kornmann 2011	0/334	3/335		0.13 [0.01, 1.30]
Brusasco 2003	6/405	5/400	_ 	1.19 [0.36, 3.90]
Subtotal (95% CI)	1093	1118	•	0.56 [0.22, 1.46]
Total events: 6 (Salmeterol 50 μ g), 1 Heterogeneity: Chi ² = 4.33, df = 2 (Test for overall effect: Z = 1.19 (P = 3 12 months	$P = 0.11$; $I^2 = 54\%$	7/361		0.43 [0.12, 1.50]
Calverley 2003b [TRISTAN]				
Subtotal (95% CI) Total events: 3 (Salmeterol 50μ g), 7 Heterogeneity: not applicable Test for overall effect: Z = 1.32 (P = 4.36 months		361	•	0.43 [0.12, 1.50]
Calverley 2007 [TORCH]	205/1521	232/1524	•	0.87 [0.71, 1.06]
Subtotal (95% CI) Total events: 205 (Salmeterol 50 μ g Heterogeneity: not applicable Test for overall effect: Z = 1.37 (P =		1524	•	0.87 [0.71, 1.06]
			0.002 0.1 1 10 50)
		Fav	ours salmeterol 50 µ g Favours placeb	o (Continued

Study or subgroup	Salmeterol 50 µ g n/N	Placebo n/N	I		Peto s Ratio xed,95% Cl	(Continued) Peto Odds Ratio Peto,Fixed,95% Cl
Total (95% CI)	3546	3575		•		0.83 [0.69, 1.01]
Total events: 214 (Salmeterol 50 μ	g), 251 (Placebo)					
Heterogeneity: $Chi^2 = 7.03$, df = 5	$(P = 0.22); I^2 = 29\%$					
Test for overall effect: $Z = 1.82$ (P =	= 0.068)					
Test for subgroup differences: Chi ²	= 2.69, df = 3 (P = 0.44), l ² =0.0%					
				1		
			0.002	0.1	I IO 500	
		Favo	ours salmeterol 5	Оµg	Favours placebo	

Analysis 4.5. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 5 People with one or more non-fatal serious adverse events.

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration]

Outcome: 5 People with one or more non-fatal serious adverse events

Study or subgroup	Salmeterol 50 µ g	Placebo	Odds Ratio	Weight	Odds Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
I 3 months					
Rennard 2001	10/132	7/135		1.2 %	1.50 [0.55, 4.06]
Hanrahan 2008	11/290	19/293		3.3 %	0.57 [0.27, 1.22]
Subtotal (95% CI)	422	428	•	4.5 %	0.81 [0.45, 1.46]
Total events: 21 (Salmeterol 50	ı g), 26 (Placebo)				
Heterogeneity: $Chi^2 = 2.29$, df =	= $ (P = 0. 3); ^2 = 56\%$				
Test for overall effect: $Z = 0.70$	(P = 0.49)				
2 6 months					
SLMF4010 2005	1/17	3/17		0.5 %	0.29 [0.03, 3.13]
Mahler 2002	7/160	11/181		1.8 %	0.71 [0.27, 1.87]
Hanania 2003	5/177	11/185	<u> </u>	1.9 %	0.46 [0.16, 1.35]
Kornmann 2011	19/334	26/335		4.5 %	0.72 [0.39, 1.32]
Brusasco 2003	49/405	56/400	-	9.1 %	0.85 [0.56, 1.28]
			0.02 0.1 1 10 50		
		Favours salm	neterol 50 µ g Favours placebo		

⁽Continued ...)

					(
Study or subgroup	Salmeterol 50 µ g	Placebo	Odds Ratio	Weight	Odds Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Subtotal (95% CI)	1093	1118	*	17.8 %	0.74 [0.55, 1.01]
Total events: 81 (Salmeterol 50 µ	ı g), 107 (Placebo)				
Heterogeneity: $Chi^2 = 1.76$, df =	= 4 (P = 0.78); I ² =0.0%				
Test for overall effect: $Z = 1.93$ ((P = 0.054)				
3 12 months					
Calverley 2003b [TRISTAN]	69/372	54/361	-	8.2 %	1.29 [0.88, 1.91]
Subtotal (95% CI)	372	361	•	8.2 %	1.29 [0.88, 1.91]
Total events: 69 (Salmeterol 50 µ	g), 54 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.30$ ((P = 0.19)				
4 36 months					
Calverley 2007 [TORCH]	617/1542	633/1544	-	69.5 %	0.96 [0.83, .]
Subtotal (95% CI)	1542	1544	•	69.5 %	0.96 [0.83, 1.11]
Total events: 617 (Salmeterol 50	μ g), 633 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.56$ ((P = 0.58)				
Total (95% CI)	3429	3451	•	100.0 %	0.94 [0.83, 1.06]
Total events: 788 (Salmeterol 50	μ g), 820 (Placebo)				
Heterogeneity: Chi ² = 9.15, df =	= 8 (P = 0.33); I ² = I 3%				
Test for overall effect: $Z = 0.98$ ((P = 0.33)				
Test for subgroup differences: Ch	ni ² = 5.25, df = 3 (P = 0.15),	l ² =43%			
			0.02 0.1 1 10 50		
		Favours saln	neterol 50 µ g Favours placeb	00	

Analysis 4.6. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 6 Predose FEVI (mL).

Review: Long-acting beta₂-agonists for chronic obstructive pulmonary disease

Comparison: 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration]

Outcome: 6 Predose FEV₁ (mL)

Study or subgroup Salmeterol	50 µ g N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV.Random,95% CI	Weight	Mean Difference IV,Random,95% CI
	14	Tical(SD)	11	1 (GB)			14,14110011,7576 CI
onths nrahan 2008	276	223.1 (218.2)	275	80.4 (204.1)		20.5 %	42.70 107.42, 177.98
		. ,		. ,			
nard 2001	109	150 (323.65)	105	-20 (297.16)		→ I2.I%	170.00 [86.80, 253.20]
otal (95% CI)	385		380		•	32.6 %	146.86 [114.38, 179.34]
pgeneity: Tau ² = 0.0; Chi ² = 0.35, df = 1	(P = 0.5	5); I ² =0.0%					
r overall effect: $Z = 8.86 (P < 0.00001)$							
onths	170	01 (200)	105	1 (200)		15 4 04	
nania 2003	178	91 (300)	185	I (300)		15.6 %	90.00 [28.27, 151.73]
nmann 2011	333	90 (430)	335	-20 (430)		15.0 %	0.00 [44.78, 75.22]
nler 2002	159	107 (460)	181	-4 (460)		→ I0.2 %	.00 [3.00, 209.00]
1F4010 2005	17	-94 (239.1)	17	-30 (235) 🕇		5.2 %	-64.00 [-223.37, 95.37]
otal (95% CI)	687		718		-	46.1 %	87.93 [39.05, 136.80]
pgeneity: Tau ² = 681.60; Chi ² = 4.12, df	= 3 (P =	: 0.25); I ² =279	%				
r overall effect: Z = 3.53 (P = 0.00042)							
nonths							
verley 2003b [TRISTAN] (I)	372	323 (2 2)	361	1264 (209)		21.3 %	59.00 [28.52, 89.48]
otal (95% CI)	372		361		+	21.3 %	59.00 [28.52, 89.48]
ogeneity: not applicable							
r overall effect: $Z = 3.79 (P = 0.00015)$							
(22) (22)	1444		1459		•	100.0 %	101.01 [59.84, 142.18]
pgeneity: Tau ² = 1830.26; Chi ² = 19.57,	df = 6 (F	$P = 0.003$); $ ^2 =$	=69%				
r overall effect: $Z = 4.81$ (P < 0.00001)							
r subgroup differences: $Chi^2 = 15.15$, df	= 2 (P =	= 0.00), l ² =87	%				

Favours placebo

Favours salmeterol 50 µ g

(1) All data except that from Calverley 2003b [TRISTAN] (endpoint scores) were entered as change from baseline

Analysis 4.7. Comparison 4 Salmeterol 50 μ g versus placebo [subgrouped by trial duration], Outcome 7 Withdrawal.

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 4 Salmeterol 50 µ g versus placebo [subgrouped by trial duration]

Outcome: 7 Withdrawal

Study or subgroup	Salmeterol 50 µ g n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% CI
3 months					
Mahler 1999	9/135	23/143	•	2.4 %	0.37 [0.17, 0.84]
Rennard 2001	22/132	29/135		2.8 %	0.73 [0.40, 1.35]
Hanrahan 2008	44/293	64/294	_ _	6.3 %	0.64 [0.42, 0.97]
Subtotal (95% CI)	560	572	•	11.5 %	0.60 [0.44, 0.83]
Total events: 75 (Salmeterol 50 μ Heterogeneity: Chi ² = 1.79, df = Test for overall effect: Z = 3.11 (F 2 6 months	2 (P = 0.41); $I^2 = 0.0\%$				
SLMF4010 2005	7/17	7/17		0.5 %	1.00 [0.26, 3.92]
Hanania 2003	57/177	59/185		4.5 %	1.01 [0.65, 1.58]
Mahler 2002	45/160	69/181		5.4 %	0.64 [0.40, 1.00]
Kornmann 2011	50/334	70/335		6.9 %	0.67 [0.45, 0.99]
Brusasco 2003	76/405	103/400		9.8 %	0.67 [0.48, 0.93]
Subtotal (95% CI)	1093	1118	•	27.1 %	0.72 [0.59, 0.88]
Total events: 235 (Salmeterol 50 , Heterogeneity: Chi ² = 3.17, df = Test for overall effect: Z = 3.21 (F 3 12 months Calverley 2003b [TRISTAN]	$4 (P = 0.53); I^2 = 0.0\%$	140/361	-	11.2 %	0.74 [0.55, 1.01]
	372	361		11.2 %	
Subtotal (95% CI) Total events: 119 (Salmeterol 50 , Heterogeneity: not applicable Test for overall effect: Z = 1.92 (F 4 36 months Calverley 2007 [TORCH]	u g), 140 (Placebo)	501 694/1545	•	11.2 %	0.74 [0.55, 1.01]
Subtotal (95% CI)	1544	1545	•	50.2 %	0.74 [0.64, 0.86]
Total events: 582 (Salmeterol 50 μ Heterogeneity: not applicable Test for overall effect: Z = 4.07 (F	µ g), 694 (Placebo)	1919		J U .2 /0	
Total (95% CI)	3569	3596	•	100.0 %	0.72 [0.65, 0.80]
		Favours sa	0.2 0.5 1 2 5 Imeterol 50 µ g Favours placet		(Continued

						(
Study or subgroup	Salmeterol 50 µ g	Placebo	00	dds Ratio	Weight	Odds Ratio
	n/N	n/N	M-H,Fixe	ed,95% Cl		M-H,Fixed,95% CI
Total events: 1011 (Salmeterol 5	0µg), 1258 (Placebo)					
Heterogeneity: $Chi^2 = 6.26$, df =	= 9 (P = 0.71); l ² =0.0%					
Test for overall effect: $Z = 6.24$ ((P < 0.00001)					
Test for subgroup differences: Cl	hi ² = 1.40, df = 3 (P = 0.71),	$ ^2 = 0.0\%$				
			0.2 0.5 1	2 5		
		Favours salr	meterol 50 µ g	Favours placebo		

Analysis 5.1. Comparison 5 [Sensitivity analysis-ICS use] All LABA versus placebo, Outcome I Quality of life (SGRQ).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 5 [Sensitivity analysis—ICS use] All LABA versus placebo

Outcome: I Quality of life (SGRQ)

Study or subgroup	LABA		Placebo			M Differe	ean nce		Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IN	V,Fixed,S	95% CI			IV,Fixed,95% CI
l Formoterol 12 µ g twice daily	·									
Bogdan 2011 (1)	199	38.2 (14.5)	206	42.9 (14.5)					3.8 %	-4.70 [-7.52, -1.88]
Calverley 2003a	255	0.8 (17)	256	4.7 (17)					3.5 %	-3.90 [-6.85, -0.95]
Doherty 2012 (2)	243	-4.93 (14.5)	236	-2.88 (14.5)		-+-			4.5 %	-2.05 [-4.65, 0.55]
Rennard 2009	495	-2.9 (13.3)	481	-1.5 (12.7)		-#-			11.5 %	-1.40 [-3.03, 0.23]
Szafranski 2003	201	-3.6 (15)	205	-0.03 (15)					3.6 %	-3.57 [-6.49, -0.65]
Tashkin 2008 [SHINE]	284	-1.24 (11.35)	300	-1.02 (12.41)		+			8.2 %	-0.22 [-2.15, 1.71]
Tashkin 2012	209	-6.19 (15.2)	212	-2.88 (15.2)					3.6 %	-3.31 [-6.21, -0.41]
8 /	Subtotal (95% CI) 1886 Heterogeneity: Chi ² = 10.68, df = 6 (P = 0.10); l ² =44% Test for overall effect: Z = 4.76 (P < 0.00001)					•			38.7 %	-2.16 [-3.04, -1.27]
2 Formoterol 24 μ g twice daily	,									
					-20 -10	0	10	20		
					Favours LAB	A	Favours p	lacebo		
				as e	endpoint score	es.				(Cartinuada)
										(Continued)

								(
Study or subgroup	LABA		Placebo			Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	ľ	V,Fixed,95% (IV,Fixed,95% CI
Wadbo 2002	61	0 (8.59)	60	I.5 (8.9034)		-+-	3.1 %	-1.50 [-4.62, 1.62]
Subtotal (95% CI)	61		60			•	3.1 %	-1.50 [-4.62, 1.62]
Heterogeneity: not applicable								
Test for overall effect: $Z = 0.94$	(P = 0.35)							
3 Salmeterol 50 $_{\rm \mu}$ g twice daily								
Brusasco 2003	405	-2.8 (14.087)	400	-1.5 (14)		-	8.1 %	-1.30 [-3.24, 0.64]
Calverley 2003b [TRISTAN]	372	45.2 (7.7149)	361	46.3 (9.5)		-	19.3 %	-1.10 [-2.35, 0.15]
Calverley 2007 [TORCH]	1521	-0.8 (14.0772)	1524	0.2 (14.0772)		-	30.5 %	-1.00 [-2.00, 0.00]
SLMF4010 2005	17	-7.1 (15.2555)	17	2.7 (16.0801)	← +		0.3 %	-9.80 [-20.34, 0.74]
Subtotal (95% CI)	2315		2302			•	58.2 %	-1.12 [-1.84, -0.39]
Heterogeneity: $Chi^2 = 2.70$, df =	= 3 (P = 0.	44); l ² =0.0%						
Test for overall effect: $Z = 3.02$	(P = 0.002	5)						
Total (95% CI)	4262		4258			•	100.0 %	-1.53 [-2.08, -0.98]
Heterogeneity: Chi ² = 16.55, df	= (P =	0.12); I ² =34%						
Test for overall effect: $Z = 5.44$	(P < 0.000	01)						
Test for subgroup differences: C	hi ² = 3.17,	df = 2 (P = 0.20)	, I ² =37%					
					-20 -10	0 1	0 20	
					Favours LAE	BA Favo	ours placebo	

as endpoint scores.

(1) Change from baseline data and endpoint data were pooled in the analysis. Most studies reported change from baseline but data for Bogdan 2011 and Calverley 2003b [TRISTAN] are entered

(2) SDs for Doherty 2012 and Szafranski 2003 were imputed based on population variance and that of other arms within the studies

Analysis 5.2. Comparison 5 [Sensitivity analysis-ICS use] All LABA versus placebo, Outcome 2 Severe exacerbations (hospitalisations).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 5 [Sensitivity analysis—ICS use] All LABA versus placebo

Outcome: 2 Severe exacerbations (hospitalisations)

Study or subgroup	LABA n/N	Placebo n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% Cl
I Formoterol 12 µ g twice daily	,				
Doherty 2012	5/243	12/236	←	13.7 %	0.39 [0.14, 1.13]
Calverley 2003a	73/255	79/256		64.4 %	0.90 [0.61, 1.31]
Subtotal (95% CI)	498	492	-	78.1 %	0.81 [0.57, 1.15]
Total events: 78 (LABA), 91 (Pla Heterogeneity: $Chi^2 = 2.09$, df Test for overall effect: $Z = 1.16$	$= (P = 0. 5); ^2 =$	=52%			
2 Salmeterol 50 µ g twice daily Brusasco 2003	20/405	20/400	_	21.9 %	0.99 [0.52, 1.86]
Subtotal (95% CI)	405	400		21.9 %	0.99 [0.52, 1.86]
Total events: 20 (LABA), 20 (Pla Heterogeneity: not applicable Test for overall effect: $Z = 0.04$					
Total (95% CI)	903	892	-	100.0 %	0.85 [0.62, 1.16]
Total events: 98 (LABA), 111 (F	Placebo)				
Heterogeneity: $Chi^2 = 2.35$, df	$= 2 (P = 0.3 I); I^2 =$	=15%			
Test for overall effect: $Z = 1.04$	(P = 0.30)				
Test for subgroup differences: C	$Chi^2 = 0.28, df = 1$	(P = 0.59), I ² =0.0%			
			0.2 0.5 1 2 5		

Favours LABA Favours placebo

Analysis 6.1. Comparison 6 [Sensitivity analysis-attrition] All LABA versus placebo, Outcome I Quality of life (SGRQ).

Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease

Comparison: 6 [Sensitivity analysis—attrition] All LABA versus placebo

Outcome: I Quality of life (SGRQ)

Study or subgroup	LABA		Placebo		Me Differen		Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95	5% CI	IV,Fixed,95% C
I Formoterol 12 $_{\mu}$ g twice daily							
Bogdan 2011 (1)	199	38.2 (14.5)	206	42.9 (14.5)		3.8 %	-4.70 [-7.52, -1.88]
Calverley 2003a	255	0.8 (17)	256	4.7 (17)		3.5 %	-3.90 [-6.85, -0.95]
Campbell 2005	215	-3.81 (13.5737)	217	-4.61 (13.5737)		4.7 %	0.80 [-1.76, 3.36]
Dahl 2001	181	41.7 (16.8)	86	46.8 (17.6)		1.5 %	-5.10 [-9.55, -0.65]
Doherty 2012 (2)	243	-4.93 (14.5)	236	-2.88 (14.5)		4.5 %	-2.05 [-4.65, 0.55]
Rossi 2002	159	40.9 (17.8)	80	45.3 (18.7)		1.3 %	-4.40 [-9.34, 0.54]
Tashkin 2008 [SHINE]	284	-1.24 (11.35)	300	-1.02 (12.41)		8.2 %	-0.22 [-2.15, 1.71]
Tashkin 2012	209	-6.19 (15.2)	212	-2.88 (15.2)		3.6 %	-3.31 [-6.21, -0.41]
Subtotal (95% CI)	1745		1593		•	31.2 %	-2.07 [-3.06, -1.08]
Heterogeneity: $Chi^2 = 16.51$, df = 7	7 (P = 0.0	12); I ² =58%					
Test for overall effect: $Z = 4.09$ (P =	= 0.00004	3)					
2 Formoterol 24 µ g twice daily							
Dahl 2001	169	43.5 (19.4)	86	46.8 (17.6)		1.4 %	-3.30 [-8.03, 1.43]
Rossi 2002	171	42.3 (19)	80	45.3 (18.7)		1.2 %	-3.00 [-7.99, 1.99]
Wadbo 2002	61	0 (8.59)	60	1.5 (8.9034)		3.1 %	-1.50 [-4.62, 1.62]
Subtotal (95% CI)	401		226		-	5.7 %	-2.25 [-4.56, 0.06]
Heterogeneity: $Chi^2 = 0.50$, df = 2); l ² =0.0%					
Test for overall effect: $Z = 1.91$ (P =	= 0.056)						
3 Salmeterol 50 µ g twice daily Brusasco 2003	405	-2.8 (14.087)	400	-1.5 (14)		8.1 %	-1.30 [-3.24, 0.64]
Calverley 2003b [TRISTAN] (3)	372	45.2 (7.7149)	361	46.3 (9.5)		19.4 %	-1.10 [-2.35, 0.15]
Calverley 2007 [TORCH]	1521	-0.8 (14.0772)	1524	0.2 (14.0772)	-	30.6 %	-1.00 [-2.00, 0.00]
Kornmann 2011	292	-5.6 (15.4)	274	-1.5 (14.9)	<u> </u>	4.9 %	-4.10 [-6.60, -1.60]
Subtotal (95% CI)	2590		2559		•	63.0 %	-1.31 [-2.01, -0.61]
Heterogeneity: $Chi^2 = 5.27$, $df = 3$	(P = 0.15); I ² =43%					
						<u> </u>	
					-10 -5 0	5 10	
					Favours LABA	Favours placebo	

(Continued ...)

Study or subgroup	LABA		Placebo		Dif	Mean ference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fix	ed,95% Cl		IV,Fixed,95% CI
Test for overall effect: $Z = 3.69$ (P = 0.00023)							
Total (95% CI)	4736		4378		•		100.0 %	-1.60 [-2.15, -1.05]
Heterogeneity: $Chi^2 = 24.10$, df	= 14 (P = 0.04)	; I ² =42%						
Test for overall effect: $Z = 5.67$ (P < 0.00001)							
Test for subgroup differences: Ch	$hi^2 = 1.82$, df =	2 (P = 0.40), I ² :	=0.0%					
				L				
				-10	-5	0 5	10	
				Fav	ours LABA	Favours pla	acebo	

data for Bogdan 2011, Dahl 2001, Rossi 2002, and Calverley 2003b [TRISTAN] are entered as endpoint scores.

(1) Last available score with imputed SD (based on other studies). Change from baseline data and endpoint data were pooled in the analysis. Most studies reported change from baseline but

(2) SDs for Doherty 2012 and Szafranski 2003 were imputed based on population variance and that of other arms within the studies

(3) Adjusted mean at endpoint

ADDITIONAL TABLES

Table 1. Length of included studies with summary demographics

Trial length	Study IDs	Mean age, years, median (range)	Male, %, median (range)
3 months	Aalbers 2002; Bogdan 2011; Dahl 2001; Hanrahan 2008; Mahler 1999; Nelson 2007; Rennard 2001; Wadbo 2002; Watkins 2002	63.5 (62 to 67)	66.5 (52 to 87)
6 months	Brusasco 2003; Campbell 2005; Doherty 2012; Hanania 2003; Kornmann 2011; Mahler 2002; SLMF4010 2005; Tashkin 2008 [SHINE]; Tashkin 2012; Vogelmeier 2008	63 (59 to 65)	75 (63 to 88)
12 months	Calverley 2003a; Calverley 2003b [TRISTAN]; Dahl 2010; Rennard 2009; Rossi 2002; Szafranski 2003	63.5 (63 to 64)	77.5 (75 to 80)
36 months	Calverley 2007 [TORCH]	65 (N/A)	76

Table 2. Baseline severity within the included studies

FEV1 % predicted at baseline	Study IDs	Mean baseline SGRQ, median (range)	
$30\% \le \text{mean} < 40\%$	Brusasco 2003; Calverley 2003a; Doherty 2012; Szafranski 2003; Wadbo 2002	50 (47 to 53)	
40% ≤ mean < 50%	Calverley 2003b [TRISTAN]; Calverley 2007 [TORCH]; Dahl 2010; Hanania 2003; Hanrahan 2008; Mahler 1999; Mahler 2002; Rennard 2009; Tashkin 2008 [SHINE]	50 (48 to 55)	
50% ≤ mean < 60%	Aalbers 2002; Bogdan 2011; Campbell 2005; Dahl 2010; Kornmann 2011; Vogelmeier 2008	45 (44 to 49)	
Five studies did not report mean % predicted FEV1 at baseline; 10 of the studies presented here did not			

provide baseline SGRQ.

APPENDICES

Appendix I. Sources and search methods for the Cochrane Airways Group Specialised Register (CAGR)

Electronic searches: core databases

Database	Frequency of search
CENTRAL (The Cochrane Library)	Monthly
MEDLINE (Ovid)	Weekly
EMBASE (Ovid)	Weekly
PsycINFO (Ovid)	Monthly
CINAHL (Ebsco)	Monthly
AMED (Ebsco)	Monthly

Handsearches: core respiratory conference abstracts

Conference	Years searched
American Academy of Allergy, Asthma and Immunology (AAAAI)	2001 onwards
American Thoracic Society (ATS)	2001 onwards
Asia Pacific Society of Respirology (APSR)	2004 onwards
British Thoracic Society Winter Meeting (BTS)	2000 onwards
Chest Meeting	2003 onwards
European Respiratory Society (ERS)	1992, 1994, 2000 onwards
International Primary Care Respiratory Group Congress (IPCRG)	2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ)	1999 onwards

MEDLINE Search strategy used to identify trials for the CAGR

COPD search

- 1. Lung Diseases, Obstructive/
- 2. exp Pulmonary Disease, Chronic Obstructive/
- 3. emphysema\$.mp.
- 4. (chronic\$ adj3 bronchiti\$).mp.
- 5. (obstruct\$ adj3 (pulmonary or lung\$ or airway\$ or airflow\$ or bronch\$ or respirat\$)).mp.
- 6. COPD.mp.
- 7. COAD.mp.
- 8. COBD.mp.
- 9. AECB.mp.
- 10. or/1-9

Filter to identify RCTs

- 1. exp "clinical trial [publication type]"/
- 2. (randomised or randomised).ab,ti.
- 3. placebo.ab,ti.
- 4. dt.fs.
- 5. randomly.ab,ti.
- 6. trial.ab,ti.
- 7. groups.ab,ti.
- 8. or/1-7
- 9. Animals/
- 10. Humans/

11. 9 not (9 and 10)12. 8 not 11The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases

Appendix 2. Search strategy for Clinicaltrials.gov

search terms: formoterol OR salmeterol OR LABA OR long-acting OR "long acting" condition: COPD study type: interventional studies

CONTRIBUTIONS OF AUTHORS

Chris Mavergames and Kayleigh Kew assessed studies for inclusion. Chris, Julia Walters and Kayleigh extracted data from the papers and assessed studies for risk of bias. Kayleigh analysed the data and wrote the review, with input from Julia.

DECLARATIONS OF INTEREST

None known.

SOURCES OF SUPPORT

Internal sources

• No sources of support supplied

External sources

• NIHR, UK. Programme grant funding

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Studies were analysed in four trial duration subgroups rather than the two stated in the protocol (\leq one year or > one year). It was not deemed appropriate to organise subgroups according to severity at baseline because the study populations were similar, and so this was not performed. An additional sensitivity analysis related to the use of other medications during the trials was conducted to deal with several studies in which the proportion of participants taking inhaled steroids fell just above or just below the 50% cut-off for exclusion.

INDEX TERMS

Medical Subject Headings (MeSH)

Administration, Inhalation; Adrenergic beta-2 Receptor Agonists [*administration & dosage]; Drug Administration Schedule; Pulmonary Disease, Chronic Obstructive [drug therapy; mortality]; Quality of Life; Randomized Controlled Trials as Topic

MeSH check words

Female; Humans; Male